0001104659-20-053384.txt : 20200429 0001104659-20-053384.hdr.sgml : 20200429 20200429161647 ACCESSION NUMBER: 0001104659-20-053384 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200429 DATE AS OF CHANGE: 20200429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 20830540 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 10-Q 1 abt-20200331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation		I.R.S. Employer Identification No.
		36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, Without Par Value		ABT		New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large Accelerated Filer	☒	Accelerated Filer	☐
Non-Accelerated Filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of March 31, 2020, Abbott Laboratories had 1,768,845,326 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents


Part I - Financial Information
	Page
Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Balance Sheet	5
Condensed Consolidated Statement of Shareholders’ Investment	6
Condensed Consolidated Statement of Cash Flows	7
Notes to the Condensed Consolidated Financial Statements	8

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 4. Controls and Procedures	22

Part II - Other Information

Item 1. Legal Proceedings	22

Item 1A. Risk Factors	22

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	23

Item 6. Exhibits	24

Signature	25

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)


	Three Months Ended March 31
	2020		2019
Net sales	$	7,726	$	7,535

Cost of products sold, excluding amortization of intangible assets		3,281		3,160
Amortization of intangible assets		561		486
Research and development		578		672
Selling, general and administrative		2,548		2,478
Total operating cost and expenses		6,968		6,796

Operating earnings		758		739

Interest expense		139		171
Interest (income)		(18)		(23)
Net foreign exchange (gain) loss		5		6
Other (income) expense, net		(1)		(47)
Earnings from continuing operations before tax		633		632
Tax expense (benefit) on earnings from continuing operations		89		(40)
Earnings from continuing operations		544		672

Earnings from discontinued operations, net of tax		20		—

Net Earnings	$	564	$	672

Basic Earnings Per Common Share —
Continuing operations	$	0.31	$	0.38
Discontinued operations		0.01		—
Net earnings	$	0.32	$	0.38

Diluted Earnings Per Common Share —
Continuing operations	$	0.30	$	0.38
Discontinued operations		0.01		—
Net earnings	$	0.31	$	0.38

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share		1,768,901		1,763,278
Dilutive Common Stock Options		11,677		13,295
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options		1,780,578		1,776,573

Outstanding Common Stock Options Having No Dilutive Effect		4,035		4,011

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)


	Three Months Ended March 31
	2020		2019
Net Earnings	$	564	$	672
Foreign currency translation gain (loss) adjustments		(1,144)		122
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $15 in 2020 and $7 in 2019		57		23
Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $48 in 2020 and $(8) in 2019		166		(29)
Other comprehensive income (loss)		(921)		116
Comprehensive Income (Loss)	$	(357)	$	788


	March 31,		December 31,
	2020		2019
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(6,068)	$	(4,924)
Net actuarial (losses) and prior service (cost) and credits		(3,483)		(3,540)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges		165		(1)
Accumulated Other Comprehensive Income (Loss)	$	(9,386)	$	(8,465)

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)


	March 31,		December 31,
	2020		2019
Assets
Current Assets:
Cash and cash equivalents	$	3,377	$	3,860
Short-term investments		291		280
Trade receivables, less allowances of $389 in 2020 and $384 in 2019		5,292		5,425
Inventories:
Finished products		2,873		2,784
Work in process		615		560
Materials		1,080		972
Total inventories		4,568		4,316
Prepaid expenses and other receivables		1,970		1,786
Total Current Assets		15,498		15,667
Investments		790		883
Property and equipment, at cost		16,707		16,799
Less: accumulated depreciation and amortization		8,800		8,761
Net property and equipment		7,907		8,038
Intangible assets, net of amortization		16,265		17,025
Goodwill		22,927		23,195
Deferred income taxes and other assets		3,390		3,079
	$	66,777	$	67,887
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings	$	204	$	201
Trade accounts payable		3,181		3,252
Salaries, wages and commissions		949		1,237
Other accrued liabilities		4,408		4,035
Dividends payable		637		635
Income taxes payable		165		226
Current portion of long-term debt		1,264		1,277
Total Current Liabilities		10,808		10,863
Long-term debt		16,804		16,661
Post-employment obligations, deferred income taxes and other long-term liabilities		8,738		9,062
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued		—		—
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2020: 1,978,112,501 ; 2019: 1,976,855,085		23,731		23,853
Common shares held in treasury, at cost — Shares: 2020: 209,267,175 ; 2019: 214,351,838		(9,913)		(10,147)
Earnings employed in the business		25,786		25,847
Accumulated other comprehensive income (loss)		(9,386)		(8,465)
Total Abbott Shareholders’ Investment		30,218		31,088
Noncontrolling Interests in Subsidiaries		209		213
Total Shareholders’ Investment		30,427		31,301
	$	66,777	$	67,887

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Shareholders’ Investment

(Unaudited)

(in millions except shares and per share data)


	Three Months Ended March 31
	2020		2019
Common Shares:
Balance at January 1
Shares: 2020: 1,976,855,085; 2019: 1,971,189,465	$	23,853	$	23,512
Issued under incentive stock programs
Shares: 2020: 1,257,416; 2019: 2,283,041		53		76
Share-based compensation		245		237
Issuance of restricted stock awards		(420)		(364)
Balance at March 31
Shares: 2020: 1,978,112,501; 2019: 1,973,472,506	$	23,731	$	23,461

Common Shares Held in Treasury:
Balance at January 1
Shares: 2020: 214,351,838; 2019: 215,570,043	$	(10,147)	$	(9,962)
Issued under incentive stock programs
Shares: 2020: 5,333,626; 2019: 6,544,927		253		303
Purchased
Shares: 2020: 248,963; 2019: 266,128		(19)		(20)
Balance at March 31
Shares: 2020: 209,267,175; 2019: 209,291,244	$	(9,913)	$	(9,679)

Earnings Employed in the Business:
Balance at January 1	$	25,847	$	24,560
Impact of adoption of new accounting standard		(5)		—
Net earnings		564		672
Cash dividends declared on common shares (per share — 2020: $0.36; 2019: $0.32)		(641)		(568)
Effect of common and treasury share transactions		21		(51)
Balance at March 31	$	25,786	$	24,613

Accumulated Other Comprehensive Income (Loss):
Balance at January 1	$	(8,465)	$	(7,586)
Other comprehensive income (loss)		(921)		116
Balance at March 31	$	(9,386)	$	(7,470)

Noncontrolling Interests in Subsidiaries:
Balance at January 1	$	213	$	198
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases		(4)		6
Balance at March 31	$	209	$	204

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)


	Three Months Ended March 31
	2020		2019
Cash Flow From (Used in) Operating Activities:
Net earnings	$	564	$	672
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation		267		267
Amortization of intangible assets		561		486
Share-based compensation		233		226
Trade receivables		(104)		(170)
Inventories		(437)		(286)
Other, net		(369)		(483)
Net Cash From Operating Activities		715		712

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment		(360)		(335)
Acquisitions of businesses and technologies, net of cash acquired		—		(78)
Sales (purchases) of other investment securities, net		(36)		2
Other		3		15
Net Cash (Used in) Investing Activities		(393)		(396)

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other		51		13
Repayments of long-term debt		(1)		(500)
Purchases of common shares		(236)		(217)
Proceeds from stock options exercised		89		127
Dividends paid		(638)		(565)
Net Cash (Used in) Financing Activities		(735)		(1,142)

Effect of exchange rate changes on cash and cash equivalents		(70)		4

Net Decrease in Cash and Cash Equivalents		(483)		(822)
Cash and Cash Equivalents, Beginning of Year		3,860		3,844
Cash and Cash Equivalents, End of Period	$	3,377	$	3,022

The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2019. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.

Recent Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

Note 3 — Revenue

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

The following table provides revenues by sales category:


	Three Months Ended March 31, 2020						Three Months Ended March 31, 2019
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	813	$	813	$	—	$	752	$	752
Other		—		231		231		—		240		240
Total		—		1,044		1,044		—		992		992

Nutritionals —
Pediatric Nutritionals		518		571		1,089		453		576		1,029
Adult Nutritionals		294		521		815		294		469		763
Total		812		1,092		1,904		747		1,045		1,792

Diagnostics —
Core Laboratory		267		722		989		249		812		1,061
Molecular		65		74		139		40		68		108
Point of Care		103		35		138		109		26		135
Rapid Diagnostics		368		192		560		326		211		537
Total		803		1,023		1,826		724		1,117		1,841

Medical Devices -
Rhythm Management		228		246		474		252		262		514
Electrophysiology		164		224		388		174		231		405
Heart Failure		152		51		203		143		41		184
Vascular		230		395		625		266		443		709
Structural Heart		136		182		318		136		188		324
Neuromodulation		137		40		177		152		41		193
Diabetes Care		186		566		752		152		414		566
Total		1,233		1,704		2,937		1,275		1,620		2,895

Other		8		7		15		8		7		15
Total	$	2,856	$	4,870	$	7,726	$	2,754	$	4,781	$	7,535

Remaining Performance Obligations

As of March 31, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.4 billion in the Diagnostics segment and approximately $400 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter.

These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Other Contract Assets and Liabilities

Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Changes in the contract liabilities during the period are as follows:


(in millions)
Contract Liabilities
Balance at December 31, 2019	$	294
Unearned revenue from cash received during the period		105
Revenue recognized related to contract liability balance		(94)
Balance at March 31, 2020	$	305

Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended March 31, 2020 and 2019 were $541 million and $668 million, respectively. Net earnings allocated to common shares for the three months ended March 31, 2020 and 2019 were $561 million and $668 million, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2020 includes $320 million of pension contributions and the payment of cash taxes of approximately $125 million. The first three months of 2019 includes $313 million of pension contributions and the payment of cash taxes of approximately $185 million.

Earnings from discontinued operations, net of tax, in the first quarter of 2020 include the recognition of $20 million of tax benefits as a result of the resolution of various tax positions related to the previous sale of a business that was reported as a discontinued operation.

The following summarizes the activity for the first three months of 2020 related to the allowance for doubtful accounts as of March 31, 2020:


(in millions)
Allowance for Doubtful Accounts
Balance at December 31, 2019	$	228
Impact of adopting ASU 2016-13		7
Provisions/charges to income		21
Amounts charged off and other deductions		(15)
Balance at March 31, 2020	$	241

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivables. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of March 31, 2020 and December 31, 2019 are as follows:


	March 31,		December 31,
(in millions)	2020		2019
Long-term Investments
Equity securities	$	741	$	836
Other		49		47
Total	$	790	$	883

Abbott’s long-term investments as of March 31, 2020, declined versus the balance as of December 31, 2019, due in part to the impairment of an investment for approximately $50 million.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Abbott's equity securities as of March 31, 2020, include approximately $289 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of March 31, 2020 with a carrying value of approximately $275 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $162 million that do not have a readily determinable fair value. The $162 million carrying value includes cumulative unrealized gains of approximately $50 million.

In the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired a research & development (R&D) asset valued at $102 million, which was immediately expensed. The $102 million of expense was recorded in the R&D line of Abbott's Condensed Consolidated Statement of Earnings.

Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:


	Three Months Ended March 31
									Cumulative Gains
									(Losses) on
					Net Actuarial				Derivative
	Cumulative Foreign				(Losses) and Prior				Instruments
	Currency Translation				Service (Costs)				Designated as
	Adjustments				and Credits				Cash Flow Hedges
(in millions)	2020		2019		2020		2019		2020		2019
Balance at January 1	$	(4,924)	$	(4,912)	$	(3,540)	$	(2,726)	$	(1)	$	52
Other comprehensive income (loss) before reclassifications		(1,144)		122		7		(1)		176		(17)
Amounts reclassified from accumulated other comprehensive income		—		—		50		24		(10)		(12)
Net current period comprehensive income (loss)		(1,144)		122		57		23		166		(29)
Balance at March 31	$	(6,068)	$	(4,790)	$	(3,483)	$	(2,703)	$	165	$	23

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange (gain) loss; and amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 12 for additional details.

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $22.9 billion at March 31, 2020 and $23.2 billion at December 31, 2019. Foreign currency translation adjustments decreased goodwill by approximately $268 million in the first three months of 2020. The amount of goodwill related to reportable segments at March 31, 2020 was $2.8 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $16.1 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2020.

The gross amount of amortizable intangible assets, primarily product rights and technology was $27.3 billion as of March 31, 2020 and $27.6 billion as of December 31, 2019, and accumulated amortization was $12.3 billion as of March 31, 2020 and $11.9 billion as of December 31, 2019. Foreign currency translation adjustments decreased intangible assets by $204 million for the first three months of 2020. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2020, $2.0 billion in 2021, 2022, and 2023 and $1.9 billion in 2024.

Indefinite-lived intangible assets, which relate to in-process R&D acquired in a business combination, were approximately $1.2 billion and $1.3 billion as of March 31, 2020 and December 31, 2019, respectively.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Note 7 — Restructuring Plans

From 2017 to 2020, Abbott management approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the Medical Devices segment, and Alere Inc. (Alere) into the Diagnostic Products segment, in order to leverage economies of scale and reduce costs. In the first three months of 2020, charges of $9 million were recognized, of which $3 million is recorded in Cost of products sold, $1 million is recorded in Research and development and $5 million as Selling, general and administrative expense. The following summarizes the activity for the first three months of 2020 related to these actions and the status of the related accrual as of March 31, 2020:


(in millions)
Accrued balance at December 31, 2019	$	46
Restructuring charges recorded in 2020		9
Payments and other adjustments		(18)
Accrued balance at March 31, 2020	$	37

From 2017 to 2020, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first three months of 2020, charges of $23 million were recognized, of which $1 million is recorded in Cost of products sold, $1 million is recorded in Research and development and $21 million as Selling, general and administrative expense. The following summarizes the activity for the first three months of 2020 related to these restructuring actions and the status of the related accrual as of March 31, 2020:


(in millions)
Accrued balance at December 31, 2019	$	79
Restructuring charges recorded in 2020		23
Payments and other adjustments		(8)
Accrued balance at March 31, 2020	$	94

Note 8 — Incentive Stock Program

In the first three months of 2020, Abbott granted 3,956,637 stock options, 568,471 restricted stock awards and 5,042,550 restricted stock units under its incentive stock program. At March 31, 2020, approximately 112 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2020 is as follows:


	Outstanding		Exercisable
Number of shares		32,412,976		23,330,203
Weighted average remaining life (years)		6.5		5.5
Weighted average exercise price	$	53.83	$	44.69
Aggregate intrinsic value (in millions)	$	849	$	798

The total unrecognized share-based compensation cost at March 31, 2020 amounted to approximately $687 million which is expected to be recognized over the next three years.

Note 9 — Debt and Lines of Credit

On February 24, 2019, Abbott redeemed the $500 million outstanding principal amount of its 2.80% Notes due 2020.

Note 10 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.0 billion at March 31, 2020 and $6.8 billion at December 31, 2019 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2020 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2020 and December 31, 2019, Abbott held the gross notional amount of $9.5 billion and $9.1 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $554 million and $546 million as of March 31, 2020 and December 31, 2019, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at March 31, 2020 and December 31, 2019 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2020 and December 31, 2019:


	Fair Value - Assets					Fair Value - Liabilities
	March 31,		Dec. 31,			March 31,		Dec. 31,
(in millions)	2020		2019		Balance Sheet Caption	2020		2019		Balance Sheet Caption

Interest rate swaps designated as fair value hedges	$	216	$	48	Deferred income taxes and other assets	$	—	$	—	Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:
Hedging instruments		247		110	Prepaid expenses and other receivables		92		56	Other accrued liabilities
Others not designated as hedges		117		38	Prepaid expenses and other receivables		97		33	Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary		—		—	n/a		554		546	Long-term debt
	$	580	$	196		$	743	$	635

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2020 and 2019.


	Gain (loss) Recognized in Other				Income (expense) and Gain (loss)
	Comprehensive Income (loss)				Reclassified into Income
(in millions)	2020		2019		2020		2019		Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	227	$	(19)	$	11	$	15	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary		(8)		—		—		—	n/a

Interest rate swaps designated as fair value hedges		n/a		n/a		168		43	Interest expense

Losses of $165 million and gains of $49 million were recognized in the three months ended March 31, 2020 and 2019, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

The carrying values and fair values of certain financial instruments as of March 31, 2020 and December 31, 2019 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.


	March 31, 2020				December 31, 2019
	Carrying		Fair		Carrying		Fair
(in millions)	Value		Value		Value		Value

Long-term Investment Securities:
Equity securities	$	741	$	741	$	836	$	836
Other		49		49		47		47
Total Long-term Debt		(18,068)		(20,998)		(17,938)		(20,772)
Foreign Currency Forward Exchange Contracts:
Receivable position		364		364		148		148
(Payable) position		(189)		(189)		(89)		(89)
Interest Rate Hedge Contracts:
Receivable position		216		216		48		48

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:


			Basis of Fair Value Measurement
			Quoted		Significant
			Prices in		Other		Significant
	Outstanding		Active		Observable		Unobservable
(in millions)	Balances		Markets		Inputs		Inputs
March 31, 2020:
Equity securities	$	304	$	304	$	—	$	—
Interest rate swap derivative financial instruments		216		—		216		—
Foreign currency forward exchange contracts		364		—		364		—
Total Assets	$	884	$	304	$	580	$	—

Fair value of hedged long-term debt	$	3,064	$	—	$	3,064	$	—
Foreign currency forward exchange contracts		189		—		189		—
Contingent consideration related to business combinations		67		—		—		67
Total Liabilities	$	3,320	$	—	$	3,253	$	67

December 31, 2019:
Equity securities	$	357	$	357	$	—	$	—
Interest rate swap derivative financial instruments		48		—		48		—
Foreign currency forward exchange contracts		148		—		148		—
Total Assets	$	553	$	357	$	196	$	—

Fair value of hedged long-term debt	$	2,890	$	—	$	2,890	$	—
Foreign currency forward exchange contracts		89		—		89		—
Contingent consideration related to business combinations		68		—		—		68
Total Liabilities	$	3,047	$	—	$	2,979	$	68

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Note 11 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $90 million to $125 million. The recorded accrual balance at March 31, 2020 for these proceedings and exposures was approximately $110 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 12 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized in continuing operations for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:


	Defined Benefit Plans				Medical and Dental Plans
	March 31,		March 31,		March 31,		March 31,
(in millions)	2020		2019		2020		2019
Service cost - benefits earned during the period	$	85	$	64	$	12	$	6
Interest cost on projected benefit obligations		75		84		12		13
Expected return on plan assets		(192)		(178)		(7)		(7)
Net amortization of:
Actuarial loss, net		63		33		8		6
Prior service cost (credit)		—		—		(7)		(8)
Net cost - continuing operations	$	31	$	3	$	18	$	10

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2020 and 2019, $320 million and $313 million, respectively, were contributed to defined benefit plans and $11 million was contributed to the post-employment medical and dental benefit plans in each year.

Note 13 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2020, taxes on earnings from continuing operations include approximately $47 million in excess tax benefits associated with share-based compensation. Earnings from discontinued operations, net of tax, in the first three months of 2020 reflect the recognition of $20 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. In the first three months of 2019, taxes on earnings from continuing operations include a $78 million reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA) and approximately $65 million in excess tax benefits associated with share-based compensation.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between $230 million and $520 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through 2015 and the former St. Jude Medical consolidated group which are settled through 2013.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to the Condensed Consolidated Financial Statements

March 31, 2020

(Unaudited)

Note 14 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology and Heart Failure, Vascular, Neuromodulation, Structural Heart and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.


	Three Months Ended March 31
	Net Sales to				Operating
	External Customers				Earnings
(in millions)	2020		2019		2020		2019
Established Pharmaceutical Products	$	1,044	$	992	$	181	$	159
Nutritional Products		1,904		1,792		459		380
Diagnostic Products		1,826		1,841		405		434
Medical Devices		2,937		2,895		803		847
Total Reportable Segments		7,711		7,520		1,848		1,820
Other		15		15
Net sales	$	7,726	$	7,535
Corporate functions and benefit plans costs						(132)		(102)
Net interest expense						(121)		(148)
Share-based compensation (a)						(233)		(226)
Amortization of intangible assets						(561)		(486)
Other, net (b)						(168)		(226)
Earnings from continuing operations before taxes					$	633	$	632

(a)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three months ended March 31, 2019 also includes a charge associated with an R&D asset acquired and immediately expensed.

Table of Contents

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract impact which products are sold; price controls, competition and rebates impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.

During the first quarter of 2020, the coronavirus (COVID-19) pandemic affected Abbott’s diversified health care businesses in various ways. As is further described below, some businesses faced challenges, others have been relatively stable, and still others are performing at the levels required to successfully meet new demands. Beginning in February, cardiovascular and neuromodulation procedures and routine core laboratory diagnostic testing volumes declined in China as that country implemented quarantine restrictions and postponed non-emergency health care activities. As March progressed, procedures and routine testing volumes in China steadily improved from the low levels seen in February. As COVID-19 spread geographically, the impact initially expanded to certain countries in Asia and Europe beginning in late February, and more broadly across Europe and the U.S. during the last few weeks of March. As the health care industry in these countries shifted their focus to fighting COVID-19, the impact on cardiovascular and neuromodulation device procedures and routine diagnostic testing volumes was similar to what was experienced in China in February. Due to the critical nature of these products, Abbott anticipates increased demand when health care services return to more normal levels.

Abbott has mobilized its teams across multiple fronts to develop and launch three new diagnostic tests for COVID-19. In March, Abbott launched a molecular test to detect COVID-19 on its ID NOW™ rapid point-of-care platform in the U.S. pursuant to an Emergency Use Authorization (EUA). Abbott also launched a molecular test on its m2000™ RealTime lab-based platform to detect COVID-19 pursuant to an EUA in the U.S. and CE Mark. In April, Abbott launched a serology blood test on its ARCHITECT^® i1000SR and i2000SR laboratory instruments for the detection of an antibody to determine if someone was previously infected. The serology test was granted an EUA in the U.S. on April 26, 2020 and CE Mark on April 24, 2020.

Abbott is continually implementing business continuity plans in the face of the global crisis. Due to the critical nature of its products and services, Abbott is generally exempt from governmental orders in the U.S. and other countries requiring businesses to cease operations. To protect its employees, the majority of its office-based work is being conducted remotely and the company has implemented strict travel restrictions. Abbott has taken aggressive steps to limit exposure and enhance the safety of its facilities for employees working to continue to supply healthcare products to hospital and other customers.

With respect to Abbott’s financial position, at the end of the first quarter of 2020, Abbott’s cash and cash equivalents and short-term investments totaled approximately $3.7 billion and existing credit agreements are in place that would provide additional access to $5 billion, if needed.

Due to uncertainties regarding the duration and impact of the current COVID-19 pandemic, Abbott is unable to predict the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations.

Table of Contents

The following table details sales by reportable segment for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.


	Net Sales to External Customers
	Three Months		Three Months
	Ended		Ended				Impact of		Total Change
	March 31,		March 31,		Total		Foreign		Excl. Foreign
(in millions)	2020		2019		Change		Exchange		Exchange

Established Pharmaceutical Products	$	1,044	$	992	5.2	%	(4.1)	%	9.3	%
Nutritional Products		1,904		1,792	6.3		(1.0)		7.3
Diagnostic Products		1,826		1,841	(0.8)		(1.5)		0.7
Medical Devices		2,937		2,895	1.4		(1.5)		2.9
Total Reportable Segments		7,711		7,520	2.5		(1.8)		4.3
Other		15		15	5.3		(1.1)		6.4
Net sales	$	7,726	$	7,535	2.5		(1.8)		4.3

Total U.S.	$	2,856	$	2,754	3.7		—		3.7

Total International	$	4,870	$	4,781	1.8		(2.8)		4.6

Note: In order to compute results excluding the impact of foreign exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Net sales growth in 2020, excluding the impact of foreign exchange, was driven by growth in the Established Pharmaceuticals and Nutritional Products reportable segments.

Excluding the impact of foreign exchange, total net sales increased 4.3 percent in the first quarter of 2020. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first quarter as the relatively stronger U.S. dollar decreased total international sales by 2.8 percent and total sales by 1.8 percent.

Table of Contents

The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.


							Impact of		Total Change
	March 31,		March 31,		Total		Foreign		Excl. Foreign
(in millions)	2020		2019		Change		Exchange		Exchange
Established Pharmaceutical Products —
Key Emerging Markets	$	813	$	752	8.1	%	(5.0)	%	13.1	%
Other Emerging Markets		231		240	(3.7)		(1.0)		(2.7)

Nutritionals —
International Pediatric Nutritionals		571		576	(0.8)		(1.0)		0.2
U.S. Pediatric Nutritionals		518		453	14.3		—		14.3
International Adult Nutritionals		521		469	11.2		(2.6)		13.8
U.S. Adult Nutritionals		294		294	0.1		—		0.1

Diagnostics —
Core Laboratory		989		1,061	(6.8)		(1.9)		(4.9)
Molecular		139		108	29.1		(1.2)		30.3
Point of Care		138		135	2.4		(0.3)		2.7
Rapid Diagnostics		560		537	4.3		(1.1)		5.4

Medical Devices -
Rhythm Management		474		514	(7.9)		(1.4)		(6.5)
Electrophysiology		388		405	(4.0)		(1.1)		(2.9)
Heart Failure		203		184	9.9		(0.7)		10.6
Vascular (a)		625		709	(11.9)		(1.1)		(10.8)
Structural Heart		318		324	(1.8)		(1.6)		(0.2)
Neuromodulation		177		193	(8.7)		(0.9)		(7.8)
Diabetes Care		752		566	32.9		(2.7)		35.6

(a) Vascular Product Lines:
Coronary and Endovascular		603		675	(10.7)		(1.2)		(9.5)

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased 13.1 percent compared to the first three months of 2019 led by growth in Russia and various countries in Latin America and southeast Asia. Other Emerging Markets, excluding the effect of foreign exchange, decreased by 2.7 percent in the first three months of 2020.

International Pediatric Nutritional sales, excluding the effect of foreign exchange, were relatively flat in the first three months of 2020 versus the comparable 2019 period. Growth across Abbott’s pediatric products in various countries in Asia and Latin America along with higher consumer purchases in several countries in advance of shelter in place restrictions related to the COVID-19 pandemic were offset by challenging market dynamics in the Greater China infant category, including the unfavorable impact of COVID-19. U.S. Pediatric Nutritional sales increased 14.3 percent primarily due to increased demand in late March in advance of shelter in place restrictions related to the COVID-19 pandemic. The 13.8 percent increase in International Adult Nutritional sales, excluding the effect of foreign exchange, reflects continued growth of the Glucerna^® and Ensure^® brands in several countries. U.S. Adult Nutritional sales were relatively flat due to the timing of retailer stocking for promotional programs.

In the Diagnostics segment, Core Laboratory sales decreased 4.9 percent, excluding the effect of foreign exchange, as the volume of routine testing performed in hospital and other laboratories was negatively impacted by COVID-19. In April 2020, Abbott launched a lab-based serology blood test for the detection of the antibody, IgG, that identifies if a person was previously infected with COVID-19. The 30.3 percent increase in Molecular Diagnostics sales, excluding the effect of foreign exchange, reflects higher volumes due to the launch in March 2020 of Abbott’s RealTime SARS-CoV-2 test for use on Abbott’s m2000 RealTime System to detect COVID-19.

In Rapid Diagnostics, sales increased 5.4 percent, excluding the effect of foreign exchange, as increased testing for flu in the U.S. was partially offset by the unfavorable impact of COVID-19 on routine diagnostic testing performed in various countries outside of the U.S. In late March, Abbott launched a molecular test for the detection of COVID-19 that is run on Abbott’s point-of-care ID NOW instruments.

Excluding the effect of foreign exchange, total Medical Devices sales grew 2.9 percent; the increase was driven by double-digit growth in Diabetes Care and Heart Failure partially offset by the impact of the COVID-19 pandemic on Abbott’s other medical device businesses. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre^®, Abbott’s continuous glucose monitoring system, internationally and in the U.S. FreeStyle Libre sales totaled $604 million in the first quarter of 2020, which reflected a 62.5 percent increase, excluding the effect of foreign exchange, over the first three months of 2019 when Libre sales totaled $379 million.

Table of Contents

In Heart Failure, sales growth was driven by continued market adoption of Abbott's HeartMate 3^® Left Ventricular Assist Device (LVAD) for people living with advanced heart failure as well as increased sales of Abbott’s CentriMag™ circulatory support system for use in acute hospital care. In Abbott’s other cardiovascular and neuromodulation businesses, revenues were negatively impacted by reduced procedure volumes due to the COVID-19 pandemic.

In April 2017, Abbott received a warning letter from the U.S. Food and Drug Administration (FDA) related to its manufacturing facility in Sylmar, CA which was acquired by Abbott on January 4, 2017 as part of the acquisition of St. Jude Medical. This facility manufactures implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and monitors. Abbott prepared and executed a comprehensive plan of corrective actions. On April 28, 2020, Abbott received a letter from the FDA indicating that, based on the FDA’s evaluation, it appeared that Abbott had addressed the items in the warning letter. As a result, the warning letter is considered closed.

The gross profit margin percentage was 50.3 percent for the first quarter of 2020 compared to 51.6 percent for the first quarter of 2019. The decrease primarily reflects the increase in intangible amortization expense and the unfavorable effect of foreign exchange on gross margin in 2020.

Research and development expenses decreased $94 million, or 14.1 percent, in the first quarter of 2020. The 2020 decrease in R&D expense was primarily driven by the immediate expensing of an R&D asset valued at $102 million in the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc. For the three months ended March 31, 2020, research and development expenditures totaled $309 million for the Medical Devices segment, $134 million for the Diagnostic Products segment, $46 million for the Nutritional Products segment and $43 million for the Established Pharmaceutical Products segment.

Selling, general and administrative (SG&A) expenses for the first quarter of 2020 increased 2.8 percent due primarily to higher selling and marketing costs to drive growth across various businesses.

Restructuring Plans

The results for the first three months of 2020 reflect charges under approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical and Alere or as a part of various cost reduction programs. Abbott recorded employee related severance and other charges of $32 million in the first three months of 2020 related to these initiatives, of which $4 million is recognized in Cost of products sold, $2 million is recognized in Research and development and $26 million is recognized in SG&A. See Note 7 to the financial statements, “Restructuring Plans,” for additional information regarding these charges.

Other (Income) Expense, net

Other (income) expense, net decreased $46 million in the first quarter of 2020 from $47 million of income in 2019 to $1 million in 2020. The decrease in income in the first quarter of 2020 as compared to 2019 was due to an impairment of an equity investment of approximately $50 million in 2020.

Interest Expense, net

Interest expense, net decreased $27 million in the first quarter of 2020 due to a reduction in interest expense resulting from the favorable impact of the euro debt financing in November of 2019 and the repayment of debt in 2019.

Taxes on Earnings

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between $230 million and $520 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott's federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through 2015 and the former St. Jude Medical consolidated group which are settled through 2013.

Liquidity and Capital Resources March 31, 2020 Compared with December 31, 2019

The reduction of cash and cash equivalents from $3.9 billion at December 31, 2019 to $3.4 billion at March 31, 2020 primarily reflects the payment of dividends and capital expenditures, partially offset by cash generated from operations in the first three months of 2020. Working capital was $4.7 billion at March 31, 2020 and $4.8 billion at December 31, 2019. The decrease in working capital in 2020 primarily reflects the decrease in cash and cash equivalents partially offset by an increase in inventory.

Table of Contents

In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first three months of 2020 totaled $715 million, an increase of $3 million over the prior year as the negative impact of an increased investment in working capital was offset by lower cash taxes paid and higher operating earnings. Other, net in Net cash from operating activities for the first three months of 2020 was a use of $369 million and includes $320 million of pension contributions and the payment of cash taxes of approximately $125 million. Other, net in Net cash from operating activities for the first three months of 2019 was a use of $483 million and includes $313 million of pension contributions and the payment of cash taxes of approximately $185 million.

In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. This bond redemption authorization superseded the board’s previous authorization under which $700 million had not yet been redeemed. In December 2019, Abbott redeemed $2.850 billion of debt. After this redemption, $2.15 billion of the $5 billion debt redemption authorization remains available.

At March 31, 2020, Abbott’s long-term debt rating was A- by Standard & Poor’s Corporation and A3 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2023.

In October 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott’s common shares from time to time. The new authorization is in addition to the $270 million unused portion of the share repurchase program authorized in 2014.

On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to $3 billion. No shares have been issued under this authorization.

In the first quarter of 2020, Abbott declared a quarterly dividend of $0.36 per share on its common shares, which represents an increase of approximately 12.5 percent over the $0.32 per share dividend declared in the first quarter of 2019.

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2019 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties, including the impact of the COVID-19 pandemic on Abbott's operations and financial results, that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors'', in the 2019 Annual Report on Form 10-K and in Item 1A, “Risk Factors”, in the quarterly report for the quarter ended March 31, 2020. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 4.Controls and Procedures

(a)

Evaluation of disclosure controls and procedures. The President and Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b)

Changes in internal control over financial reporting. During the quarter ended March 31, 2020, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, 2019.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019, except for the following:

Abbott is subject to risks related to public health crises, such as widespread outbreaks of infectious diseases like the COVID-19 pandemic.

As a global healthcare company, public health crises, such as the widespread outbreaks of infectious diseases like the COVID-19 pandemic, may negatively impact Abbott's operations. Health concerns and significant changes in political or economic conditions caused by such outbreaks can cause significant reductions in demand for routine diagnostic testing and medical device procedures or increased difficulty in serving customers, disrupt manufacturing and supply chains, and negatively affect our operations as well as the operations of our suppliers, distributors and other third-party partners. Furthermore, such widespread outbreaks may impact the broader economies of affected countries, including negatively impacting economic growth, the proper functioning of financial and capital markets, foreign currency exchange rates, and interest rates. Due to uncertainties regarding the duration and impact of the current COVID-19 pandemic, Abbott is unable to predict the extent to which the COVID-19 pandemic may have a material effect on its business, financial condition or results of operations.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds


						(d) Maximum
						Number (or
					(c) Total Number	Approximate
					of Shares (or	Dollar Value) of
	(a) Total				Units) Purchased	Shares (or Units)
	Number of		(b) Average		as Part of	that May Yet Be
	Shares (or		Price Paid per		Publicly	Purchased Under
	Units)		Share (or		Announced Plans	the Plans or
Period	Purchased		Unit)		or Programs	Programs
January 1, 2020 - January 31, 2020	2,957	⁽¹⁾	$	85.89	0	$	3,270,234,923	⁽²⁾
February 1, 2020 - February 29, 2020	0	⁽¹⁾	$	0	0	$	3,270,234,923	⁽²⁾
March 1, 2020 - March 31, 2020	0	⁽¹⁾	$	0	0	$	3,270,234,923	⁽²⁾
Total	2,957	⁽¹⁾	$	85.89	0	$	3,270,234,923	⁽²⁾

(1) These shares include the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 2,957 in January, 0 in February, and 0 in March.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

(2) On September 11, 2014, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2014 Plan”). On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time (the “2019 Plan”). The 2019 Plan is in addition to the unused portion of the 2014 Plan.

Table of Contents

Item 6. Exhibits


Exhibit No.		Exhibit

3.1		By-Laws of Abbott Laboratories, as amended and restated, effective April 24, 2020, filed as Exhibit 3.1 to the Abbott Laboratories Current Report on Form 8-K filed on February 27, 2020.

31.1		Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2		Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders' Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements.

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101).

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


ABBOTT LABORATORIES


By:	/s/ Robert E. Funck, Jr.
	Robert E. Funck, Jr.
	Executive Vice President, Finance and Chief Financial Officer

	Date: April 29, 2020

EX-31.1 2 abt-20200331xex31d1.htm EXHIBIT 31.1 abt_Ex31_1

Exhibit 31.1

Certification of Chief Executive Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Robert B. Ford, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;

4. Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and

5. Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: April 29, 2020

/s/ Robert B. Ford

Robert B. Ford

President and

Chief Executive Officer

EX-31.2 3 abt-20200331xex31d2.htm EXHIBIT 31.2 abt_Ex31_2

Exhibit 31.2

Certification of Chief Financial Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Robert E. Funck, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: April 29, 2020

/s/ Robert E. Funck, Jr.

Robert E. Funck, Jr.

Executive Vice President, Finance

and Chief Financial Officer

EX-32.1 4 abt-20200331xex32d1.htm EXHIBIT 32.1 abt_Ex32_1

Exhibit 32.1

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert B. Ford
Robert B. Ford
President and
Chief Executive Officer
April 29, 2020

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 abt-20200331xex32d2.htm EXHIBIT 32.2 abt_Ex32_2

Exhibit 32.2

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2020 as filed with the Securities and Exchange Commission (the “Report”), I, Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
April 29, 2020

EX-101.SCH 6 abt-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Statement of Earnings link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 41005 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Post-Employment Benefits - (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statement of Shareholders' Investment link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Incentive Stock Program link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Debt and Lines of Credit link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Incentive Stock Program (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 31403 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue - Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Revenue - Remaining Performance Obligations Default (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Revenue - Practical Expedient (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Supplemental Financial Information - Income Statement (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Supplemental Financial Information - Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Supplemental Financial Information - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - Supplemental Financial Information - General (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Restructuring Plans (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Incentive Stock Program - General (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Incentive Stock Program - Options (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Debt and Lines of Credit (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - New Accounting Standards link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - New Accounting Standards (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 abt-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 abt-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 abt-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information Document Information [Table] Document Information [Line Items] Document and Entity Information Document Type Document Transition Report Document Quarterly Report Document Period End Date Entity File Number Entity Registrant Name Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Trading Symbol Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Statement of Earnings Statement [Table] Statement Statement Revenue from Contract with Customer, Excluding Assessed Tax Net sales Net Sales to External Customers Cost of Goods Sold Cost of products sold, excluding amortization of intangible assets The aggregate expense (excluding discontinued operations) charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Amortization of Intangible Assets Excluding Discontinued Operations Amortization of intangible assets Amortization of intangible assets Research and Development Expense Research and development Selling, General and Administrative Expense. Selling, general and administrative Costs and Expenses Total operating cost and expenses Operating Income (Loss) Operating Earnings Operating earnings Interest Expense. Interest expense Investment Income, Interest Interest (income) Foreign Currency Transaction Gain (Loss), before Tax Net foreign exchange (gain) loss Other Nonoperating Income (Expense) Other (income) expense, net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings from continuing operations before taxes Income Tax Expense (Benefit) Tax expense (benefit) on earnings from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Earnings from continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Earnings from discontinued operations, net of tax Net Income (Loss) Attributable to Parent Net earnings Net Earnings Net Earnings Earnings Per Share, Basic [Abstract] Basic Earnings Per Common Share Income (Loss) from Continuing Operations, Per Basic Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Discontinued operations (in dollars per share) Earnings Per Share, Basic Net earnings (in dollars per share) Earnings Per Share, Diluted [Abstract] Diluted Earnings Per Common Share Income (Loss) from Continuing Operations, Per Diluted Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Discontinued operations (in dollars per share) Earnings Per Share, Diluted Net earnings (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding Common Stock Options Having No Dilutive Effect (in shares) Condensed Consolidated Statement of Comprehensive Income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation gain (loss) adjustments Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $15 in 2020 and $7 in 2019 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $48 in 2020 and $(8) in 2019 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Net current period comprehensive income (loss) Other comprehensive income (loss) Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive Income (Loss) Changes in Accumulated Other Comprehensive Income (Loss) Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax Net actuarial (losses) and prior service (cost) and credits AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Cumulative gains (losses) on derivative instruments designated as cash flow hedges Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss) Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (costs) and credits, taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Net gains (losses) for derivative instruments designated as cash flow hedges, taxes Condensed Consolidated Balance Sheet Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Short-term Investments Short-term investments Accounts Receivable, Net, Current Trade receivables, less allowances of $389 in 2020 and $384 in 2019 Inventory, Net [Abstract] Inventories: Inventory, Finished Goods, Net of Reserves Finished products Inventory, Work in Process, Net of Reserves Work in process Inventory, Raw Materials, Net of Reserves Materials Inventory, Net Total inventories Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer. Prepaid Expense and Other Receivables Prepaid expenses and other receivables Assets, Current Total Current Assets Long-term Investments Investments Long-term Investments Property, Plant and Equipment, Gross Property and equipment, at cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Property, Plant and Equipment, Net Net property and equipment Intangible Assets, Net (Excluding Goodwill) Intangible assets, net of amortization Goodwill Goodwill Deferred Income Taxes and Other Assets, Noncurrent Deferred income taxes and other assets Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Investment Liabilities, Current [Abstract] Current Liabilities: Short-term Debt Short-term borrowings Accounts Payable, Trade, Current Trade accounts payable Employee-related Liabilities, Current Salaries, wages and commissions Other Accrued Liabilities, Current Other accrued liabilities Dividends Payable, Current Dividends payable Income taxes payable Long-term Debt, Current Maturities Current portion of long-term debt Liabilities, Current Total Current Liabilities Long-term Debt, Excluding Current Maturities Long-term debt Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer. Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities Post-employment obligations, deferred income taxes and other long-term liabilities Commitments and Contingencies Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Shareholders' Investment: Preferred Stock, Value, Issued Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued Common Stock, Value, Issued Common shares, without par value Authorized - 2,400,000,000 shares, Issued at stated capital amount - Shares: 2020: 1,978,112,501; 2019: 1,976,855,085 Treasury Stock, Common, Value Common shares held in treasury, at cost - Shares: 2020: 209,267,175 ; 2019: 214,351,838 Retained Earnings (Accumulated Deficit) Earnings employed in the business Stockholders' Equity Attributable to Parent End of the period Beginning of the period Total Abbott Shareholders' Investment Stockholders' Equity Attributable to Noncontrolling Interest Noncontrolling Interests in Subsidiaries Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance at end of period Balance at beginning of period Total Shareholders' Investment Liabilities and Equity Total Liabilities and Shareholders' Investment Allowance for Doubtful Accounts Receivable, Current Trade receivables, allowances (in dollars) Preferred Stock, Par or Stated Value Per Share Preferred shares, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred shares, authorized shares Preferred Stock, Shares Issued Preferred shares, issued shares Common Stock, Shares Authorized Common shares, authorized shares Common Stock, Shares, Issued Common shares, issued shares Treasury Stock, Common, Shares Common shares held in treasury, shares Condensed Consolidated Statement of Shareholders' Investment Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Shareholders' Investment Stock Issued During Period, Value, Stock Options Exercised Issued under incentive stock programs Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Share-based compensation Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock awards Treasury Stock, Value, Acquired, Cost Method Purchased Cumulative Effect of New Accounting Principle in Period of Adoption Impact of adoption of new accounting standards Dividends, Common Stock, Cash Cash dividends declared on common shares This element represents the effect on retained earning due to common and treasury stock transactions. Effect of Common and Treasury Share Transactions Effect of common and treasury share transactions This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations. Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations Noncontrolling Interests' share of income, business combinations, net of distributions and share repurchases Common Stock, Shares, Outstanding Balance at end of period (in shares) Balance at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issued under incentive stock programs (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issued under incentive stock programs (in shares) Treasury Stock, Shares, Acquired Purchased (in shares) Common Stock, Dividends, Per Share, Declared Cash dividends declared per common share Condensed Consolidated Statement of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flow From (Used in) Operating Activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net earnings Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net earnings to net cash from operating activities - Depreciation Depreciation Amortization of Intangible Assets Amortization of intangible assets Share-based Compensation Share-based compensation Increase (Decrease) in Accounts Receivable Trade receivables Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Operating Assets and Liabilities, Net Other, net Net Cash Provided by (Used in) Operating Activities Net Cash From Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flow From (Used in) Investing Activities: Payments to Acquire Property, Plant, and Equipment Acquisitions of property and equipment The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets. Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process Acquisitions of businesses and technologies, net of cash acquired Payments for (Proceeds from) Investments Sales (purchases) of other investment securities, net Payments for (Proceeds from) Other Investing Activities Other Net Cash Provided by (Used in) Investing Activities Net Cash (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flow From (Used in) Financing Activities: Proceeds from (Repayments of) Short-term Debt Net borrowings (repayments) of short-term debt and other Repayments of Long-term Debt Repayments of long-term debt Payments for Repurchase of Common Stock Purchases of common shares Proceeds from Stock Options Exercised Proceeds from stock options exercised Payments of Ordinary Dividends, Common Stock Dividends paid Net Cash Provided by (Used in) Financing Activities Net Cash (Used in) Financing Activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net Decrease in Cash and Cash Equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents, End of Period Cash and Cash Equivalents, Beginning of Year Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation New Accounting Standards New Accounting Pronouncements and Changes in Accounting Principles [Text Block] New Accounting Standards Revenue Revenue from Contract with Customer [Text Block] Revenue Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Supplemental Financial Information Comprehensive Income (Loss) Note [Text Block] Changes in Accumulated Other Comprehensive Income (Loss) Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Restructuring Plans Incentive Stock Program Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Incentive Stock Program Debt and Lines of Credit Debt Disclosure [Text Block] Debt and Lines of Credit Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Financial Instruments, Derivatives and Fair Value Measures Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Litigation and Environmental Matters Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Post-Employment Benefits Taxes on Earnings Income Tax Disclosure [Text Block] Taxes on Earnings Segment Information EX-101.PRE 10 abt-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statement of Comprehensive Income
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (costs) and credits, taxes	$ 15	$ 7
Net gains (losses) for derivative instruments designated as cash flow hedges, taxes	$ 48	$ (8)

XML 13 R50.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 580	$ 196
Fair Value - Liabilities	743	635
Designated as hedging instrument \| Interest rate swaps \| Deferred income taxes and other assets \| Fair value hedges
Derivative instruments, notional amount and fair value
Fair Value - Assets	216	48
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	247	110
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	92	56
Designated as hedging instrument \| Debt \| Long-term Debt \| Net investment hedges
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	554	546
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	117	38
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	$ 97	$ 33

XML 14 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Shareholders' Investment (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Increase (Decrease) in Shareholders' Investment
Cash dividends declared per common share	$ 0.36	$ 0.32
Common Shares:
Increase (Decrease) in Shareholders' Investment
Balance at beginning of period (in shares)	1,976,855,085	1,971,189,465
Issued under incentive stock programs (in shares)	1,257,416	2,283,041
Balance at end of period (in shares)	1,978,112,501	1,973,472,506
Common Shares Held in Treasury:
Increase (Decrease) in Shareholders' Investment
Balance at beginning of period (in shares)	214,351,838	215,570,043
Issued under incentive stock programs (in shares)	5,333,626	6,544,927
Purchased (in shares)	248,963	266,128
Balance at end of period (in shares)	209,267,175	209,291,244

XML 15 R54.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters (Details) $ in Millions	Mar. 31, 2020 USD ($)
Loss Contingencies
Maximum expected cleanup exposure for individual site	$ 4
Maximum expected cleanup exposure in aggregate	10
Legal proceedings and environmental exposures
Loss Contingencies
Recorded accrual balance for legal proceedings and exposures	110
Legal proceedings and environmental exposures \| Minimum
Loss Contingencies
Estimation of possible loss	90
Legal proceedings and environmental exposures \| Maximum
Loss Contingencies
Estimation of possible loss	$ 125

XML 16 R12.htm IDEA: XBRL DOCUMENT

Revenue

3 Months Ended

Mar. 31, 2020

Revenue

Revenue

Note 3 — Revenue

The following table provides revenues by sales category:


	Three Months Ended March 31, 2020						Three Months Ended March 31, 2019
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	813	$	813	$	—	$	752	$	752
Other		—		231		231		—		240		240
Total		—		1,044		1,044		—		992		992

Nutritionals —
Pediatric Nutritionals		518		571		1,089		453		576		1,029
Adult Nutritionals		294		521		815		294		469		763
Total		812		1,092		1,904		747		1,045		1,792

Diagnostics —
Core Laboratory		267		722		989		249		812		1,061
Molecular		65		74		139		40		68		108
Point of Care		103		35		138		109		26		135
Rapid Diagnostics		368		192		560		326		211		537
Total		803		1,023		1,826		724		1,117		1,841

Medical Devices -
Rhythm Management		228		246		474		252		262		514
Electrophysiology		164		224		388		174		231		405
Heart Failure		152		51		203		143		41		184
Vascular		230		395		625		266		443		709
Structural Heart		136		182		318		136		188		324
Neuromodulation		137		40		177		152		41		193
Diabetes Care		186		566		752		152		414		566
Total		1,233		1,704		2,937		1,275		1,620		2,895

Other		8		7		15		8		7		15
Total	$	2,856	$	4,870	$	7,726	$	2,754	$	4,781	$	7,535

Remaining Performance Obligations

Other Contract Assets and Liabilities

Changes in the contract liabilities during the period are as follows:


(in millions)
Contract Liabilities
Balance at December 31, 2019	$	294
Unearned revenue from cash received during the period		105
Revenue recognized related to contract liability balance		(94)
Balance at March 31, 2020	$	305

XML 17 R16.htm IDEA: XBRL DOCUMENT

Restructuring Plans

3 Months Ended

Mar. 31, 2020

Restructuring Plans

Restructuring Plans

Note 7 — Restructuring Plans


(in millions)
Accrued balance at December 31, 2019	$	46
Restructuring charges recorded in 2020		9
Payments and other adjustments		(18)
Accrued balance at March 31, 2020	$	37


(in millions)
Accrued balance at December 31, 2019	$	79
Restructuring charges recorded in 2020		23
Payments and other adjustments		(8)
Accrued balance at March 31, 2020	$	94

XML 18 R35.htm IDEA: XBRL DOCUMENT

Revenue - Practical Expedient (Details)	3 Months Ended
Revenue - Practical Expedient (Details)	Mar. 31, 2020
Revenue
Practical expedient in remaining performance obligations related to contracts	true

XML 19 R31.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Tables)

3 Months Ended

Mar. 31, 2020

Post-Employment Benefits

Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans


	Defined Benefit Plans				Medical and Dental Plans
	March 31,		March 31,		March 31,		March 31,
(in millions)	2020		2019		2020		2019
Service cost - benefits earned during the period	$	85	$	64	$	12	$	6
Interest cost on projected benefit obligations		75		84		12		13
Expected return on plan assets		(192)		(178)		(7)		(7)
Net amortization of:
Actuarial loss, net		63		33		8		6
Prior service cost (credit)		—		—		(7)		(8)
Net cost - continuing operations	$	31	$	3	$	18	$	10

XML 20 R39.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information - Allowance for Doubtful Accounts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Allowances for Doubtful Accounts and Product Returns
Balance at beginning period	$ 228
Impact of adopting ASU 2016-13	241
Provisions/charges to income	21
Amounts charged off and other deductions	(15)
Balance at end of period	241
Restatement Adjustment \| 2016-13
Allowances for Doubtful Accounts and Product Returns
Impact of adopting ASU 2016-13	7
Balance at end of period	$ 7

EXCEL 21 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�)6?6@/0&Y,. ^N [ M93[43\*(U4*K:Z2[MW42KBC0([')W+I#GSO_GXVVM:>7%C!4R!A-0D(!Z GJ3!A*DH<-D M'M-X3/I >! )",*P% 9*85,I<\G@( &_/QD92) !R:!!,CH,&\6)BHSGC*4Y M"U("0A'*"\IG9.6@K!R0%?A:YU-?F&44A:]IBL,X)RF=*>P"%%0 @@)'ZP(* M/D=658H"32"4T,Q".2P+I? WG4Z%<3)#,=,6T/U%A,#/_@GA.\JH!]V\"$0) M0SD)>P0(92Q+4SH7&]PL$+FCD'K0V!LCA' <5A( Y(S2 F35*ZF8$6"%,:"$M&XZN6 M^N G?1MMU;DQ;DZ,3H?;Q!-VXR\X7[M;AA^+'S3=%>6[T(>R::,79>QP]2-P MKY215FGZ8#4>[:UHV%1R;]PRLVO=70VZC5&G_MJ3#'>OU7]02P,$% @ M%8*=4'8M&%K P (!$ !@ !X;"]W;W)K8Q9G73[;?NK%3O?:^KIEO[Y[Z_/ =!MS^KNN@^Z(MJS#]'W=9% M;R[;4]!=6E47EMS%=RC',I:-5VI&Z]5Q[7_(IYWE \= M1L4_I;IUBW-O*.5-ZV_#Q\ZA MX_+\9_0_Q^)-,6]%IW:Z^K<\].>UG_G>01V+:]5_T;>_U%Q0['MS]9_4NZJ, M?'!BHQ@K=?%].I;->+Q-_Z39W UWH+D#W3N8W+_K(.<. M\E>':"Q^.]VM2S%,"O$LS6#NA\9Q[,;_3+6=:7W?B#1; M!>]#H%FSG32TU-P5@8E^3T$HQ9:L[C'+L .2'*>0L HY]I<,*\[6Q-E"?:101^9/2 \R3:SBY7,[ YHR&$D MAT9R<&>(&Y*Y90:J7%,30U'D]NS. M'6-+F&4$6,:];LFF5,R7&J 1#G 0YA@!CN6<8P0(95D!FCAT,)XPQ0A0+.<4 M(QM03V3-?Z@2CMPDW(ZT$O$G=@,! ) #'G0"2 ND1:KZY M%2>.9Y(P$ D ,>=OX82 */F"@U1"1*XG"H.3 #AS#DX"X$SY<@%$D<,*!B?9 MX*20@Y-L*CZL^;,7H,K(-3*8GF33DT).3[*Y*#-K)86JR#4ZF)YDOU-2R-\I M9]%R4R)ERE_CD"JT1B=8["MKU9[&+7CG[?6UZ8<-W*+UOLU_H6%?RMJW9OL_ M;=9_A9F^'7PNVE/9=-Z;[LVN=]R;'K7NE3$9?C"C=5;%X7Y1J6,_G*;FO)WV M[--%KR_S]XC@_E%D\S]02P,$% @ %8*=4,8X6Z&U 0 TP, !D !X M;"]W;W)K&UL?5/1;IPP$/P5RQ\0?;! E9LEMKF2/^^MB&$MC0OV+O,S,[:ZVQ$\V1; $>>M>IL3EOG M^B-CMFQ!"WN#/73^3XU&"^=#TS#;&Q!5)&G%>)*\8UK(CA99S)U-D>'@E.S@ M;(@=M!;FUPD4CCG=T9?$@VQ:%Q*LR'K1P#=PW_NS\1%;5"JIH;,2.V*@SNG= M[GA* SX"?D@8[6I/0B<7Q*<0?*YRF@1#H*!T04'XY0KWH%00\C9^SIIT*1F( MZ_V+^L?8N^_E(BSJ"D@EH,RCW@^ GF?FXIF9O_ E=0'AZ<^!HE M*AN_I!RL0SVK>"M:/$^K[.(Z3G\XGVG;!#X3^$(XQ#IL*A2=?Q!.%)G!D9CI M['L1KGAWY/YLRI",1Q'_>?/69Z\%3_89NP:A&7.:,'R%V2T(YM67$GRKQ(G_ M0[\];//WFQ;WD;__C\4_!-)-@30*I&_VN(5)_RK"5H>JP31QG"PI<>CB**^R MR\3>Q5MDK_!IW+\*T\C.D@LZ?[7Q FI$!]Y*9L M"ASV\Q-BRSLN?@-02P,$% @ %8*=4'PM&UL?5-;;MLP$+P*P0.$,FVGAB$)B%,4#= M1HJVW[2T>B!\*"1E);?ODE)4M57[(W)7,[.SY#(=C'UV#8 GKTIJE]'&^^[( MF"L:4,+=F XT_JF,5<)C:&OF.@NBC"0E&4^26Z9$JVF>QMS9YJGIO6PUG"UQ MO5+"OIU FB&C&_J>>&KKQH<$R]-.U/ 5_+?N;#%BLTK9*M"N-9I8J#)ZMSF> M=@$? =];&-QB3T(G%V.>0_!09C0)AD!"X8."P.4*]R!E$$(;+Y,FG4L&XG+_ MKOXI]HZ]7(2#>R-_M*5O,GJ@I(1*]-(_F>$S3/WL*9F:_P)7D @/3K!&8:2+ M7U+TSALUJ: 5)5['M=5Q'<8_?#_1U@E$O"9<(AUV%@H.O\HO,A3:P9BQ[/O M1+CBS9'CV10A&8\B_D/S#K/7G"?[E%V#T(0YC1B^P&QF!$/UN01?*W'B?]'W MAW7^=M7B-O*W_[#XF\!N56 7!7;_[7$-<_M'$;8X5 6VCN/D2&%Z'4=YD9TG M]H['2_D%'\?]4=BZU8YKC1=0&>,!K20W.$,-OK YD%#YL/V >SO.V1AX MTTU/B,WO./$4$L#!!0 ( !6"G5"O7#@IL0$ -(# 9 >&PO=V]R M:W-H965TIVF35NG4 M:MOG'!B(FA"6A*/]]W4"1]G&^H78YOGYV7'2P=AGUP!X\J)5ZS+:>-_M&7-% M UJX*]-!BW\J8[7PZ-J:NFA6QIGL;8T>:IZ;V2+1PM<;W6 MPKX>0)DAHQMZ"3S*NO$AP/*T$S4\@?_1'2UZ;&8II8;62=,2"U5&[S;[PR[@ M(^"GA,$M;!(Z.1GS')QO94:3( @4%#XP"#S.< ]*!2*4\7OBI'/)D+BT+^Q? M8N_8RTDXN#?JERQ]D]%;2DJH1*_\HQF^PM3/-253\]_A# KA00G6*(QR\4N* MWGFC)Q:4HL7+>,HVGL.%GWV YQ.>O^-C&3;6B<(_"R_RU)J!V''TG0@WO-ES M'$T1@G$2\1]J=Q@]YSRY2=DY$$V8PXCA"\QF1C!DGTOPM1('_D_Z]>UZ_G95 MXC;F;_\C\0^"W2K!+A+L/NQQ#?.W2K88J@9;QVURI#!]&S=Y$9T7]H['2WF' MC]O^(&PM6T=.QN/5Q@NHC/& 4I(K7*$&']CL**A\,&_0MN.:C8XWW?2"V/R, M\S=02P,$% @ %8*=4*K;1A:V 0 TP, !D !X;"]W;W)K&UL?5-_CY0P$/TJ33_ %=A=73= V=%@Y1T7]H9WCOS9MVFH_&/KD.P)-G);4K:.=]?V+,51TH[NY,#QK_ M-,8J[C&T+7.]!5Y'DI(L2Y)73'&A:9G'W,66N1F\%!HNEKA!*6Y_G$&:L: I M?4D\BK;S(<'*O.0K!A[J@23 $$BH?%#@N-W@ *8,0VO@^:]*E9""N]R_J[V+OV,N5.W@P M\INH?5?0(R4U-'R0_M&,[V'NYT#)W/Q'N(%$>'""-2HC7?R2:G#>J%D%K2C^ M/*U"QW6<_NP.,VV;D,V$;"$<8QTV%8K.WW+/R]R:D=CI['L>KC@]97@V54C& MHXC_T+S#[*W,DC,-D*DRX(ANI+B6RKQ#G[BWXX;O-WFQ9WD;_[ MA\7?!/:; OLHL/]OCQN8-/FC"%L=J@+;QG%RI#*#CJ.\RBX3>Y_%2_D%G\;] M$[>MT(YKC1?0&.,!K21W.$,=OK ED-#XL'V->SO-V11XT\]/B"WON/P) M4$L#!!0 ( !6"G5#(!HHDM0$ -,# 9 >&PO=V]R:W-H965T-\=&7-% UJX&]-!BW\J M8[7P&-J:NI<<3[N CX ?$@:WV)/0 MR<68YQ!\+C.Z"89 0>&#@L#E"O>@5!!"&S\G33J7#,3E_E7]8^P=>[D(!_=& M/N>-GE30BA8O MXRK;N [CG_WM1%LG$G 9\(AUF%CH>C\07B1I]8,Q(YGWXEPQ$ S5YQ)\K<2)_T/?'];YVU6+V\C?_L?B M'P*[58%=%-B]V^,:AO]5A"T.58.MXS@Y4IB^C:.\R,X3>\?CI;S!QW'_*FPM M6TM0$ -,# 9 >&PO=V]R:W-H965TAN=T,DXPJ7>NG M$'RM"[P+AD! Y8("\\L%[D"((.1M_)XU\5(R$-?[%_4OL7??RYE9N-/BD=>N M*_ >HQH:-@CWH,=[F/NYQFAN_AM<0'AX<.)K5%K8^$758)V6LXJW(MGSM'(5 MUW'ZDR8S;9M 9P)="/M8ATR%HO//S+$R-WI$9CK[GH4K3@[4GTT5DO$HXC]O MWOKLI:1)FI-+$)HQQPE#5YAD01"OOI2@6R6.]!_Z]7Z;GVY:3",__8_%-P+9 MID 6!;(/>]S"9.^*D-6A2C!M'">+*CVH.,JK[#*QMS1>RBM\&O?OS+1<6736 MSE]MO(!&:P?>RN[*SU#G7]@2"&AS/-V10XW<]/B"SON/P+4$L#!!0 M ( !6"G5#+HH@PM $ -,# 9 >&PO=V]R:W-H965T=6JM1EMG.N.C-FB 2WL'7;0^C\5&BV<#TW- M;&= E)&D%>.;S3W30K8T3V/N;/(4>Z=D"V=#;*^U,#]/H'#(:$)OB6=9-RXD M6)YVHH8OX+YV9^,C-JN44D-K);;$0)71A^1XV@5\!'R3,-C%GH1.+H@O(?A8 M9G03#(&"P@4%X9$3U79:NR>B! MDA(JT2OWC,,'F/K94S(U_PFNH#P\./$U"E0V?DG16X=Z4O%6M'@=5]G&=1C_ M\!MMG< G I$ATA@8Z'H_$DXD:<&!V+&L^]$N.+DR/W9%"$9CR+^\^:MSUYS MGNQ3=@U"$^8T8O@"D\P(YM7G$GRMQ(G_0]\?UOG;58O;R-_^Q^(? KM5@5T4 MV+W9XQKF_J\B;'&H&DP=Q\F2 OLVCO(B.T_L X^7\AL^COMG86K96G)!YZ\V M7D"%Z,!;V=SY&6K\"YL#!94+VW=^;\8Y&P.'W?2$V/R.\U]02P,$% @ M%8*=4+O".VBU 0 TP, !D !X;"]W;W)K&UL M?5/;;M0P$/T5RQ]0;[PI7:V22-U6""205D7 LS>97%1?@NULRM\S=M(0(/0E M]DS..7/&'F>CL<^N!?#D14GM.J:UH<$*[)> M-/ %_-?^;#%BBTK5*="N,YI8J'-ZGQQ/:;R4W_!IW#\+VW3:D8OQ>+7Q FIC M/*"5W0W.4(LO; DDU#YL[W!OISF; F_Z^0FQY1T7OP!02P,$% @ %8*= M4# "5T>U 0 TP, !D !X;"]W;W)K&UL?5-A MCY0P$/TK37_ %;J[NFZ Y/:,T423S1GUHZ!?:&=Y[ M\Z:=9J.Q3ZX%\.19J\[EM/6^/S'FRA:T<'>FAP[_U,9JX3&T#7.]!5%%DE:, M)\DKIH7L:)'%W,46F1F\DAU<+'&#UL+^.(,R8TY3^I)XE$WK0X(562\:^ S^ M2W^Q&+%%I9(:.B=-1RS4.;U/3^=]P$? 5PFC6^U)Z.1JS%,(/E0Y38(A4%#Z MH"!PN<$#*!6$T,;W69,N)0-QO7]1?Q=[QUZNPL=]DY=N<'BFIH!:#\H]F M? ]S/P=*YN8_P@T4PH,3K%$:Y>*7E(/S1L\J:$6+YVF575S'Z0\_S+1M I\) M?"$<8QTV%8K.WPHOBLR:D=CI['L1KC@]<3R;,B3C4<1_:-YA]E;P]$W&;D%H MQIPG#%]AT@7!4'TIP;=*G/E?],-QF[_;M+B+_-T_+/XFL-\4V$>!_7][W,#P MY(\B;'6H&FP3Q\F1T@Q='.55=IG8>QXOY1=\&O=/PC:R<^1J/%YMO(#:& ]H M);G#&6KQA2V!@MJ'[6O&UL?5-A;]L@ M$/TKB!]0$I)T661;:CI-F[1)4:>UGXE]ME'!N(#C[M_OP*[KMMZ^&.[\WKMW M<"2]L8^N!O#D6:O&I;3VOCTPYO(:M'!7IH4&_Y3&:N$QM!5SK0511))6C*]6 MUTP+V= LB;F3S1+3>24;.%GB.JV%_7,$9?J4KNE+XDY6M0\)EB6MJ. 7^-_M MR6+$)I5":FB<- VQ4*;T9GTX;@,^ NXE]&ZV)Z&3LS&/(?A>I'05#(&"W <% M@5="*%L_#*INX]L.?W>>1MDS@(X%/ MA'VLPX9"T?D7X4666-,3.YQ]*\(5KP\!+)8[\ WVW7^9O%BUN(G_S#XMO!+:+ MLHL/UOCTL8_JX( MFQVJ!EO%<7(D-UT31WF6G2;VAL=+>84/X_Y3V$HVCIR-QZN-%U :XP&MK*YP MAFI\85.@H/1A^PGW=IBS(?"F'9\0F]YQ]A=02P,$% @ %8*=4*)LYA^U M 0 TP, !D !X;"]W;W)K&UL?5/1;IPP$/P5 MRQ\0WQG2G$Z E$M4M5(KG5*U??;! E9LEMKF2/^^MB&4MC0OV+O,S,[:ZVQ$ M\VQ; $=>M.IL3EOG^B-CMFQ!"WN#/73^3XU&"^=#TS#;&Q!5)&G%^&[WCFDA M.UID,7W/QD=L M4:FDALY*[(B!.J?W^^,I#?@(^"9AM*L]"9U<$)]#\+'*Z2X8 @6E"PK"+U=X M *6"D+?Q8]:D2\E 7.]?U=_'WGTO%V'A =5W6;DVIP=**JC%H-P3CA]@[N>6 MDKGY3W %Y>'!B:]1HK+Q2\K!.M2SBK>BQ\/W)_-F5(QJ.(_[QYZ[/7@O,D8]<@-&-.$X:O M,/L%P;SZ4H)OE3CQ?^BWAVU^LFDQB?SD/Q;_$$@W!=(HD+[9XQ8F_:L(6QVJ M!M/$<;*DQ*&+H[S*+A-[S^.E_(9/X_Y9F$9VEES0^:N-%U C.O!6=C=^AEK_ MPI9 0>W"]L[OS31G4^"PGY\06]YQ\0M02P,$% @ %8*=4-J-Q-*U 0 MTP, !D !X;"]W;W)K&UL?5/1CML@$/P5Q << M"4FN461;NEQ5M5(K15>U?2;VVD8'K LXOOY] ?M''9CPIT:KA0^A;9CK+(@JD;1B?+.Y9UI(0XLL MY2ZVR+#W2AJX6.)ZK87]<0:%0TZW]#7Q))O6QP0KLDXT\!G\E^YB0\1FE4IJ M,$ZB(1;JG#YL3^=]Q"? 5PF#6^Q)[.2*^!R##U5.-]$0*"A]5!!AN<$C*!6% M@HWODR:=2T;B/J+[)RK ]3/P=*IN8_ MP@U4@$"\T/&;E%HPIQ'#%]@MC." M!?6Y!%\K<>9_T0_'=?YNU>(N\7?_L/B;P'Y58)\$]O_M<0US_T<1MCA4#;9) MX^1(B;U)H[S(SA/[P-.E_(*/X_Y)V$8:1Z[HP]6F"Z@1/00KF[LP0VUX87.@ MH/9Q^R;L[3AG8^"QFYX0F]]Q\1-02P,$% @ %8*=4%2:J@"T 0 TP, M !D !X;"]W;W)K&UL?5-A;]L@$/TKB!]0$I*N M461;:EI-F[1)4:=MGXE]ME&!\P#'W;\?8-?S-J]?#'=^[]T[.+(![;-K 3QY MT=T?&7-F"%NX&.S#A3XU6"Q]"VS#761!5(FG%^&;SCFDA#2VRE#O; M(L/>*VG@;(GKM1;VYPD4#CG=TM?$DVQ:'Q.LR#K1P!?P7[NS#1&;52JIP3B) MAEBH^CE(AP\H/HN*]_F]$!)!;7HE7_"X0-,_=Q2,C7_":Z@ M CPZ"35*5"Y]2=D[CWI2"5:T>!E7:=(Z3'\.$VV=P"<"GPF'5(>-A9+S1^%% MD5DQ:Q2:,*<1PQ>8[8Q@07TN MP==*G/@_]-O#.G^W:G&7^+O_6/Q#8+\JL$\"^S=[7,/\[9(M#E6#;=(X.5)B M;](H+[+SQ-[S="F_X>.X?Q:VD<:1"_IPM>D":D0/P MA;T=YVP,/';3$V+S.RY^ 5!+ P04 " 5@IU0SH_[J+4! #3 P &0 M 'AL+W=O^]>V>?TP'-LVT ''G5JK49 M;9SK#HS9H@$M[ UVT/H_%1HMG ]-S6QG0)21I!7C27+'M) MS=.8.YD\Q=XI MV<+)$-MK+SD+"P^H?LC2-1G=4U)")7KEGG#X!%,_MY1,S7^!"R@/#TY\ MC0*5C5]2]-:AGE2\%2U>QU6V<1W&/_Q*6R?PB0(7HP%M);OP,-?Z%S8&"RH7M.[\W MXYR-@<-N>D)L?L?Y3U!+ P04 " 5@IU0OL1*6\4! X! &0 'AL M+W=OZ2@SO'= M[G!,'=X#_G0PZN4K.4KXZXWN5X\@) @ZE<0S,+A>X!\X=D97Q=^'$:TH7 MN-V_LS_ZVFTM9Z;A7O*7KC)MCO<855"SD9MG.3W!4D^*T5+\#[@ MW"GQ.8H M)=?^B\I1&RD6%BM%L+=Y[7J_3O-)DBQAX0"Z!- U8._SD#F15_[ #"LR)2>D MYKL?F&OQ[D#MW93.Z:_"GUGQVGHO!8UW&;DXH@5SG#%T@_E $,N^IJ"A%$?Z M)3S=A^/CH,38Q\=;B5$:)DB"!(DG2#[52*]J#&'B<)(TF"0-$"1724*8ZTK( MIG,"5./?K$:E''L_+QOO.A9WU'?^ S[/U$^FFJ[7Z"R-?3^^R[64!JR4Z,9J M:>T8KP:'VKCM-[M7\V.>#2.'94[)^K,H_@-02P,$% @ %8*=4-T@."_( M 0 . 0 !D !X;"]W;W)K&UL=51M;YLP$/XK MEG] #20D:01(3:=IDU8IZK3MLP/'B^H79IO0_OO:AC*6>5^P[_S<<\_Y?&2C M5"^Z!3#HE3.A<]P:TQ\)T64+G.H[V8.P)[54G!IKJH;H7@&M?!!G)(FB'>&T M$[C(O.^LBDP.AG4"S@KI@7.JWD[ Y)CC&'\XGKNF-O]!_MG7[NMY4(U/$KVJZM,F^,#1A74=&#F68Y?8*XG MQ6@N_AM<@5FX4V)SE))I_T7EH(WD,XN5PNGKM';"K^-TLHOGL'! ,@NQ?$QL7=3.J>_"G]FQ6OKO1;)9I>1JR.:,:<) MDZPP\8(@EGU)D812G))_PM-#.'X3E+CQ\9NUQ&@?)M@&";:>8/M7C?N;&D.8 M_ZA,@TG2 ,']39( 9AO=)"&KSG%0C7^S&I5R$'Y>5MYE+!X2W_D_\&FFGJAJ M.J'111K[?GR7:RD-6"G1G=72VC%># :U<=N]W:OI,4^&D?T\IV3Y613O4$L# M!!0 ( !6"G5 >R80/Q0$ #@$ 9 >&PO=V]R:W-H965T<"UWQ2^L5T !:]2M&; G?6#D="3-6!9.9.#="[G49IR:Q; MZI:800.K0Y(4A";)!R(9[W&9A]A9E[D:K> ]G#4RHY1,_SF!4%.!=_@M\,S; MSOH *?.!M? =[(_AK-V*K"PUE] ;KGJDH2GP_>YXRCP^ 'YRF,QFCGPE%Z5> M_.)+7>#$&P(!E?4,S U7> A/)&S\7OAQ*ND3]S.W]B?0NVNE@LS\*#$+U[; MKL 'C&IHV"CLLYH^PU)/AM%2_%>X@G!P[\1I5$J8\$75:*R2"XNS(MGK//(^ MC-.\DV5+6CR!+@ET33@$'3(+!>>/S+(RUVI">C[[@?DKWAVI.YO*!\-1A#UG MWKCHM:3I+B=73[1@3C.&;C#O".+85PD:DSC1_]*S0SQ_'[6X#_G[K<7D4YP@ MC1*D@2#]IT9Z4V,,LX^+9%&1+$*0WHC$,-F-"-G3[CE1BD+SDIRY[QTKHW7A8#&^NE'-]?S8YX7 M5@U+GY+U9U'^!5!+ P04 " 5@IU0V@Q7;;@! #3 P &0 'AL+W=O M@+-<*&:AS?)L!$,@H'1!@?GE G<@1!#R-EXG33R7#,3E_D/] M(?;N>SDS"W=:_.:5:W.\QZB"FO7"/>GA$:9^KC&:FO\.%Q >'ISX&J46-GY1 MV5NGY:3BK4CV-JYC\GCE69$8/R(QGW[%P MQ1?SGS5N?O10TO(X653J7L517F3G MB;V-MT@^X>.X_V"FX=]%%9D<#>]ZN"BD M1R&8^G4&+J<<[_"+X[%K6N,G M<^KP'O"]@TEO]LA59331UCJ23!:BO\,-^ 6[I38'*7D MVG]1.6HCQ<)BI0CV/*]=[]=I/CD&%9F2$U)S M[P?F?O'N1&UO2N?TK?!G5KRVWEM!XW<9N3FB!7.>,72#V:T(8MG7%#24XDS_ M"4_2&PO=V]R:W-H965T MYT-VKS:%L"A-RF4S7'K7'RF9>3^!T$.. M$_R9>.9-ZT*"%%G'&G@!][,[&Q^16:7B$I3E6B$#=8[ODN,I#?@(^,5AL(L] M"IU+LS" MO1:_>>7:'!\PJJ!FO7#/>O@&4S\[C*;F?\ 5A(<')[Y&J86-7U3VUFDYJ7@K MDKV-*U=Q'<8_NW2BK1/H1* SX1#KD+%0=/[ '"LRHP=DQK/O6+CBY$C]V90A M&8\B_O/FK<]>"[J[S<@U"$V8TXBA"TPR(XA7GTO0M1(G^A]]=UCG;U-D4:E[%4=YD9TG]H[&2_D+ M'\?]B9F&*XLNVOFKC1=0:^W 6]G<^!EJ_0N; P&U"]N]WYMQSL; Z6YZ0F1^ MQ\4'4$L#!!0 ( !6"G5!@)Q[[W0$ (% 9 >&PO=V]R:W-H965T MA.\USENC1F.A.BR!<'T@QR@ MMU]JJ00S-E0-T8,"5ODBP0F-HH0(UO6XR'SNK(I,7@WO>C@KI*]",/7G!%R. M.=[A>^*E:UKC$J3(!M; =S _AK.R$5E8JDY KSO9(P5UCI]VQU/J\![PLX-1 MK_;(=7*1\M4%7ZH<1\X0<"B-8V!VN<$S<.Z(K(W?,R=>)%WA>G]G_^1[M[U< MF(9GR7]UE6ES_(A1!36[@QAWA&)@R)Q@(!N1$*8?5@D"8HD 8+#1B2$B<,B M:5 D#1 D&Y$0)MV(D-4=%* :/WT:E?+:^\E?99=)6BGJ[WVX$%K/J#VB:T;W^V M(1R7XP_V+C.SL_8Z[;5YMPV 0Y]2*)OAQKEV3X@M&I#,WN@6E/]3:2.9\Z&I MB6T-L#*2I" T26Z)9%SA/(VYH\E3W3G!%1P-LIV4S'P=0.@^PRM\2;SRNG$A M0?*T937\!/>K/1H?D4FEY!*4Y5HA U6&[U?[PR;@(^"-0V]G>Q0Z.6G]'H+O M98:38 @$%"XH,+^QL>HB:>2@3C?7]2?8N^^EQ.S\*#%;UZZ)L,[ MC$JH6"?QGB]'8_ \X@_#PX,37*+2P\8N*SCHM1Q5O1;+/8>4JKOVH M?Z$M$^A(H%<$,A2*SA^98WEJ=(_,\VE-_-D5(QJ.(_[QYZ[/GG-[N M4G(.0B/F,&#H#+.:$,2K3R7H4HD#_8^^W2WSUXL6UY&_GENDVV6!S:+ )@IL M_NGQVU6/"YB[Y*H(F1VJ!%/'<;*HT)V*HSS+3A-[3^.E_(4/X_["3,V512?M M_-7&"ZBT=N"M)#=^AAK_PJ9 0.7"]L[OS3!G0^!T.SXA,KWC_ ]02P,$% M @ %8*=4&X3[<2X 0 TP, !D !X;"]W;W)K&UL;5-A;]L@$/TKB!]0$I(V:61;:EI5F[1*4:=MGXE]ME'!YP&.VW]?P*[K M=?YBN/-[[][!D?1H7FP-X,BK5HU-:>U<>V#,YC5H8:^PA<;_*=%HX7QH*F9; M Z*()*T87ZUNF!:RH5D23)=@Y)1LX&6([K85Y.X+"/J5K^I%XEE7M0H)E M22LJ^ GN5WLR/F*32B$U-%9B0PR4*;U;'X[;@(^ WQ)Z.]N3T,D9\24$WXN4 MKH(A4)"[H"#\1M_1TTZE0S$^?Y#_3'V[GLY"POWJ/[(PM4IW5-2 M0"DZY9ZQ_P9C/]>4C,W_@ LH#P].?(T9:>)O>/Q4C[AP[@_"5/)QI(S M.G^U\0)*1 ?>RNK*SU#M7]@4*"A=V.[\W@QS-@0.V_$)L>D=9^]02P,$% M @ %8*=4/?N,J>%"0 ZD0 !D !X;"]W;W)K&ULE9SK;B.Y%81?Q? #K'AX>!W8!F8<+!(@ 08;)/FML=L7K"Y>23/>O'UT MLR/UJ?*0?\:67$V1IUGDUZV:OGI=KGY?/PW#YN+/^6RQOKY\VFQ>/DTFZ[NG M83Y=_[)\&1;;OSPL5_/I9OMR]3A9OZR&Z?W^H/ELXIU+D_GT>7%Y<[5_[^OJ MYFKY?3-[7@Q?5Q?K[_/Y=/7?+\-L^7I]*9=O;_SV_/BTV;TQN;EZF3X._QPV M_WKYNMJ^FKRWQU/K[6^N_ M[D>_';J^+)<7]\/#]/ML\]OR]:_#<43Q\N(X_+\//X;9 M5K[KR?8S[I:S]?[?B[OOZ\UR?FQEVY7Y],_#S^?%_N?KX2\I'P_#!_CC ?[] M %\^/$"/!^CH@,FA9_NA_F6ZF=Y]V;^YKM__; M=K3K[;L_;GP.5Y,?NX:.FB\'C3_1R+MBLFW]_2,\^H@OWASN*>)-B3!,I1< ,9-I#;3TB!#92?UZ*8:OL2Q[4 HAS) M6:FP)Q74HN(&Q&&7N?9J"#&J_+P>1\W9]"O9C0J"5+D02POT]&?QMB;%D2:P M8Z7#LH(]*]:TMB;6DN+"V+= 5:LGG<'>%6M>3ZN*32>IHR38=I(;2I*;2F)5 MO"38PF(][ MK GM/:GM)/#:?=S\OR5%S5I+JQB5!JLQJXK&/O?6Q+TJ:P.;S MOJ,FV'Q>&VJB9K1%_+@D5I0#ZPMVL0=;;R$+M,?>\[&C(MA[WNYXMB()&*>: MDB!5(+NOQS;VUL;;K8TT@"?1:%_O"AH/-IZ&C(MA\VD"M M1\VY)[PI"5")L-Y@'RL@UT+(5;'YM(-=%9M/&^A5 9E6S>.:(,BM9"E0[&,% M!%L(P09LOM!!L &;+S00;+!L*E['\P2J,JE)P#X.@& K(=B [1=Z+CK)56<# MP09 L-FP"5(ESP:$G1RLDX76!-LO="!LP/8+#0@; ,*.[RE\K#GO"79Q /Q: MR:85L/5"![]&;+W8P*_1DFD9E>-#R7D_L'\C(%<&OQ&;+G:0:\2FBPWD&@&4 MCJOQD>2\']BY$5!K)1P?R=V>#FJ-V&ZQ@5JCY=$BXR45B')D)Q?[-@)FK>SV M%S9<[B T7&Y@U6AH%%;$B6I&$G9L L;*M.V'3I0YB3=ATJ8%8DX51KR/1 M+1(%LCTD[-X$B+42AD_8>*F#6!,V7FH@UF19%%0$B&A%R(U6P*N5#0<;+W7P M:L+&2PV\FBR)BCO!R&-)D,H3V$S8PPGP:F5WG['U<@>O9FR]W,"KV9)HE/'. M"T0ADJTB8P]G1*NDJ!E;+W?0:L;6RPVTFBV'QCSV#12192!C#V?K877$>AE; M+W>P:B;?N :*0R")0L(.+=; Z M,LT*-E[IH-:"C5<:J+58(*UFLP$B<8G,^8(M7*R%U;%Y1KZJ[,#6@IU7&K"U M6"+U:7QA@T2!3)**+5RMA=41;*W8>;4#6RMV7FW UHKNH8[OQP/1Z?<8YWW! M%J[6PNK(?E6Q\VH'ME;LO-J K17<0M6Q;9#($;ZJV,+56ECI<+#Q:@>V5FR\ MVH"MU0)I&N^^0,,POI*,@/6OLI**8RF!GIB (SD!UQ(4J( C60'7$A9PX"ZJCGD>J\@"*8[$!1P 6&$1"D<" ZXG M,>!(9,"U9 8<"@V,[YE@%3W=)#7@ ,@*2U(XDAMP'2@K++8C#3#[)CH=LXX7 M&"3R9 ,1F@ ".,LV,F'!'>D 6F'1'6E VC?1&=,F&T8"*J7](=X&02 5@K7" M\CO2 ;;"$CS2@+9OHK,9D\PJ@U1\SA!O@SR0"J%;83$>Z>!;84$>:2#<-]%Y M#F<,=$CEZ0)!4D$"8D'*OA\2$N81W\&Y0N(\XAM(]TUTGMHS6S9017JZ239( M0#A(A4T\$NH1W\&[0F(]XAN(]TUT-AN\<1-2L=OY0C)" D)"RO()0J(]XCNX M5TBX1WP#^;Z)SJ\%Q]$_B71'Q$6_A7+=IJ,7,& MJ *[$!:2%Q(0&%)A2$2"/J(]!$RB/J(M!*PH1V#6&:3*;)TAN2$!P2%EB04A M<1_1'@(F@1_1%@)6R[;>V\H E;*]B:2'!,2'U--&B"6UAX!)[$=""P$' +?V MV@"HA.4\A62(!(2(U+/%BD1_)/0P, G_2&AAX&#I5J+A&:0*#%])DDA E$@] M;818,O0P,(D 26AAX&#I-HYO>",1"XT*21,)B!,IRUD*"0))Z"%@$@62T$+ MP;)M\N9R$J@RO B:1(4DM!)Q AE;-M<%/5*/^ M$'># )*R1(B0X)"D'@(FT2%)+02< -L6LV=#%3W=Q-T@B*3*")@$B"3U$#") M$$EJ(> $[NZ._Y/L+52Q9*20/)* 0))2C"8Q(DD]!$R"1));"#@#MC51?JBB M]R!(*DE +$F5-D(LF7L(F 2*)+<0< :A!;-I(Q$[V22;)""[A M7Q(KDMS"O_GCP.U;80 E4YHA&24!(255MKV1<)'D'@(F\2+)+02 )RY+%_\,3_FSD\!>0?T]7C\V)] M\6VYV2SGU[N'3#PLEYMAVTGWR_:\/0W3^_<7L^%AL_MU9\#5X>$;AQ>;Y>NE05D[]WP$6[\8E_VW@MSX6V&T&V;M@9OH'^WNRE604#R[&LH%:EJ#T) MIXV_)<\[DM@ A_A10JM&<\]:.0CQ9A>?CQL_M!D!AUQ;"F:&*[P YY;)Y/&K M)_4'31LXGM_8/SKSQLR!*7@1_&=YU,7&3WWO""=VX?I5M)^@-[3PO=[]%[@" M-W";B='(!5?NU\LO2HNJ9S&I5.R]&\O:C6W/?PO# V@?0(< VGGIA%SF'YAF MV5J*UI/=X3?,_L?DF9JSR>VF.PKWS22OS.XUBZ)D'5PM48_9=1@ZPI !$1CV M08)B$CLZ"8^B)4X0H3E&CB >$=!T@1/$*$'L"*)_,DAQ@@5*L)AD$$6KNU/J M,(G#U!TF#D-<)4%5$L3G3)I+E&#YN,\4)4@?\)E.?,[:7*$BJZE(/$- 0OS2 MAH\;)3/WGB!9D/N+CX'HC YZ^;>$(A31O0X&BF=T\!HATR*)XIDB(7B5D/\H M$X+7"4$*97JJ&"B9T<$KA4Q+!3E5#'3_\ 2CA[(">78M0GFYN-2N/XUVAS:T MI>ZA_0OO>MA7)L]EK;R#T.:Y=H_J20@-)I?PR7@N3-L<%AQ.VDZ79BZ[WM$M MM&CZOA@,S3G[ U!+ P04 " 5@IU0(+6L5[D! #1 P &0 'AL+W=O M; /@R)N2K2I[IT4+9P,L;U2 MW+P?0>HAHQOZX7@2=>.\@^5IQVOX!>YW=S)HL9FE% I:*W1+#%09O=T4$@H7">@>-V@3N0TA.AC->)D\XI/7!Y_F"_ M#[5C+6=NX4[+/Z)T34;WE)10\5ZZ)ST\P%3/-253\3_A A+#O1+,46AIPTJ* MWCJM)A:4HOC;N(LV[,-XL]M/L'5 / 'B&8"Y?2UCHJ#\.W<\3XT>B!E[WW'_ MQ)M#C+TIO#.T(MRA>(O>2[Y-]BF[>*(IYCC&Q(N8S1S!D'U.$:^E.,9?X-?[ M=?QV5>(VX+<+?!SMU@F258(D$"3_U?CM4XU?8SYK9(N6*C!U&"9+"MVW89 7 MWGE>;^/P)/_"QV%_Y*86K25G[?!A0_LKK1V@D.@*)ZC!_S4;$BKGCSL\FW'* M1L/I;OI ;/[%^5]02P,$% @ %8*=4.(?-E_N 0 P4 !D !X;"]W M;W)K&UL=53;CILP$/T5Q'O78$)H(X*TV:IJI5:* MMMKVV2'#1>L+M4W8_GU]82F;>%^P9WSFG#G&=CD)^:PZ !V],,K5/NZT'G8( MJ;H#1M2=&(";E49(1K0)98O4((&<71&C""?)%C'2\[@J7>XHJU*,FO8L$C"!7#Y-:S2/KY"3$LPV^G?=Q8AL""K6V#,0,%W@ 2BV1:>//S!DODK9P M/7]E_^*\&R\GHN!!T-_]67?[^&,S\0^XO3'39[4]NDVPJW9II7)GNILCPIT<42S9B#Q^ 5)ET0R+ O$C@D<< W MY5E6A FR8(^9(\C>]/A.!YL@P<81;-X0X"N3'K-U&.XP^-,F+)('1?* 2'8E MXC'Y2B1-\K#(-BBR#8ALKD2V-R(?WG-2!$6*@$A^)5+<;%=VXP2M#B$#V;KK MIZ):C-Q=_55VN>'W[M2C_W#_//P@LNVYBDY"FZO@#FPCA ;32G)GK';F15H" M"HVVT\+,I;^7/M!BF)\&UL?53MCIP@%'T5X@,L?N]T MHB;K-$V;M,EDF[:_&;U^9$$LX+A]^P(ZKCO:_A'NY9QSST4@&;EXD0V 0J^, M=C)U&J7Z(\:R:( 1^BQK(70$I+8A3[KAMC1MK.R1*;.XLL MX8.B;0=G@>3 &!%_V[I1)H&SI"%%I6P9=++E M'1)0I".$ MMOG)F6WU(U$D2P0?D9A^5D_,F?".@=[,PB3MWMDUW:W4V6L61'&"KT9HQN03 MQE]AO 6!M?I2PM\KD?L;>G1X7^&T _FP7R+8[2*P_&#%]]U_"(2[ J$5"-]M MP^/=-DR8V&*ZR63HW36RQ<3Q8=](M&LDVC%RMUMYM#42WQO98K9&\.J0,!"U MO4\2%7SHE/D;J^QR99]\<\CN\KF^RM/->Y.9WH%O1-1M)]&%*WV$[4&K.%>@ M+;H/VF.CGYXEH% I,WW4YB:)@( %D& 9 >&PO=V]R:W-H965T2?DLZH =/#"6:,V8:5UNR9$E15PJNY$"XWY71)G M)(FB.>&T;L(B=[&]+')QT:QN8"\#=>&:-G$\O[%_<>:-F0-5L!/L=WW4U29L_689(2)!P0Q[$.)!"NQ3=ZE9\NW%78(9(672%$7 MJ;(/'S!VF\=N09!,C"&:9X4(R5$B&"$EP@CE* M,/_\5BQ0@@6B()ULA<=D(YO)?VHLT1I+I,8,)UBA!*O/NS1-!KWX$:(AF][\ MZ-UYIB.G_LPQ4)Q.Q)#1@^0@SZYWJ: 4ET;;FS^*#OWQ/K$/>A+?VK[I'OHK MC6^Z/Z@\UXT*#D*;=N$>]4D(#49C=&?.JC)]?E@P.&D[79BY],W.+[1H^T9. MAG^3XA]02P,$% @ %8*=4'(@T"$G @ N 8 !D !X;"]W;W)K&ULC97=CILP$(5?!7'?-3;A)Q%!2K:J6JF5HJW:7CMD M$M :3&TG;-^^MB&4)4Z5&[#-F?/-&#QD'1>OL@10WEO-&KGV2Z7:%4*R**&F M\HFWT.@G1RYJJO14G)!L!="##:H9(D$0HYI6C9]G=FTG\HR?%:L:V E/GNN: MBC];8+Q;^]B_+KQ4IU*9!91G+3W!=U _VIW0,S2Z'*H:&EGQQA-P7/L;O-IB M8@*LXF<%G9R,/5/*GO-7,_ER6/N!R0@8%,I84'V[P#,P9IQT'K\'4W]DFL#I M^.K^R1:OB]E3"<^<_:H.JES[J>\=X$C/3+WP[C,,!46^-U3_%2[ M-QDHAD% M9])>O>(L%:\'%YU*3=_Z>]78>S?X7\/< 60((&, Z6OI03;SCU31/!.\\T2_ M^2TU[QBOB-Z;PBS:K;#/=/)2KU[R,(XS=#%&@V;;:\A$@T<%TNXC@K@06W(3 M'H:)VR!TYAA:@_!=CG<,%DZ#A358O#-(9T7VFMAJ&JLA)'5#(B<@VF#RPH8,H_@\%31I' M#>)D6Z;T"GYN;+^>K(YM>6.[,OHG[WOZ-RI.52.]/5>Z?=DF<^1<@-*5 MEOHW,DX8')49)GHL^E[:3Q1OA_\$&G]6^5]02P,$% @ %8*=4/K9CH6# M @ [@@ !D !X;"]W;W)K&ULE5;;CILP$/T5 MQ S@S9V;BPSCK M&'\5)2'2>JMI(U9V*67[[#BB*$F-Q1-K2:/>'!FOL51;?G)$RPD^&*>:.I[K M1DZ-J\;.,V/;\3QC9TFKANRX)JE,IM<')LQ:?R \B M?[8[KG;.&.50U:01%6LL3HXK>XV>MRC6#@;QJR*=F*PM7L5>]^7I8V:[. MB%!22!T"J\>%; FE.I+*X\\0U!XYM>-T?8W^V12OBMEC0;:,_JX.LES9B6T= MR!&?J7QAW1F7>J6J&LE]R/_9@C!3E2@".% R 7UIC[^/%$=V2*'CB@ VA::AR@V0D%0(D?W4D&%/0: M>8MD4'JGIP@6+/J 8A$L6?2(9@?0M-H@G7=D*=K@SM<'P:)%@&J3>PV!)8FB M#S0$%AP"%)>@>4/B1;%>,C_.SF1ZU(2?S* 55L'.C9GR$^LXS->>F3[O\/XF M\!WS4]4(:\^DFF%FTAP9DT3EXCZIMI7J\C%N*#E*O8S5FO<3N-](U@ZW"V>\ MXN3_ %!+ P04 " 5@IU0K2? <LJ*D>NB+R5W-SLR27.>CTB^F [#H57!I"MQ9.QP(,54'@ID[ M-8!T7QJE!;,NU"TQ@P96AR+!"4V2'1&LE[C,0^ZDRUQ=+.\EG#0R%R&8_G,$ MKL8";_ M\=RWG?4)4N8#:^$[V!_#2;N(S"QU+T":7DFDH2GP_>9PS#P^ '[V M,)K%'OE.SDJ]^.!+7>#$&P(.E?4,S"U7> #./9&S\7OBQ+.D+USN;^R/H7?7 MRYD9>%#\5U_;KL![C&IHV(7;9S4^P=1/AM'4_%>X G=P[\1I5(J;\(NJB[%* M3"S.BF"O<>UE6,>)_U:V7D"G CH7T-A+% K./S/+RERK$>EX]@/S5[PY4'D^72=(5SVF M@2!]1[!=)]BN$FP#P?8=0?:AR8C9!8R,329T721;%K?X'&HOC'=]M*@L[+N 85K;I2RX*PD=\Y+Y^9X M#C@TUF\_N;V.KSD&5@W3H)+YWZ+\"U!+ P04 " 5@IU0LZRRBTD# !] M#@ &0 'AL+W=O:. DJX R-U4NY&-S\-I3P_*=,JI*#WT_ M]JJ\J-W50JT]-:L%/XNRJ-E3X[3GJLJ;/VM6\NO2!?=MX5MQ.(INP5LM3OF! M?6?BQ^FID4_>Z&575*QN"UX[#=LOW4=XV&#<&2C$SX)=VYM[ITOEF?.7[N'S M;NGZ'2-6LJWH7.3R#5XD52J M_+6_%K6Z7@?_;V:T 0X&.!K(V/\R" :#X-T@5,GWS%2J'W*1KQ8-OSI-_[9. M>;I7,T8-8]!F\P,"(\Z7T,@52(-1KF M43J-L"$@&1TB(+,(E'TPR2*E'82D@U Y""<.,JT,/296F+K'@&\+$Y%A(C-, MYFMA>DQT$^8N0] *%AE< &*:24PRB0DF6I!U;# )? 1+P@D9)B'"(.T@)1VD M\]]L1CK(9KS9S"QYF&&HU9Q$@24;\.EV\XF"!'J_^68D@%#G0\ ;70LW0\S M-N0 ^B\=$V:G0RK%(^",73F )G1B/]8EA8*%R4UR4T*TKD! $ HM+FAE@7#^ M#@9:-8"0#6,/ Z$;013Z>ED(&"9HT0Z@Q0,H]3!VL2D?B4[&A-Q9/BU ZPM0 M A/I3!(C3&34Q<2@[4732@7IG%Y*32I&54P,!A8JM.8!(7IF'Q%Z%H1IH+,A M8)CX%D)(RQY2LF?9M+8"*+TB$M+$@)B]Y! M VBBJ$FLK?A)Z=],/9E_SYE#4K?/,A1PIU,%_S[E@DJ)_+RMUE+/@^%"RO>AN M$WG?] -1_R#X:1CVO''B7/T%4$L#!!0 ( !6"G5"+OIFK=P( ,T( 9 M >&PO=V]R:W-H965TV$[=_7-BS+AJ'*OL2WF7/FC)F,TXZ+9UDPIIR7 MNFKDVBV4:A\]3^8%JZE\X"UK],F)BYHJO11G3[:"T:-UJBL/^W[HU;1LW"RU M>WN1I?RBJK)A>^'(2UU3\7?+*MZM7>2^;CR5YT*9#2]+6WIF/YCZV>Z%7GDC MRK&L62-+WCB"G=;N!CWN4&P,E /GSV;Q];AV?1,1JUBN# 35 MPY7M6%49)!W'GP'4'3F-XW3^BO[9BM=B#E2R':]^ET=5K-W8=8[L1"^5>N+= M%S8("EQG4/^-75FES4TDFB/GE;2_3GZ1BM<#B@ZEIB_]6#9V[/J3*!S<8 <\ M..#107/_SX$,#N3-867%]Y%9J9^HHEDJ>.>(_K9::CX*]$AT,G.S:7-GS[1: MJ7>O&4FBU+L:H,%FV]O@B0T:+3R-/E)@B&*+9^Y!_)YA-S>)(YB"@"J(]2<3 M?XP(#+ " 5868#65B)*;-/0VH;5I>A*;KC Q<;(H#:A0\
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htm IDEA: XBRL DOCUMENT v3.20.1

Restructuring Plans (Tables)
3 Months Ended

Mar. 31, 2020

Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations

Restructuring costs

Summary of restructuring activity

(in millions)


Accrued balance at December 31, 2019

$
46
Restructuring charges recorded in 2020

9
Payments and other adjustments

(18)
Accrued balance at March 31, 2020

$
37

Restructuring Plan from 2017 to 2020

Restructuring costs

Summary of restructuring activity

(in millions)


Accrued balance at December 31, 2019

$
79
Restructuring charges recorded in 2020

23
Payments and other adjustments

(8)
Accrued balance at March 31, 2020

$
94

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedCostLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlanStreamlineOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Litigation and Environmental Matters
3 Months Ended

Mar. 31, 2020

Litigation and Environmental Matters

Litigation and Environmental Matters
Note 11 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $90 million to $125 million. The recorded accrual balance at March 31, 2020 for these proceedings and exposures was approximately $110 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R24.htm IDEA: XBRL DOCUMENT v3.20.1

New Accounting Standards (Policies)
3 Months Ended

Mar. 31, 2020

New Accounting Standards

Recently Adopted Accounting Standards
Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.

Recent Accounting Standards Not Yet Adopted
Recent Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

X

- Definition
Disclosure of accounting policy for a new accounting pronouncement that has been issued but not yet adopted.
+ References
No definition available.
+ Details

Name: abt_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock

Namespace Prefix: abt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R45.htm IDEA: XBRL DOCUMENT v3.20.1

Restructuring Plans (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations

Restructuring costs

Accrued balance at beginning of the period $ 46

Restructuring charges in 2020 9

Payments and other adjustments (18)

Accrued balance at end of the period 37

Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations | Cost of products sold

Restructuring costs

Restructuring charges in 2020 3

Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations | Research and development

Restructuring costs

Restructuring charges in 2020 1

Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations | Selling, general and administrative expense

Restructuring costs

Restructuring charges in 2020 5

Restructuring Plan from 2017 to 2020

Restructuring costs

Accrued balance at beginning of the period 79

Restructuring charges in 2020 23

Payments and other adjustments (8)

Accrued balance at end of the period 94

Restructuring Plan from 2017 to 2020 | Cost of products sold

Restructuring costs

Restructuring charges in 2020 1

Restructuring Plan from 2017 to 2020 | Research and development

Restructuring costs

Restructuring charges in 2020 1

Restructuring Plan from 2017 to 2020 | Selling, general and administrative expense

Restructuring costs

Restructuring charges in 2020 $ 21

X

- Definition
The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.
+ References
No definition available.
+ Details

Name: abt_RestructuringReservePeriodCashSettledAndOtherAdjustments

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=abt_RestructuringPlanStreamlineOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R41.htm IDEA: XBRL DOCUMENT v3.20.1

Supplemental Financial Information - General (Details) - Cephea Valve Technologies, Inc
$ in Millions
3 Months Ended

Mar. 31, 2019

USD ($)

Business acquisitions

Research & development (R&D) asset $ 102

Research & development expense $ 102

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abt_CepheaValveTechnologiesInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R49.htm IDEA: XBRL DOCUMENT v3.20.1

Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Designated as hedging instrument | Yen-denominated long-term debt | Net investment hedges

Derivative instruments, notional amount and fair value

Term loan $ 554 $ 546

Debt Instrument, Term 5 years 5 years

Designated as hedging instrument | Foreign currency forward exchange contracts | Cash flow hedges

Derivative instruments, notional amount and fair value

Gross notional amount $ 7,000 $ 6,800

Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold 12 months

Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold 18 months

Designated as hedging instrument | Interest rate swaps | Fair value hedges

Derivative instruments, notional amount and fair value

Gross notional amount $ 2,900 2,900

Not designated as hedging instrument | Foreign currency forward exchange contracts

Derivative instruments, notional amount and fair value

Gross notional amount $ 9,500 $ 9,100

X

- Definition
Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: abt_MinimumLengthOfTimeHedgedInCashFlowHedge1

Namespace Prefix: abt_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Nominal or face amount used to calculate payment on derivative.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959
+ Details

Name: us-gaap_DerivativeNotionalAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativesFairValueLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994
+ Details

Name: us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=abt_YenDenominatedLongTermDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R21.htm IDEA: XBRL DOCUMENT v3.20.1

Post-Employment Benefits
3 Months Ended

Mar. 31, 2020

Post-Employment Benefits

Post-Employment Benefits
Note 12 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized in continuing operations for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

Defined Benefit Plans

Medical and Dental Plans

March 31,

March 31,

March 31,

March 31,
(in millions)

2020

2019

2020

2019
Service cost - benefits earned during the period

$
85

$
64

$
12

$
6
Interest cost on projected benefit obligations

75

84

12

13
Expected return on plan assets

(192)

(178)

(7)

(7)
Net amortization of:

Actuarial loss, net

63

33

8

6
Prior service cost (credit)

—

—

(7)

(8)
Net cost - continuing operations

$
31

$
3

$
18

$
10

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2020 and 2019, $320 million and $313 million, respectively, were contributed to defined benefit plans and $11 million was contributed to the post-employment medical and dental benefit plans in each year.

X

- References
No definition available.
+ Details

Name: us-gaap_PostemploymentBenefitsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 712
-URI http://asc.fasb.org/topic&trid=2197446
+ Details

Name: us-gaap_PostemploymentBenefitsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R25.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue (Tables)
3 Months Ended

Mar. 31, 2020

Revenue

Schedule of reportable segment included under sales category

Three Months Ended March 31, 2020

Three Months Ended March 31, 2019
(in millions)

U.S.

Int’l

Total

U.S.

Int’l

Total
Established Pharmaceutical Products —












Key Emerging Markets

$
—

$
813

$
813

$
—

$
752

$
752
Other

—

231

231

—

240

240
Total

—

1,044

1,044

—

992

992

Nutritionals —












Pediatric Nutritionals

518

571

1,089

453

576

1,029
Adult Nutritionals

294

521

815

294

469

763
Total

812

1,092

1,904

747

1,045

1,792

Diagnostics —












Core Laboratory

267

722

989

249

812

1,061
Molecular

65

74

139

40

68

108
Point of Care

103

35

138

109

26

135
Rapid Diagnostics

368

192

560

326

211

537
Total

803

1,023

1,826

724

1,117

1,841

Medical Devices -












Rhythm Management

228

246

474

252

262

514
Electrophysiology

164

224

388

174

231

405
Heart Failure

152

51

203

143

41

184
Vascular

230

395

625

266

443

709
Structural Heart

136

182

318

136

188

324
Neuromodulation

137

40

177

152

41

193
Diabetes Care

186

566

752

152

414

566
Total

1,233

1,704

2,937

1,275

1,620

2,895

Other

8

7

15

8

7

15
Total

$
2,856

$
4,870

$
7,726

$
2,754

$
4,781

$
7,535

Schedule of changes in contract liabilities

(in millions)


Contract Liabilities

Balance at December 31, 2019

$
294
Unearned revenue from cash received during the period

105
Revenue recognized related to contract liability balance

(94)
Balance at March 31, 2020

$
305

X

- Definition
Tabular disclosure of contract balances and changes in contract balances.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045
+ Details

Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_DisaggregationOfRevenueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R29.htm IDEA: XBRL DOCUMENT v3.20.1

Incentive Stock Program (Tables)
3 Months Ended

Mar. 31, 2020

Incentive Stock Program

Schedule of stock options outstanding and exercisable


Outstanding

Exercisable
Number of shares

32,412,976

23,330,203
Weighted average remaining life (years)

6.5

5.5
Weighted average exercise price

$
53.83

$
44.69
Aggregate intrinsic value (in millions)

$
849

$
798

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R48.htm IDEA: XBRL DOCUMENT v3.20.1

Debt and Lines of Credit (Details) - 2.80% Notes, due 2020
$ in Millions

Feb. 24, 2019

USD ($)

Debt and Lines of Credit

Repayments of debt $ 500

Interest rate percentage 2.80%

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=abt_LongTermNotesDueIn2020At2.80PercentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R44.htm IDEA: XBRL DOCUMENT v3.20.1

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Goodwill and Intangible Assets

Gross amount of amortizable intangible assets $ 27,300 $ 27,600

Accumulated amortization of intangible assets 12,300 11,900

Decrease in intangible assets due to foreign currency translation adjustments (204)

Estimated annual amortization expense, intangible assets, 2020 2,100

Estimated annual amortization expense, intangible assets, 2021 2,000

Estimated annual amortization expense, intangible assets, 2022 2,000

Estimated annual amortization expense, intangible assets, 2023 2,000

Estimated annual amortization expense, intangible assets, 2024 1,900

Indefinite-lived intangible assets related to in-process R&D acquired in a business combination $ 1,200 $ 1,300

X

- Definition
Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 34 R40.htm IDEA: XBRL DOCUMENT v3.20.1

Supplemental Financial Information - Investments (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Investments

Long-term Investments $ 790 $ 883

Equity method investments carrying value 275

Equity investment without readily determinable fair value 162

Unrealized gain 50

Impairment of investments 50

Equity securities

Investments

Long-term Investments 741 836

Other

Investments

Long-term Investments 49 $ 47

St Jude Medical | Equity securities

Investments

Securities in mutual funds held in a rabbi trust $ 289

X

- Definition
Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.
+ References
No definition available.
+ Details

Name: us-gaap_CommonStockSharesHeldInEmployeeTrust

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in equity security without readily determinable fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714
+ Details

Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714
+ Details

Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 8A
-URI http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562
+ Details

Name: us-gaap_ImpairmentOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LongTermInvestmentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=abt_StJudeMedicalInc.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R51.htm IDEA: XBRL DOCUMENT v3.20.1

Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Not designated as hedging instrument

Gain (loss) on derivatives

Income (expense) and Gain (loss) Reclassified into Income $ (165) $ 49

Foreign currency forward exchange contracts | Cash flow hedges | Designated as hedging instrument | Cost of products sold

Gain (loss) on derivatives

Gain (loss) Recognized in Other Comprehensive Income (loss) 227 (19)

Income (expense) and Gain (loss) Reclassified into Income 11 15

Debt | Net investment hedges | Designated as hedging instrument

Gain (loss) on derivatives

Gain (loss) Recognized in Other Comprehensive Income (loss) (8)

Interest rate swaps | Fair value hedges | Designated as hedging instrument | Interest expense

Gain (loss) on derivatives

Income (expense) and Gain (loss) Reclassified into Income $ 168 $ 43

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17B
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_DebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R9.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statement of Cash Flows - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cash Flow From (Used in) Operating Activities:

Net earnings $ 564 $ 672

Adjustments to reconcile net earnings to net cash from operating activities -

Depreciation 267 267

Amortization of intangible assets 561 486

Share-based compensation 233 226

Trade receivables (104) (170)

Inventories (437) (286)

Other, net (369) (483)

Net Cash From Operating Activities 715 712

Cash Flow From (Used in) Investing Activities:

Acquisitions of property and equipment (360) (335)

Acquisitions of businesses and technologies, net of cash acquired (78)

Sales (purchases) of other investment securities, net (36) 2

Other 3 15

Net Cash (Used in) Investing Activities (393) (396)

Cash Flow From (Used in) Financing Activities:

Net borrowings (repayments) of short-term debt and other 51 13

Repayments of long-term debt (1) (500)

Purchases of common shares (236) (217)

Proceeds from stock options exercised 89 127

Dividends paid (638) (565)

Net Cash (Used in) Financing Activities (735) (1,142)

Effect of exchange rate changes on cash and cash equivalents (70) 4

Net Decrease in Cash and Cash Equivalents (483) (822)

Cash and Cash Equivalents, Beginning of Year 3,860 3,844

Cash and Cash Equivalents, End of Period $ 3,377 $ 3,022

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.
+ References
No definition available.
+ Details

Name: abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_PaymentsForProceedsFromInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash (inflow) outflow from investing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfDividendsCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690
+ Details

Name: us-gaap_ProceedsFromRepaymentsOfShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from exercise of option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 37 R55.htm IDEA: XBRL DOCUMENT v3.20.1

Post-Employment Benefits - (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Defined Benefit Plans

Defined benefit plan net periodic benefit cost

Service cost - benefits earned during the period $ 85 $ 64

Interest cost on projected benefit obligations 75 84

Expected return on plans assets (192) (178)

Net amortization of:

Actuarial loss, net 63 33

Net cost - continuing operations 31 3

Post-employment Obligations and Other Long-term Liabilities:

Company contributions 320 313

Medical and Dental Plans

Defined benefit plan net periodic benefit cost

Service cost - benefits earned during the period 12 6

Interest cost on projected benefit obligations 12 13

Expected return on plans assets (7) (7)

Net amortization of:

Actuarial loss, net 8 6

Prior service cost (credit) (7) (8)

Net cost - continuing operations 18 10

Post-employment Obligations and Other Long-term Liabilities:

Company contributions $ 11 $ 11

X

- References
No definition available.
+ Details

Name: abt_DefinedBenefitPlanNetAmortizationCostsAbstract

Namespace Prefix: abt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: abt_PostemploymentObligationsAndOtherLongTermLiabilitiesAbstract

Namespace Prefix: abt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(4)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(5)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of contribution received by defined benefit plan from employer which increases plan assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanContributionsByEmployer

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cost recognized for passage of time related to defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920
+ Details

Name: us-gaap_DefinedBenefitPlanInterestCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of net periodic benefit cost (credit) for defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanServiceCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R5.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheet - USD ($)
$ in Millions

Mar. 31, 2020

Dec. 31, 2019

Current Assets:

Cash and cash equivalents $ 3,377 $ 3,860

Short-term investments 291 280

Trade receivables, less allowances of $389 in 2020 and $384 in 2019 5,292 5,425

Inventories:

Finished products 2,873 2,784

Work in process 615 560

Materials 1,080 972

Total inventories 4,568 4,316

Prepaid expenses and other receivables 1,970 1,786

Total Current Assets 15,498 15,667

Investments 790 883

Property and equipment, at cost 16,707 16,799

Less: accumulated depreciation and amortization 8,800 8,761

Net property and equipment 7,907 8,038

Intangible assets, net of amortization 16,265 17,025

Goodwill 22,927 23,195

Deferred income taxes and other assets 3,390 3,079

Total Assets 66,777 67,887

Current Liabilities:

Short-term borrowings 204 201

Trade accounts payable 3,181 3,252

Salaries, wages and commissions 949 1,237

Other accrued liabilities 4,408 4,035

Dividends payable 637 635

Income taxes payable 165 226

Current portion of long-term debt 1,264 1,277

Total Current Liabilities 10,808 10,863

Long-term debt 16,804 16,661

Post-employment obligations, deferred income taxes and other long-term liabilities 8,738 9,062

Commitments and Contingencies

Shareholders' Investment:

Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued

Common shares, without par value Authorized - 2,400,000,000 shares, Issued at stated capital amount - Shares: 2020: 1,978,112,501; 2019: 1,976,855,085 23,731 23,853

Common shares held in treasury, at cost - Shares: 2020: 209,267,175 ; 2019: 214,351,838 (9,913) (10,147)

Earnings employed in the business 25,786 25,847

Accumulated other comprehensive income (loss) (9,386) (8,465)

Total Abbott Shareholders' Investment 30,218 31,088

Noncontrolling Interests in Subsidiaries 209 213

Total Shareholders' Investment 30,427 31,301

Total Liabilities and Shareholders' Investment $ 66,777 $ 67,887

X

- Definition
Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.
+ References
No definition available.
+ Details

Name: abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: abt_PrepaidExpenseAndOtherReceivables

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522
+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(15)(b)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(1))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(1))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(13))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockCommonValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 39 R1.htm IDEA: XBRL DOCUMENT v3.20.1

Document and Entity Information
3 Months Ended

Mar. 31, 2020

shares

Document and Entity Information

Document Type 10-Q

Document Transition Report false

Document Quarterly Report true

Document Period End Date Mar. 31, 2020

Entity File Number 1-2189

Entity Registrant Name ABBOTT LABORATORIES

Entity Tax Identification Number 36-0698440

Entity Incorporation, State or Country Code IL

Entity Address, State or Province IL

Entity Address, Address Line One 100 Abbott Park Road

Entity Address, City or Town Abbott Park

Entity Address, Postal Zip Code 60064-6400

City Area Code 224

Local Phone Number 667-6100

Title of 12(b) Security Common Shares, Without Par Value

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Large Accelerated Filer

Entity Small Business false

Entity Emerging Growth Company false

Entity Shell Company false

Entity Common Stock, Shares Outstanding 1,768,845,326

Entity Central Index Key 0000001800

Current Fiscal Year End Date --12-31

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q1

Amendment Flag false

New York Stock Exchange

Document and Entity Information

Security Exchange Name NYSE

Trading Symbol ABT

Chicago Stock Exchange

Document and Entity Information

Security Exchange Name CHX

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 13
-Subsection a-13
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1-
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_EntityListingsExchangeAxis=exch_XNYS

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_EntityListingsExchangeAxis=exch_XCHI

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 40 0001104659-20-053384-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-053384-xbrl.zip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
LXDZ(*30@)Q41Z MOEVTX,C0DEA03;G%SC*!]8E59MZJE&IC$KT=QY\.Y2J4K@L".5>H.4^T!AJ? M+T_00\.KWW+;39P5!PO6SAB",I4[^4D)S11/A:04D'IIIA $%V?E%I^4=&(F M,'PZ3*A"IKQ)D:E%4;'Y;I_-9KA"'C(_'294,9[%"U-2&;(V):PDMKVLK7)H M9(A03D6Q$J..VN0*CK9)NP+?85D'C@P1"MM4)$EH-4266!#L1G/YR6B+1H8) M1>=&.KX]5YE%K0"$R>L*MK[$F"Y$'Q\*4:D])6=RZHZP2I\J-%*&.IMZG.E;SK*%#NA#$^#SJQY6JL_'G)#0<9WG:O-I&0Y-A(>F MTVNJ[A3#.*-<=-!0T,2,"(2=)JTRSE,'L[JBU4OZZZ*4S0T) (X M4]P,*_5AAG77\VIZ1K/=4H%!0T,RT$L3FI SA+4B S8WGI:S*\WRAH:%(#>J MFE7&+FE<8S+LVZ),Z5K66U=8"DRL61+I)='&"'O0)Q+&AJ'KWFSW8G"AHL@' MT=^E 6;0\L.]5,GKZH7.6,+5D+.<-"3!=@[8!:?.5&W&\NMRZPS5D$/) ^C] ML63,RQX@_AW+0N<5=1V#3@PC!GMCZ)AXCFWL:/HQ?_ZQOZJZ:?X=N[^M7+CH M]N/:A8.U^U$Q\6CM MG9 \Q+<_%./>SA<]V5Z82:Z#M9QYF1,FZTI4C/OIX?J[JW%[3TD0#W14>CM\ MYOZ&S/ZS5?HD'LBHTN=ML )_2$9:<1NL2#U$)>IO@Q/$\P5-(TY<$Y[HB!4W MP8H(GFZ%$Q$\W0HG(GBZ&59$\'0KG(C@Z58X$<'3S; "PM.SO9$C5D3X].TX M$>'3S; B_%0]=I]KKR$<0GEAGK'^[^\ MVS@H)_1SN\8]?]QYM\W \-1Y^]E0Y -UW1J3Y^]GTYT9 ,1J\ \S,\9J*$6Y M=MA][KQMPVY3"R-=.YNNG9,V+YWU?V?:O+#_^=S>&K=&K!>V*-]9CE[:,WQG MVD0Z%NE8I&.1CMT,L2(=BW3L?3KV;# J4K(OK&3[X$?RS+U\TU[]P9N.;3Q6 MIO"C&054MR,*:$0!C2B@<7.TB1S![VNC(D4PA\)1F?')&6?BZL2'_?V%*/_9+#GWY>%A>-^#O6H3EMR&6MX[EQX$@09/\ M'YJ&K!N1#$4R]!H9*FFF9=A!2\[((8@<@IO0FMMW" P#M6GT ;=K")JI>G=W M(]B]#0&Z==CM &,MBT%&ZE]9W;3,OR/9B63G=5OX7:/;P/$S8Y'ICDSWC6@/ M=>>E$!Y;6IH1(-^&2-%W+E+[G7G6Z_\=R54D5^?9A0AF4*$EK^J._U,12%-P MYJW\GV@8N A7IN%1"Y[4P_[$5D;M,JU?_ ;Z%;KX MG,3X,A+^-X1(>[4CSJMV] -U?8DYK]:A7EMWA>!?06CN':I1+^1(:"*AB9#F MQH7F_JU3!#01T$1 <_-"\_6 YC7;S'^((@"3R6LBSP%U+'UY)WO*C* *F@AB M@A4K"YHM&&X,?Y5&O4"4>XE*GRE _TYJ^%=1KJQ2+Q#K_RZY8"_W_?,@Q&MX M_!(!8G\%[:SSAB"B\_&8K6/]TNR%I%O!WT,MMRU=5&80-H%A^M.#Q@32$#X&_@ Y M#L=2/W8MZ,NU'LO5>QS.@1ZI+:WXTK+Z+3[-)W[\)G^F"?(__SJFZ>_7!;#> MC3(W%4_^=)"YOJ\7@3 1-: E $:_,%JPDV( M&0*;[F29$=?Q>A&+BYK6)U;=1K8^O1+8B,E"(0;7MXN]&ZE9"@+/B=E)OUL(B5!S7#&1,?2W41RY9/+GK@MU$UY5SO;[P_(XC[".P/BNSB=\X(._7"1(30K$ M**-MQCFNP50ZBJ76LM7Q^_'.4^/LH1:7/"5&N)OQ%+C]5'\A'#%BSM 3U ! M;K8>4>%2Y^--15X,G+E+*BMYG8FWU]M)W?DL5'@*!K,1L< EO,JBOP&"G,VO>$VD>+,1"D.R7]/8!J.-M$9\ MR?7H]X=NSHLD.,47!A7>RF%9DW&3F46J"U>+D"3]XWQ3G;4)P MBSN-L_D4KT&$?J^8ER?]F8T1!+^4\[,LA8OO/SNZT(ZC*:WPC<.K+2RNX4*Z MY!2Z.::%H &=,KTR[!N!PY<'A\A9.&?T-5^>99J J2Q8UQP5;:=@SPN%6]EW ML*WDNC"JL9HB$QMG0L:I5,GP]AW>25 J?.P<8<*WQ(3(83@O*EBLE!A4*NF2 MLA@/$JU1W6[VZLRM>0Q47VAL!IQD*(55$TNT9J5>)N_# XW@X3F7X>+5G^&YR^.K(YZ&_>3"C/^T$_.K?5A,8LBZ] MQO?/*44]L\GF9ACATAMIKG>7?-+A<1P=)"3#UU\BU(I0*TH4O8\0Q2><:5P+ MMMHCRK!LRG(42BQ0V28W=_M-#[:\JS3AI*H(MR+<^E[>UOUF?7[&@LI M7NDE/*%OE#:+=3+24$VW>2QI^GB%3F"B:\818$6.5G08=$.(U5B+BS15'2V4 M2G.KE.9;2AZ.IQYBH4.A9ZNP?)W+/9! ,=&G6&SID>RYFS[1A9Z/7.BY%PB. M7,-O?R%HAYM-W?"F8EF&/+8M8:R"KNZ#_G.[5YM8L"DEU:"X;%-FC0U#Y7K9 MEG=5-+H4=(F,G A:HF#9?5PJ>AVRA K+S!EK8>A%G8M7ZZ5YMIUIRK4I I3H M8E&$)A&:?(<3P_.CBM#HZ_G9H(=S6"1L5W7&*<.4^W97H6.Q&PK9:BOT-C:$V@0Z(:-^8A0=94S=5,94!#-?'&8N=;9&DI7,NMSM]]AX MARF)V7BE;W+7:LB0;P[ZB>F#.O"8_39K.;>B5%][I]JG(MKZ:[GG$;VTF,L>PR19K=^J(BT R" M&Z_=%$F'@]\1W$1P<\T<\.^&-Y<^CILF&FZ'=YPJ1['J>H57&S16NE:_WK5< ML-C!NMY0%BZ;7R_ADKEF"^%-T' *BP G ISO[=]VOQ8[%#/F9\L0] MGDG[L$2A$-0MA'Q _P?P6\%=-M&-68\AN9C@-Z="*B/%9"UFS4 LJZ.C/Q-^ M '_R3K^]*H=[>8KIDQ@K&!I4'#,FH#E;^Y> C3@3M"F(_36%TO1W#-V-^W<, M2O31E$0H7K$)E*_8# F8>3P-^,BL;GJO61JZ9(OP6W :TD/,/U9$[X.,M@5# M%E3O#>@)\!5+0X8/-X&QED4 =00^ SU8UD35#AXL>'?X/#U S]? [FZ?+,;& MOC/O?1%.V@0@5M\1M*.)O26? MR$@YXS%&3QF%8I1%V1ZR6\MPGNIN0=:#-8SYEV'R_VL^VEDYG'N,7_R[U32&\:&+M1J2[>@Y/I:B$1_NJ.! M 9:Z@13<@?KQ?Q?V@-=:KM9OJ4V)[4RXX82;+)A:\3@&1[_!?.P8N3<::5_, MZH)A\%B]5=;T=4/&^LT)H&5J2A!Q!QH,XB&#K Y.4$+_0$!;?#T0RS_K'79AT1,M! #",BJ["5O[,:$)83X#5R! M!53W[%1^)\R]TY?9T3P@23:@R,$)V,[#^F/@QF//ANLNIQO:4-E^NK?678WB M!FLDMR=.OF.+@#N![9[(!K1ZULR QFL!*3$SD:ZCU3[$$ JGA,KC"V>-=&$91-Z$LV9 %DE MO; M-#0#WR%P7'N)GC5>;XIIKK-.F/7M#.MOY>EE%(Q)=?!<7=$M3([K=JD_:Z:* MA1;DX,,)#N[T"_D8B(4'"XH=KRC6W+M#/A5^WA ?ZK9E!/[1$\HG4[4$+Z99 M@UWEU&FK4N=3>.O]<8D0Y0]U)S$HK/M5N^"RC4JYN%XX3*&71]!&AY. ][JS MH_S!$FZ:U#E9F&K0297%)Y2>Z'-!&C:T@4(TMXJZ7NMSL+R0$SF -A4[0K>U:QM)8V4OW"&6="Y#:)I:UI-LJ61BB\V\HLQG73LA,BBX]A#NZ!.B=##] M6##_'95W>REH$^ ."2'ZS9G>8P+&32 B(CIPCV@"[4\4+"V6@FR@%09V-DS/ M)FNMVV_W'O+": MO\6W@#C3=%6?NK[0!LM[=@YWMJ?)RW!6H"JO06A;73#^)-3=2J^0+#57:ZZ_ M;?"=8<$<%0?([J4>3H7'7D&U1[_?$]\3>Z)/)/[E-D[OHOYJ4,[D31>O8H6V MJ4SF:@@VLT\AQ_GB6Z$+!H*>R,6-TE.B%CE/_-F, ^D +'TPUS?9#JH^8"C9+='3B/3@L M";+Y).#UW>#W@%2L3ZDZG%77 >H:U#RZGU3]/IW.KHN@3G.=I!"?-\EE1FQ- M43PEO -ZF^9#EQW1X&?$"3 $@M%U]--[IE'7+@NY-8UUL$&QD5"-LH)[ :U3 M;2+>S@#\- /0IB\N;^+^KN97T?L/7Z(*^*PNV1;;M\0<($ W+79:3W8B02)! M<.3_IM,4_U?T&+@N2&K5_\0!:!NR^^C$M@@!$JJW%>RX7D&%GW\T^J=7GDQV M>TQVF3*4PG)8X@&7&5&36UEYXBTK_VQOYX9T+@_'GE0Z)YZ3!PM^X;(V-6,5 MUVD,W2)$O8_[.[[2D0]7C@Y\ZAEH29-0SBY*'5(1=TZ%'IR9##UR_T#$"^YH M<6BM16":L?;_$Q;+?^?@;FIERX:?+"'$QD'4$&45C&7-8RU\#(JI7?9DZ\)2 M_$BLDY+,;E!&A:Q-GPU<2O:6L9:+"-AZ%FI5 MP12KD9W.@.TS(F-8\4S%67K:'MYMOKR1/!$+,("Y!/#[:RB/1VH93K^;>/^# M2G.$$#>2/O4O25[__@_\9V_P5(BB*#EP%CQ\G_N'7A(D0V+8/]^7 OH$6T2X MW0/&;A4$N4MRW*?WX?C!++U___=_#F<;IG9@J0^6,?,-+N%E*$Y!? SWEDI< MF, W_Q)41W#-8%DT_4"0NY3'7_O41K3P6/*!IO\9>_P1+3]$NX6PB1]0Z*@8 MA/^MW4=>$';WF6YZYV2__$CX&J!G'SW58X.E+\_#@[#<"#&X5X.J_8]N(WLJ M!GTICP<1!H6UO> U5+TL@AD-Y0P% BI\Q)J^.K!^+4MZ+.W^O/S]<*PJ0*D3 M+-V0@^R[CCTV94D6T >7>SO*Z3*1;7XF4Q'Z8((FHN3 _?'>!6=TC+X7>H\' M,$A& I3YB],$:%/@:O]^!2@>Z_@IY14\0\03='*"2SC@QP)-\B1!3G@A,1GS M9'*,"\08 F?_/"E7-AEYS8Q5S VN0W'QDEI5FN2E;):9WB9F0NBTBSSK0,PH].EAV&2]FM'5.G;30R.-Y\J0@X!(]IGD\ M"5(\B:=2?!I@(D^DI0E-4@ @7KZ;"H]3"SDDEU6Y!FYQ)MS3ML0)^E:HFO= MC45;;0Y(5DMV#4L<))NI*I9D6TT].6 MLN)+C:&U%T4FZUNKF9JPJ^3A;:2^'Z7Z-:^NSZ2FZ9MEUQTC1R107SZ@5 M>=H$"5IT3M%U,D]TMKSCEK!"GY"E<6933D/^/]+UPJFM;6!:ABU:M@%-'Z-) M;3]'BD'N$U0>\&R"ZP1D4D05=T6LLRX+]2 MXGV=-[]F'X=ZW2"/-H6,@!^["RP2?!ITEKP,=6_SA39YQA%)EH@DR&E>"H9W M%(V,"-P'@JDO,[N/O$V>CY*>@]VQ'F)E6WK,IH#?T9]+K_ #.XR*-H(E37R( M_>7]_/?C%Y_-@(%[2\^C0TM4P1H8<%TQ *5<7R!K"V?D;2"\EW@I"GZVN_D M7_9"//MG3)Q!'4EF3"R21_TB_I<,)^_0[G7Y&=.*+D;W( ML'**Z.%C=]4B,W 3=R+?>'<$X04+T-V'J09U0/J)^.+'(3Z).W[-O+WG5-7] M'E-'MX80TQJ3#ES_+B/J>KQ-8K;EKOM#@UW4N,1DA$E6;?V1[G^OY&T<3*2M MR \MKL(L,9HHKY1:!?+VQ/9\GY1K'EVN.7FKY?R)A6?D,^(<A?*_.#EU3D_V/8R:KL]8;#%-C=K5^Q>ORI=0:MG=*'9R>J)K+(RDZ-9?I0F M^!X*9+V:\SLZ>H@M/5+R(N&N,_*_ ^!RM&D!:- &H8L^C+20-1G2S=LY!()P M?0P8K%AW,&K2&"=/QE@VT6X\G]UP010-[W#[1(#QU\\^\&-_WB='$<*#*]3!F,=H'^T' M^RQC-XD@J(G[2WIWF6::>GBV".Y!#.3@C7 S8* +ISN:[7Z/HR?_\N.K*+7X MQ=!F$%KV7KP;*HRA(;!O*#?P&)G^< GT%!FQXB98@3^D$A$K M;H(5] .-1ZPX)RM>4T#=,T[O,B6WU<[@/_(Q[;RC*=F""Q)1V!_N)0+'$K4< MEE]70.8]M'D)VR_7RB'\[\46^1)JWFG!H'?IP@NH=NZ\-/_ :5]7+;:UIDAXB/FY0VGXA>KMW5N M,'F%-%RTGM;Y,>') <\GULLZR :[7D BNYJ6\O:HOV:SVHPU'0O,T_,SA:Z# MF9XHG]7NXPS%+M8)I4/9I12SK#0$$QV[)W[\)I_KC74"5\^\6;^(3AP?@^Z. MNP[#L?M$C M<66YQ7N=9D[EV%_-X;PR8C8%-RCVHTDQ'751.[S<&/F05_8AKQB1N&]R^:!\ M37*] K1#]+MTS\:[1VTXD9.^;-.KS(EJT7: 9:E @E/P>CP^EMH_A>H3T.$K M-4?D%,+2R#&M.J6.CA(2(:KCSS8/NU.']T1(X*@+XSX>$'F]'_1ZKUE;^MW; M_S. Z!56]MFN[Y\J@ET>-:?VA4"RMY MQ-HS199;28[H:5(3^KI)A(J)U&M+:'_6G:\/7ST[?VJQGTP,1T+R V&A0@&( MZ4O@FV;S*(?W,$?7\['EA?>0&/1Y9%$&FHC2>N$WU@*T>+:Y>^WN>JGWQ^ 2 MH9>FHSU6*OR)*E+L"T8NCPI&^B];"Z9HJX)Q\+BOG"C=&H'G.TEWI M0KS *H720FN5EY)08MY?B?+5:6/37")?WC96+$O1LQ3#TU)5E9F3I>NCO.#7 ML;(NC;I,;8,7E0JKR3+7L[N;V9E ]#E6;B5%*!$5,LXV:'/>JE%U?=F?OB47 M-,H"?@N?9SC37JQJ',F!:F962A@]>5.Z0J;G>,X+W71\JRGQ5"8Q(ZLY'.^\ MB<]1SN]'^$[VTERQMG5IUBU.-MWJ:C;E9E?(\I\T'*6JV"T&HW2>3-ES0W!F MJ)3?,XR_M13?XTM/]YWP^PYK?I[TWI:E%814NE+""$Y-UG!MR-<3YVA3$:7W MHMWHM\KE_;0&SDV$_*?7U"@=>-W+$ M?H44UB^7L+H[IKJ35-5GMM)&+9_K,?727*G(F6I<3]K%>._B1U):ELRT!R-1 MQ!H=&I!56S&KE9:?F)IZ8_[51[:99Q#KL^>]XO>'W ;?JLK,T; MH<2=Y&C>7T;FY3'RS/F7%WXJ"5\R0_++YD%?:95X>K1I5MU"ON.LFNW+8?K'>S>9'U,5O/S+SP9Q* M4)++]I-BI2N9(R)1=/R\Q_2I_E$G\QXO7?O^?:'\VRC(']0X%@@I1:9QBAZC&<:@> M<3>7RN-"S\VR C];KEF3=Y.< T-U@QGTNZU3-8Y)/K7HC?"B@T&Q;NAEKCON\*U3-8YKZU1> MSZW=/%91TM52(T6HC3:J,AU:$>,6M9P]SUA88^-TQGDI6T]UT#-#*QI:987< MD#S@"LM.9YSJE0KYVNFZR:F<4NYU^#K6Z==F:SVCV$/."=6C1C6NV?6F5J"+ M299H+M5TKY@6AVDT>IB4T8';-)!!7?5V6Y9P MFH:4[SKR(-"$4!7? MJ2$LOE[!Y5=D"@?IRG#]&LHE>J5],A%[37YE#>=3J0MXUNTTY[)5MNQQ^7W^ M->/ YW;=)3A*:&,72U5W ?#XU%BBYP06:9T3MU-C6E]Q#$L+F>L,CRQ2 MJ9Y_@TEZ%-A#D68,2!<_>SSCAF3:F[,_*[. "&B6--_Q/NXWBQTDJ97QAI@N M]-LSMB%L-3:,M-?;S)"R\6R.6(^+K"./>A.?_Q.4O1/,G4BO]#84R9@G^#1QN^==AL, M//(5'YF()F&V.]SNGB!39[>\O2TI*SM'X#J'D8/,9^A970_X%>)GP<>NDXQC M!T+=259;<[:3:M+E=:)>&0FHZNM/C"1^)I/A'HAAUB'^F/!?="-$]GK%[\R' M__>E;SX>8HSU)/ORY].>H6?G_#N:B;W%47\_MVPD/8V)]U>360NRBKSQO&YX MW#J9O\MFV^5!7\T,L3Y@G$R7EI:5K8/:,IUH.K9+X/5IM;MRX>TD)"_S=F+# M[07P#9MW:<9?-/J. :9PBH\7;&G^7-@+Y/Z,0Y&EY$J;+[Z$H*>TBFOT.:VQU4^,0?Z&3$BAMA!1ZQXD98@3]0 M=,2+V^#% TU%K+@15D0(=2NLB!#J)B\/O.C;7KOX\"WEG;_D;%ZD"/E9+AW M-2/2_/<'\>.\%"$>:/+JETW^W)WU/41L/$8'SG)9X[V.0"0]]R@][&,LZ9AN MY\I"O B8R\+3GT?1 L"W;S79;WDNMU6$;(/ M!-_?>Y;9S/2R,Z)#;['^DNX#K91=YCN?<506Q(P/+)ROUT^/5E!-LF*BQL4+ MFX9"T<->JU!^$5@XK\&\[PJK$9Q$<'(3<'+@ M\OP13DJUI#6LURMUULVL*[-J4UXP"00G%+J\\3.1P'Y"M3G?O;+/\9+ZGBL( M)%]+!+\[N/^+ 1:"K,$)^+^J\B3XPU_/WXYW@6"8Z%;\WV?(G[TQQ^J^ >_S M<8UX!ZY]O%;4N3*Y#O I;@+QEV0;2-A/HM/X970:O^SL[-23\16SO5/)+"0" M0AQ;4+O 6!![U-+[(WG4T:4LNR+3G4HAL[3=Z=2_E2BF M,W;)D<)5G*PZRW* XCO3S]K>$9\3*WH"GP&P@B92[Q-;OHJP)JM*N3O'XH-5 M=438&EF:M_R[ILG$ _W<;B\*'GW%X%$$+1&TO,HS>PE:$DD7%_"Y!;C"E)8T M, 7\MHBNL4._C"0?J#,6*/H[;X[I;]/N2('>V:^[GQ[?KW(X)^TZEG0;WD.Z>N L?3U?& M=3'=%+AXR3+543SE=,RI?Q>>)I\#M"B*%.E^I/L7T?WSA)V.=1\_H?S#;8TC MMJ5Q A-HMY5J=KO%-HV4GT+5%L.%>3ZI$L;%[KH_"62>O.O^?+P-=>RP=.CV M0'%\[,SD)RO%/1Y!H7ODH]?OZ\1=/V$!-R)!PXXG5SN#!3X[BW.WCKGP[<^] M,@%C#1WMT^:NKFMK8"+?W+OAW$5$/OP[*@=1UZTA@%/>T?WD]<]F?9[G"=BVBC]W 3:U6COWW+/ZT;P$1J''[ A#1QCL*VT9*YA:YCI%NBJ ME9N^I%]^<8G@,/IT6/O9[S_<8'&<2Y=1 6/KL91*^&IN2B4[-:XBR9BPU)79 M4)NF%=&Y6'F4]+X\"IJ8=^^YBEH.HIS.K $DV?IZ]5$:6BP/QH8M&&Z,(!'& MX^E]212X9@ MN=]YZ6)-OPB>(/T"T5"$'G_9^3.(%X^E#O:%-ZJZ-D5'48AS M9LZ&+@02/,8B'F@,*CC*4P[K!4V:??':XCD2>Q$N84=2!]>NE]"?TB4EZBGE6=P MD0RBR@NO9,(2ZA._FLW,#E:K=;#5@>A\8J41\XI^SG!:A>+$GS?G$A +91 MCJ=:?-].CLI'U1W)-Q#]>#HEE(,.4;\-'0^O'9P4O%N8/FX8A]@M/VALW>;=B*H) :E4[C MF)@ ?"HM IY,DB0_3B3&?#(Q(2=2&B.))'E4SNM5WWA2 NQUWTEVS*DBP8J&FR=YDF)FO0&=_]7;0- VBB MUSL1N;308Q=G:$?MB0*"**]ML]_3&;GSGD!YG_GCO%;,NZ?MOPSE'/X%6A6X M KCX@#BQYY> BL@(4/Z0(;*\1@!PNFB3*&AN#)H8^&S4W7GL0@=!-\'QVASO MHXFM>: *!298&?H;].1CFFYY?@7WT'F(2:B2B7'07-(\6._/F"-;L]@4511# M7_,?Y]M%T]_3(I-Y$_O/1_L9!H6V;"I'H9J\SR4V8%+>Y_B3WJ0GX:4 ):L* MR9%Q Y3Q*@^BJ,I,7AXW-1;,65[5G6#<1[J:Z^QS"CQD,?9S$ MKMOK K&>+FI/# MW7(+
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�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end XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 42 R13.htm IDEA: XBRL DOCUMENT v3.20.1

Supplemental Financial Information
3 Months Ended

Mar. 31, 2020

Supplemental Financial Information

Supplemental Financial Information
Note 4 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended March 31, 2020 and 2019 were $541 million and $668 million, respectively. Net earnings allocated to common shares for the three months ended March 31, 2020 and 2019 were $561 million and $668 million, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2020 includes $320 million of pension contributions and the payment of cash taxes of approximately $125 million. The first three months of 2019 includes $313 million of pension contributions and the payment of cash taxes of approximately $185 million.

Earnings from discontinued operations, net of tax, in the first quarter of 2020 include the recognition of $20 million of tax benefits as a result of the resolution of various tax positions related to the previous sale of a business that was reported as a discontinued operation.

The following summarizes the activity for the first three months of 2020 related to the allowance for doubtful accounts as of March 31, 2020:

(in millions)

Allowance for Doubtful Accounts

Balance at December 31, 2019

$
228
Impact of adopting ASU 2016-13

7
Provisions/charges to income

21
Amounts charged off and other deductions

(15)
Balance at March 31, 2020

$
241

The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivables. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.

The components of long-term investments as of March 31, 2020 and December 31, 2019 are as follows:

March 31,

December 31,
(in millions)

2020

2019
Long-term Investments

Equity securities

$
741

$
836
Other

49

47
Total

$
790

$
883

Abbott’s long-term investments as of March 31, 2020, declined versus the balance as of December 31, 2019, due in part to the impairment of an investment for approximately $50 million.

Abbott's equity securities as of March 31, 2020, include approximately $289 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.

Abbott also holds certain investments as of March 31, 2020 with a carrying value of approximately $275 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $162 million that do not have a readily determinable fair value. The $162 million carrying value includes cumulative unrealized gains of approximately $50 million.

In the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired a research & development (R&D) asset valued at $102 million, which was immediately expensed. The $102 million of expense was recorded in the R&D line of Abbott's Condensed Consolidated Statement of Earnings.

X

- Definition
The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.
+ References
No definition available.
+ Details

Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R17.htm IDEA: XBRL DOCUMENT v3.20.1

Incentive Stock Program
3 Months Ended

Mar. 31, 2020

Incentive Stock Program

Incentive Stock Program
Note 8 — Incentive Stock Program

In the first three months of 2020, Abbott granted 3,956,637 stock options, 568,471 restricted stock awards and 5,042,550 restricted stock units under its incentive stock program. At March 31, 2020, approximately 112 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2020 is as follows:


Outstanding

Exercisable
Number of shares

32,412,976

23,330,203
Weighted average remaining life (years)

6.5

5.5
Weighted average exercise price

$
53.83

$
44.69
Aggregate intrinsic value (in millions)

$
849

$
798

The total unrecognized share-based compensation cost at March 31, 2020 amounted to approximately $687 million which is expected to be recognized over the next three years.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R38.htm IDEA: XBRL DOCUMENT v3.20.1

Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cash flow disclosures

Payment of cash taxes $ 125 $ 185

Discontinued operations

Cash flow disclosures

Net tax benefits primarily as a result of the resolution of various tax positions related to prior years 20

Defined Benefit Plans

Cash flow disclosures

Pension contributions $ 320 $ 313

X

- Definition
Amount of contribution received by defined benefit plan from employer which increases plan assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920
+ Details

Name: us-gaap_DefinedBenefitPlanContributionsByEmployer

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for taxes classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForOtherTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28511-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314
+ Details

Name: us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue - Remaining Performance Obligations (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

Diagnostic Products

Remaining Performance Obligations

Remaining performance obligations $ 3,400

Medical Devices

Remaining Performance Obligations

Remaining performance obligations $ 400

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01

Remaining Performance Obligations

Expected timing of satisfication period (in months) 24 months

Percentage of remaining performance obligation expected to be recognized in period 60.00%

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01

Remaining Performance Obligations

Expected timing of satisfication period (in months) 12 months

Percentage of remaining performance obligation expected to be recognized in period 17.00%

X

- Definition
Represents the percentage of revenue recognized for remaining performance obligations
+ References
No definition available.
+ Details

Name: abt_RevenueremainingperformanceObligationExpectedTimingPercentage

Namespace Prefix: abt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of transaction price allocated to performance obligation that has not been recognized as revenue.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045
+ Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-04-01

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-04-01

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R30.htm IDEA: XBRL DOCUMENT v3.20.1

Financial Instruments, Derivatives and Fair Value Measures (Tables)
3 Months Ended

Mar. 31, 2020

Financial Instruments, Derivatives and Fair Value Measures

Summary of the amounts and location of certain derivative financial instruments

Fair Value - Assets

Fair Value - Liabilities

March 31,

Dec. 31,

March 31,

Dec. 31,

(in millions)

2020

2019

Balance Sheet Caption

2020

2019

Balance Sheet Caption

Interest rate swaps designated as fair value hedges

$
216

$
48

Deferred income taxes and other assets

$
—

$
—

Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:

Hedging instruments

247

110

Prepaid expenses and other receivables

92

56

Other accrued liabilities
Others not designated as hedges

117

38

Prepaid expenses and other receivables

97

33

Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary

—

—

n/a

554

546

Long-term debt

$
580

$
196

$
743

$
635

Schedule of derivatives gain (loss) in OCI and earnings

Gain (loss) Recognized in Other

Income (expense) and Gain (loss)

Comprehensive Income (loss)

Reclassified into Income

(in millions)

2020

2019

2020

2019

Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges

$
227

$
(19)

$
11

$
15

Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary

(8)

—

—

—

n/a

Interest rate swaps designated as fair value hedges

n/a

n/a

168

43

Interest expense

Schedule of carrying values and fair values of certain financial instruments

March 31, 2020

December 31, 2019

Carrying

Fair

Carrying

Fair
(in millions)

Value

Value

Value

Value

Long-term Investment Securities:

Equity securities

$
741

$
741

$
836

$
836
Other

49

49

47

47
Total Long-term Debt

(18,068)

(20,998)

(17,938)

(20,772)
Foreign Currency Forward Exchange Contracts:

Receivable position

364

364

148

148
(Payable) position

(189)

(189)

(89)

(89)
Interest Rate Hedge Contracts:

Receivable position

216

216

48

48

Schedule of assets and liabilities measured at fair value on a recurring basis

Basis of Fair Value Measurement

Quoted

Significant

Prices in

Other

Significant

Outstanding

Active

Observable

Unobservable
(in millions)

Balances

Markets

Inputs

Inputs
March 31, 2020:

Equity securities

$
304

$
304

$
—

$
—
Interest rate swap derivative financial instruments

216

—

216

—
Foreign currency forward exchange contracts

364

—

364

—
Total Assets

$
884

$
304

$
580

$
—

Fair value of hedged long-term debt

$
3,064

$
—

$
3,064

$
—
Foreign currency forward exchange contracts

189

—

189

—
Contingent consideration related to business combinations

67

—

—

67
Total Liabilities

$
3,320

$
—

$
3,253

$
67

December 31, 2019:

Equity securities

$
357

$
357

$
—

$
—
Interest rate swap derivative financial instruments

48

—

48

—
Foreign currency forward exchange contracts

148

—

148

—
Total Assets

$
553

$
357

$
196

$
—

Fair value of hedged long-term debt

$
2,890

$
—

$
2,890

$
—
Foreign currency forward exchange contracts

89

—

89

—
Contingent consideration related to business combinations

68

—

—

68
Total Liabilities

$
3,047

$
—

$
2,979

$
68

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R23.htm IDEA: XBRL DOCUMENT v3.20.1

Segment Information
3 Months Ended

Mar. 31, 2020

Segment Information

Segment Information
Note 14 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.

Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.

Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology and Heart Failure, Vascular, Neuromodulation, Structural Heart and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.

The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

Three Months Ended March 31

Net Sales to

Operating

External Customers

Earnings
(in millions)

2020

2019

2020

2019
Established Pharmaceutical Products

$
1,044

$
992

$
181

$
159
Nutritional Products

1,904

1,792

459

380
Diagnostic Products

1,826

1,841

405

434
Medical Devices

2,937

2,895

803

847
Total Reportable Segments

7,711

7,520

1,848

1,820
Other

15

15

Net sales

$
7,726

$
7,535

Corporate functions and benefit plans costs

(132)

(102)
Net interest expense

(121)

(148)
Share-based compensation (a)

(233)

(226)
Amortization of intangible assets

(561)

(486)
Other, net (b)

(168)

(226)
Earnings from continuing operations before taxes

$
633

$
632
(a) Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three months ended March 31, 2019 also includes a charge associated with an R&D asset acquired and immediately expensed.

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R27.htm IDEA: XBRL DOCUMENT v3.20.1

Changes in Accumulated Other Comprehensive Income (Loss) (Tables)
3 Months Ended

Mar. 31, 2020

Changes in Accumulated Other Comprehensive Income (Loss)

Schedule of accumulated other comprehensive income (loss), net of taxes

Three Months Ended March 31

Cumulative Gains

(Losses) on

Net Actuarial

Derivative

Cumulative Foreign

(Losses) and Prior

Instruments

Currency Translation

Service (Costs)

Designated as

Adjustments

and Credits

Cash Flow Hedges
(in millions)

2020

2019

2020

2019

2020

2019
Balance at January 1

$
(4,924)

$
(4,912)

$
(3,540)

$
(2,726)

$
(1)

$
52
Other comprehensive income (loss) before reclassifications

(1,144)

122

7

(1)

176

(17)
Amounts reclassified from accumulated other comprehensive income

—

—

50

24

(10)

(12)
Net current period comprehensive income (loss)

(1,144)

122

57

23

166

(29)
Balance at March 31

$
(6,068)

$
(4,790)

$
(3,483)

$
(2,703)

$
165

$
23

X

- References
No definition available.
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R46.htm IDEA: XBRL DOCUMENT v3.20.1

Incentive Stock Program - General (Details)
3 Months Ended

Mar. 31, 2020

shares

Incentive Stock Program

Incentive stock program, shares reserved for future grants 112,000,000

Stock options

Incentive Stock Program

Stock options granted during the period (in shares) 3,956,637

Restricted stock awards

Incentive Stock Program

Grants in period, restricted stock (in shares) 568,471

Restricted stock units

Incentive Stock Program

Awards and units granted during period (in shares) 5,042,550

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of non-option equity instruments granted to participants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=abt_RestrictedStockAwardsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 R42.htm IDEA: XBRL DOCUMENT v3.20.1

Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Changes in accumulated other comprehensive income (loss), net of income taxes

Beginning of the period $ 31,088

Net current period comprehensive income (loss) (921) $ 116

End of the period 30,218

Cumulative Foreign Currency Translation Adjustments

Changes in accumulated other comprehensive income (loss), net of income taxes

Beginning of the period (4,924) (4,912)

Other comprehensive income (loss) before reclassifications (1,144) 122

Net current period comprehensive income (loss) (1,144) 122

End of the period (6,068) (4,790)

Net Actuarial (Losses) and Prior Service (Costs) and Credits

Changes in accumulated other comprehensive income (loss), net of income taxes

Beginning of the period (3,540) (2,726)

Other comprehensive income (loss) before reclassifications 7 (1)

Amounts reclassified from accumulated other comprehensive income 50 24

Net current period comprehensive income (loss) 57 23

End of the period (3,483) (2,703)

Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges

Changes in accumulated other comprehensive income (loss), net of income taxes

Beginning of the period (1) 52

Other comprehensive income (loss) before reclassifications 176 (17)

Amounts reclassified from accumulated other comprehensive income (10) (12)

Net current period comprehensive income (loss) 166 (29)

End of the period $ 165 $ 23

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17B
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581
+ Details

Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R53.htm IDEA: XBRL DOCUMENT v3.20.1

Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - Recurring - USD ($)
$ in Millions

Mar. 31, 2020

Dec. 31, 2019

Fair value, asset and liability measures

Equity securities $ 304 $ 357

Interest rate swap derivative financial instruments, assets 216 48

Foreign currency forward exchange contracts 364 148

Total Assets 884 553

Fair value of hedged long-term debt 3,064 2,890

Foreign currency forward exchange contracts 189 89

Contingent consideration related to business combinations 67 68

Total Liabilities 3,320 3,047

Quoted Prices in Active Markets

Fair value, asset and liability measures

Equity securities 304 357

Total Assets 304 357

Significant Other Observable Inputs

Fair value, asset and liability measures

Interest rate swap derivative financial instruments, assets 216 48

Foreign currency forward exchange contracts 364 148

Total Assets 580 196

Fair value of hedged long-term debt 3,064 2,890

Foreign currency forward exchange contracts 189 89

Total Liabilities 3,253 2,979

Significant Unobservable Inputs

Fair value, asset and liability measures

Contingent consideration related to business combinations 67 68

Total Liabilities $ 67 $ 68

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476
+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability hedged in fair value hedging relationship.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4EE
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959
+ Details

Name: us-gaap_HedgedLiabilityFairValueHedge

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.
+ References
No definition available.
+ Details

Name: us-gaap_InterestRateDerivativeAssetsAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of financial and nonfinancial obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R57.htm IDEA: XBRL DOCUMENT v3.20.1

Segment Information (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Segment Information

Net Sales to External Customers $ 7,726 $ 7,535

Operating Earnings 758 739

Amortization of intangible assets (561) (486)

Earnings from continuing operations before taxes $ 633 $ 632

Annual share-based awards recognized in first quarter (as a percent) 50.00% 50.00%

Established Pharmaceutical Products

Segment Information

Net Sales to External Customers $ 1,044 $ 992

Nutritional Products

Segment Information

Net Sales to External Customers 1,904 1,792

Diagnostic Products

Segment Information

Net Sales to External Customers 1,826 1,841

Medical Devices

Segment Information

Net Sales to External Customers 2,937 2,895

Other

Segment Information

Net Sales to External Customers 15 15

Total Reportable Segments

Segment Information

Net Sales to External Customers 7,711 7,520

Operating Earnings 1,848 1,820

Total Reportable Segments | Established Pharmaceutical Products

Segment Information

Net Sales to External Customers 1,044 992

Operating Earnings 181 159

Total Reportable Segments | Nutritional Products

Segment Information

Net Sales to External Customers 1,904 1,792

Operating Earnings 459 380

Total Reportable Segments | Diagnostic Products

Segment Information

Net Sales to External Customers 1,826 1,841

Operating Earnings 405 434

Total Reportable Segments | Medical Devices

Segment Information

Net Sales to External Customers 2,937 2,895

Operating Earnings 803 847

Reconciling items

Segment Information

Corporate functions and benefit plan costs (132) (102)

Net interest expense (121) (148)

Share-based compensation (233) (226)

Amortization of intangible assets (561) (486)

Other, net $ (168) $ (226)

X

- Definition
The aggregate expense (excluding discontinued operations) charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
No definition available.
+ Details

Name: abt_AmortizationOfIntangibleAssetsExcludingDiscontinuedOperations

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.
+ References
No definition available.
+ Details

Name: abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent

Namespace Prefix: abt_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.
+ References
No definition available.
+ Details

Name: abt_CorporateAndBenefitPlanCosts

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.
+ References
No definition available.
+ Details

Name: abt_OtherCostAndExpenseOperatingAndNonoperating

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net amount of operating interest income (expense).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.10)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R7.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statement of Shareholders' Investment - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Increase (Decrease) in Shareholders' Investment

Balance at beginning of period $ 31,301

Net earnings 564 $ 672

Other comprehensive income (loss) (921) 116

Balance at end of period 30,427

Common Shares:

Increase (Decrease) in Shareholders' Investment

Balance at beginning of period 23,853 23,512

Issued under incentive stock programs 53 76

Share-based compensation 245 237

Issuance of restricted stock awards (420) (364)

Balance at end of period 23,731 23,461

Common Shares Held in Treasury:

Increase (Decrease) in Shareholders' Investment

Balance at beginning of period (10,147) (9,962)

Issuance of restricted stock awards 253 303

Purchased (19) (20)

Balance at end of period (9,913) (9,679)

Earnings Employed in the Business:

Increase (Decrease) in Shareholders' Investment

Balance at beginning of period 25,847 24,560

Impact of adoption of new accounting standards (5)

Net earnings 564 672

Cash dividends declared on common shares (641) (568)

Effect of common and treasury share transactions 21 (51)

Balance at end of period 25,786 24,613

Accumulated Other Comprehensive Income (Loss):

Increase (Decrease) in Shareholders' Investment

Balance at beginning of period (8,465) (7,586)

Other comprehensive income (loss) (921) 116

Balance at end of period (9,386) (7,470)

Noncontrolling Interests in Subsidiaries:

Increase (Decrease) in Shareholders' Investment

Balance at beginning of period 213 198

Noncontrolling Interests' share of income, business combinations, net of distributions and share repurchases (4) 6

Balance at end of period $ 209 $ 204

X

- Definition
This element represents the effect on retained earning due to common and treasury stock transactions.
+ References
No definition available.
+ Details

Name: abt_EffectOfCommonAndTreasuryShareTransactions

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.
+ References
No definition available.
+ Details

Name: abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.
+ References
No definition available.
+ Details

Name: us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_DividendsCommonStockCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R3.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statement of Comprehensive Income - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Condensed Consolidated Statement of Comprehensive Income

Net Earnings $ 564 $ 672

Foreign currency translation gain (loss) adjustments (1,144) 122

Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $15 in 2020 and $7 in 2019 57 23

Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $48 in 2020 and $(8) in 2019 166 (29)

Other comprehensive income (loss) (921) 116

Comprehensive Income (Loss) (357) $ 788

Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:

Cumulative foreign currency translation (loss) adjustments (6,068) $ (4,924)

Net actuarial (losses) and prior service (cost) and credits (3,483) (3,540)

Cumulative gains (losses) on derivative instruments designated as cash flow hedges 165 (1)

Accumulated Other Comprehensive Income (Loss) $ (9,386) $ (8,465)

X

- Definition
Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R36.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue - Other Contract Assets and Liabilities (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

Contract Liabilities

Balance at December 31, 2019 $ 294

Unearned revenue from cash received during the period 105

Revenue recognized related to contract liability balance (94)

Balance at March 31, 2020 $ 305

X

- Definition
Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.
+ References
No definition available.
+ Details

Name: abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ChangeInContractWithCustomerLiabilityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044
+ Details

Name: us-gaap_ContractWithCustomerLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045
+ Details

Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 57 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Segment Information (Tables)
3 Months Ended

Mar. 31, 2020

Segment Information

Schedule of segment information - net sales and operating earnings

Three Months Ended March 31

Net Sales to

Operating

External Customers

Earnings
(in millions)

2020

2019

2020

2019
Established Pharmaceutical Products

$
1,044

$
992

$
181

$
159
Nutritional Products

1,904

1,792

459

380
Diagnostic Products

1,826

1,841

405

434
Medical Devices

2,937

2,895

803

847
Total Reportable Segments

7,711

7,520

1,848

1,820
Other

15

15

Net sales

$
7,726

$
7,535

Corporate functions and benefit plans costs

(132)

(102)
Net interest expense

(121)

(148)
Share-based compensation (a)

(233)

(226)
Amortization of intangible assets

(561)

(486)
Other, net (b)

(168)

(226)
Earnings from continuing operations before taxes

$
633

$
632
(a) Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.
(b) Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three months ended March 31, 2019 also includes a charge associated with an R&D asset acquired and immediately expensed.

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Financial Instruments, Derivatives and Fair Value Measures
3 Months Ended

Mar. 31, 2020

Financial Instruments, Derivatives and Fair Value Measures

Financial Instruments, Derivatives and Fair Value Measures
Note 10 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.0 billion at March 31, 2020 and $6.8 billion at December 31, 2019 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2020 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2020 and December 31, 2019, Abbott held the gross notional amount of $9.5 billion and $9.1 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated a yen-denominated, 5-year term loan of approximately $554 million and $546 million as of March 31, 2020 and December 31, 2019, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at March 31, 2020 and December 31, 2019 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.

The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2020 and December 31, 2019:

Fair Value - Assets

Fair Value - Liabilities

March 31,

Dec. 31,

March 31,

Dec. 31,

(in millions)

2020

2019

Balance Sheet Caption

2020

2019

Balance Sheet Caption

Interest rate swaps designated as fair value hedges

$
216

$
48

Deferred income taxes and other assets

$
—

$
—

Post-employment obligations, deferred income taxes and other long-term liabilities

Foreign currency forward exchange contracts:

Hedging instruments

247

110

Prepaid expenses and other receivables

92

56

Other accrued liabilities
Others not designated as hedges

117

38

Prepaid expenses and other receivables

97

33

Other accrued liabilities
Debt designated as a hedge of net investment in a foreign subsidiary

—

—

n/a

554

546

Long-term debt

$
580

$
196

$
743

$
635

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2020 and 2019.

Gain (loss) Recognized in Other

Income (expense) and Gain (loss)

Comprehensive Income (loss)

Reclassified into Income

(in millions)

2020

2019

2020

2019

Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges

$
227

$
(19)

$
11

$
15

Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary

(8)

—

—

—

n/a

Interest rate swaps designated as fair value hedges

n/a

n/a

168

43

Interest expense

Losses of $165 million and gains of $49 million were recognized in the three months ended March 31, 2020 and 2019, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.

The carrying values and fair values of certain financial instruments as of March 31, 2020 and December 31, 2019 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.

March 31, 2020

December 31, 2019

Carrying

Fair

Carrying

Fair
(in millions)

Value

Value

Value

Value

Long-term Investment Securities:

Equity securities

$
741

$
741

$
836

$
836
Other

49

49

47

47
Total Long-term Debt

(18,068)

(20,998)

(17,938)

(20,772)
Foreign Currency Forward Exchange Contracts:

Receivable position

364

364

148

148
(Payable) position

(189)

(189)

(89)

(89)
Interest Rate Hedge Contracts:

Receivable position

216

216

48

48

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

Basis of Fair Value Measurement

Quoted

Significant

Prices in

Other

Significant

Outstanding

Active

Observable

Unobservable
(in millions)

Balances

Markets

Inputs

Inputs
March 31, 2020:

Equity securities

$
304

$
304

$
—

$
—
Interest rate swap derivative financial instruments

216

—

216

—
Foreign currency forward exchange contracts

364

—

364

—
Total Assets

$
884

$
304

$
580

$
—

Fair value of hedged long-term debt

$
3,064

$
—

$
3,064

$
—
Foreign currency forward exchange contracts

189

—

189

—
Contingent consideration related to business combinations

67

—

—

67
Total Liabilities

$
3,320

$
—

$
3,253

$
67

December 31, 2019:

Equity securities

$
357

$
357

$
—

$
—
Interest rate swap derivative financial instruments

48

—

48

—
Foreign currency forward exchange contracts

148

—

148

—
Total Assets

$
553

$
357

$
196

$
—

Fair value of hedged long-term debt

$
2,890

$
—

$
2,890

$
—
Foreign currency forward exchange contracts

89

—

89

—
Contingent consideration related to business combinations

68

—

—

68
Total Liabilities

$
3,047

$
—

$
2,979

$
68

The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-URI http://asc.fasb.org/topic&trid=2229140
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R11.htm IDEA: XBRL DOCUMENT v3.20.1

New Accounting Standards
3 Months Ended

Mar. 31, 2020

New Accounting Standards

New Accounting Standards
Note 2 — New Accounting Standards

Recently Adopted Accounting Standards

In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.

Recent Accounting Standards Not Yet Adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Goodwill and Intangible Assets
3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets

Goodwill and Intangible Assets
Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $22.9 billion at March 31, 2020 and $23.2 billion at December 31, 2019. Foreign currency translation adjustments decreased goodwill by approximately $268 million in the first three months of 2020. The amount of goodwill related to reportable segments at March 31, 2020 was $2.8 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $16.1 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2020.

The gross amount of amortizable intangible assets, primarily product rights and technology was $27.3 billion as of March 31, 2020 and $27.6 billion as of December 31, 2019, and accumulated amortization was $12.3 billion as of March 31, 2020 and $11.9 billion as of December 31, 2019. Foreign currency translation adjustments decreased intangible assets by $204 million for the first three months of 2020. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2020, $2.0 billion in 2021, 2022, and 2023 and $1.9 billion in 2024.

Indefinite-lived intangible assets, which relate to in-process R&D acquired in a business combination, were approximately $1.2 billion and $1.3 billion as of March 31, 2020 and December 31, 2019, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abt-20200331x10q.htm": { "axisCustom": 0, "axisStandard": 26, "contextCount": 280, "dts": { "calculationLink": { "local": [ "abt-20200331_cal.xml" ] }, "definitionLink": { "local": [ "abt-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "abt-20200331x10q.htm" ] }, "labelLink": { "local": [ "abt-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "abt-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abt-20200331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 474, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 11, "http://www.abbott.com/20200331": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 17 }, "keyCustom": 19, "keyStandard": 312, "memberCustom": 29, "memberStandard": 48, "nsprefix": "abt", "nsuri": "http://www.abbott.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.abbott.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Basis of Presentation", "role": "http://www.abbott.com/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - New Accounting Standards", "role": "http://www.abbott.com/role/DisclosureNewAccountingStandards", "shortName": "New Accounting Standards", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Revenue", "role": "http://www.abbott.com/role/DisclosureRevenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Supplemental Financial Information", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformation", "shortName": "Supplemental Financial Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss)", "role": "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLoss", "shortName": "Changes in Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Restructuring Plans", "role": "http://www.abbott.com/role/DisclosureRestructuringPlans", "shortName": "Restructuring Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Incentive Stock Program", "role": "http://www.abbott.com/role/DisclosureIncentiveStockProgram", "shortName": "Incentive Stock Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Debt and Lines of Credit", "role": "http://www.abbott.com/role/DisclosureDebtAndLinesOfCredit", "shortName": "Debt and Lines of Credit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures", "shortName": "Financial Instruments, Derivatives and Fair Value Measures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Consolidated Statement of Earnings", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings", "shortName": "Condensed Consolidated Statement of Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Litigation and Environmental Matters", "role": "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters", "shortName": "Litigation and Environmental Matters", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Post-Employment Benefits", "role": "http://www.abbott.com/role/DisclosurePostEmploymentBenefits", "shortName": "Post-Employment Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Taxes on Earnings", "role": "http://www.abbott.com/role/DisclosureTaxesOnEarnings", "shortName": "Taxes on Earnings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - Segment Information", "role": "http://www.abbott.com/role/DisclosureSegmentInformation", "shortName": "Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - New Accounting Standards (Policies)", "role": "http://www.abbott.com/role/DisclosureNewAccountingStandardsPolicies", "shortName": "New Accounting Standards (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - Revenue (Tables)", "role": "http://www.abbott.com/role/DisclosureRevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Supplemental Financial Information (Tables)", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables", "shortName": "Supplemental Financial Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Changes in Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_RestructuringCostAndReserveAxis_abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member_KX-5H8AHrEiTYdJniG42FA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Restructuring Plans (Tables)", "role": "http://www.abbott.com/role/DisclosureRestructuringPlansTables", "shortName": "Restructuring Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_RestructuringCostAndReserveAxis_abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member_KX-5H8AHrEiTYdJniG42FA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - Incentive Stock Program (Tables)", "role": "http://www.abbott.com/role/DisclosureIncentiveStockProgramTables", "shortName": "Incentive Stock Program (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Consolidated Statement of Comprehensive Income", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome", "shortName": "Condensed Consolidated Statement of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables)", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables", "shortName": "Financial Instruments, Derivatives and Fair Value Measures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31203 - Disclosure - Post-Employment Benefits (Tables)", "role": "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables", "shortName": "Post-Employment Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31403 - Disclosure - Segment Information (Tables)", "role": "http://www.abbott.com/role/DisclosureSegmentInformationTables", "shortName": "Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_yryp0w5nvEO27hs0eaHPFA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Revenue (Details)", "role": "http://www.abbott.com/role/DisclosureRevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_segment_yryp0w5nvEO27hs0eaHPFA", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_StatementBusinessSegmentsAxis_abt_DiagnosticProductsMember_fojadYOnXk2PzklvvojepA", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - Revenue - Remaining Performance Obligations (Details)", "role": "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails", "shortName": "Revenue - Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_StatementBusinessSegmentsAxis_abt_DiagnosticProductsMember_fojadYOnXk2PzklvvojepA", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R35": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - Revenue - Practical Expedient (Details)", "role": "http://www.abbott.com/role/DisclosureRevenuePracticalExpedientDetails", "shortName": "Revenue - Practical Expedient (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_ORAnmPbgX0ipf1JVSPZp3A", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details)", "role": "http://www.abbott.com/role/DisclosureRevenueOtherContractAssetsAndLiabilitiesDetails", "shortName": "Revenue - Other Contract Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_ORAnmPbgX0ipf1JVSPZp3A", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "abt:IncomeLossFromContinuingOperationsAllocatedToCommonShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Supplemental Financial Information - Income Statement (Details)", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationIncomeStatementDetails", "shortName": "Supplemental Financial Information - Income Statement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "abt:IncomeLossFromContinuingOperationsAllocatedToCommonShares", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsForOtherTaxes", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Supplemental Financial Information - Cash Flows (Details)", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails", "shortName": "Supplemental Financial Information - Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsForOtherTaxes", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_ORAnmPbgX0ipf1JVSPZp3A", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails", "shortName": "Supplemental Financial Information - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_ORAnmPbgX0ipf1JVSPZp3A", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical)", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statement of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - Supplemental Financial Information - Investments (Details)", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails", "shortName": "Supplemental Financial Information - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2019_us-gaap_BusinessAcquisitionAxis_abt_CepheaValveTechnologiesInc.Member_lPM85SALpEuym4Xh5Mvjmw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - Supplemental Financial Information - General (Details)", "role": "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails", "shortName": "Supplemental Financial Information - General (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2019_us-gaap_BusinessAcquisitionAxis_abt_CepheaValveTechnologiesInc.Member_lPM85SALpEuym4Xh5Mvjmw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_ORAnmPbgX0ipf1JVSPZp3A", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Changes in Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember_zvp5dqOvDUWvi7jSR2xwRw", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)", "role": "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)", "role": "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_RestructuringCostAndReserveAxis_abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member_CqgIFuZWvECnhEswtej9jw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Restructuring Plans (Details)", "role": "http://www.abbott.com/role/DisclosureRestructuringPlansDetails", "shortName": "Restructuring Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_RestructuringCostAndReserveAxis_abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member_CqgIFuZWvECnhEswtej9jw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_qtYjgdTe_EySPjitJtubJA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Incentive Stock Program - General (Details)", "role": "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails", "shortName": "Incentive Stock Program - General (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_qtYjgdTe_EySPjitJtubJA", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - Incentive Stock Program - Options (Details)", "role": "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails", "shortName": "Incentive Stock Program - Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_2_24_2019_To_2_24_2019_us-gaap_DebtInstrumentAxis_abt_LongTermNotesDueIn2020At2.80PercentMember_TfFFbPl4_EWcVIh0B4KdwA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Debt and Lines of Credit (Details)", "role": "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails", "shortName": "Debt and Lines of Credit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_2_24_2019_To_2_24_2019_us-gaap_DebtInstrumentAxis_abt_LongTermNotesDueIn2020At2.80PercentMember_TfFFbPl4_EWcVIh0B4KdwA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_abt_YenDenominatedLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_SsZe7CiPn0uPScVv2fSWjg", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_DebtInstrumentAxis_abt_YenDenominatedLongTermDebtMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_SsZe7CiPn0uPScVv2fSWjg", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Consolidated Balance Sheet", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_f-V-twTaN0igkgXHFtm4Tw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_f-V-twTaN0igkgXHFtm4Tw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41004 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_tuu2mcWbxE-SjE5NtFbc_g", "decimals": "-6", "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kL6PPrcN30a8a16lT_E2xQ", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41005 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "role": "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails", "shortName": "Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_kL6PPrcN30a8a16lT_E2xQ", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Litigation and Environmental Matters (Details)", "role": "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails", "shortName": "Litigation and Environmental Matters (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "abt:LossContingencyRangeOfPossibleLossMaximumIndividualSite", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_VILdsgyh3UuaT6H73c3fog", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Post-Employment Benefits - (Details)", "role": "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails", "shortName": "Post-Employment Benefits - (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "us-gaap:PostemploymentBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember_VILdsgyh3UuaT6H73c3fog", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2019_To_3_31_2019_62Qa7Gm3vEaIUbKvv7fdmQ", "decimals": "-6", "first": true, "lang": null, "name": "abt:TaxCutsAndJobsActOf2017TransitionTaxIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Taxes on Earnings (Details)", "role": "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails", "shortName": "Taxes on Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2019_To_3_31_2019_62Qa7Gm3vEaIUbKvv7fdmQ", "decimals": "-6", "first": true, "lang": null, "name": "abt:TaxCutsAndJobsActOf2017TransitionTaxIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - Segment Information (Details)", "role": "http://www.abbott.com/role/DisclosureSegmentInformationDetails", "shortName": "Segment Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "2", "lang": null, "name": "abt:AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_qhhsS0MMS0qXAOWYrq3NXw", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical)", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical", "shortName": "Condensed Consolidated Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_3_31_2020_vnDMWQlPdESfUYfUfmAMHA", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_ORAnmPbgX0ipf1JVSPZp3A", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Consolidated Statement of Shareholders' Investment", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "shortName": "Condensed Consolidated Statement of Shareholders' Investment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ftr9MJJLX06YbIcY6NyOtg", "decimals": "-6", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_I6ASby4ZkUKwClhCUe6_Sg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Parenthetical)", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical", "shortName": "Condensed Consolidated Statement of Shareholders' Investment (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_I6ASby4ZkUKwClhCUe6_Sg", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Condensed Consolidated Statement of Cash Flows", "role": "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows", "shortName": "Condensed Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "abt-20200331x10q.htm", "contextRef": "Duration_1_1_2020_To_3_31_2020_r7wbb08gAk6AkmJuYEztrw", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_qDto8lg3lEy93FL3Z1m2nA", "xsiNil": "false" } } }, "segmentCount": 77, "tag": { "abt_AdultNutritionalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the adult nutritionals, segment of the entity.", "label": "Adult Nutritionals [Member]", "terseLabel": "Adult Nutritionals" } } }, "localname": "AdultNutritionalsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_AmortizationOfIntangibleAssetsExcludingDiscontinuedOperations": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 }, "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense (excluding discontinued operations) charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets Excluding Discontinued Operations", "negatedLabel": "Amortization of intangible assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssetsExcludingDiscontinuedOperations", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "abt_AnnualShareBasedAwardsRecognizedInFirstQuarterPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of the annual cost of share-based awards which will typically be recognized in the first quarter.", "label": "Annual Share Based Awards Recognized in First Quarter Percent", "terseLabel": "Annual share-based awards recognized in first quarter (as a percent)" } } }, "localname": "AnnualShareBasedAwardsRecognizedInFirstQuarterPercent", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "percentItemType" }, "abt_CepheaValveTechnologiesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to Cephea Valve Technologies, Inc.,.", "label": "Cephea Valve Technologies Inc. [Member]", "terseLabel": "Cephea Valve Technologies, Inc" } } }, "localname": "CepheaValveTechnologiesInc.Member", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails" ], "xbrltype": "domainItemType" }, "abt_ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in cash received to be satisfied.", "label": "Contract With Customer Liability, Change In Unearned Revenue From Cash Received Recognized", "terseLabel": "Unearned revenue from cash received during the period" } } }, "localname": "ContractWithCustomerLiabilityChangeInUnearnedRevenueFromCashReceivedRecognized", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueOtherContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "abt_CoreLaboratoryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the core laboratory, segment of the entity.", "label": "Core Laboratory [Member]", "terseLabel": "Core Laboratory" } } }, "localname": "CoreLaboratoryMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_CorporateAndBenefitPlanCosts": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The reconciling item from aggregate segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to corporate functions and benefit plan costs.", "label": "Corporate and Benefit Plan Costs", "negatedLabel": "Corporate functions and benefit plan costs" } } }, "localname": "CorporateAndBenefitPlanCosts", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "abt_DeferredIncomeTaxesAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Deferred Income Taxes and Other Assets line item in the statement of financial position in which the amounts are included.", "label": "Deferred Income Taxes And Other Assets [Member]", "terseLabel": "Deferred income taxes and other assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_DefinedBenefitPlanAndOtherPostretirementBenefitPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participants with a pension and other postretirement benefit plans.", "label": "Defined Benefit Plan And Other Postretirement Benefit Plan [Member]", "terseLabel": "Defined benefit plans and medical and dental plans" } } }, "localname": "DefinedBenefitPlanAndOtherPostretirementBenefitPlanMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "domainItemType" }, "abt_DefinedBenefitPlanNetAmortizationCostsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Defined Benefit Plan Net Amortization Costs [Abstract]", "terseLabel": "Net amortization of:" } } }, "localname": "DefinedBenefitPlanNetAmortizationCostsAbstract", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "abt_DiabetesCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the Diabetes Care, segment of the entity.", "label": "Diabetes Care [Member]", "terseLabel": "Diabetes Care" } } }, "localname": "DiabetesCareMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_DiagnosticProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The diagnostics products segment of the entity.", "label": "Diagnostic Products [Member]", "terseLabel": "Diagnostic Products" } } }, "localname": "DiagnosticProductsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_EffectOfCommonAndTreasuryShareTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents the effect on retained earning due to common and treasury stock transactions.", "label": "Effect of Common and Treasury Share Transactions", "negatedLabel": "Effect of common and treasury share transactions" } } }, "localname": "EffectOfCommonAndTreasuryShareTransactions", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "abt_ElectrophysiologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the electrophysiology, segment of the entity.", "label": "Electrophysiology [Member]", "terseLabel": "Electrophysiology" } } }, "localname": "ElectrophysiologyMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_EstablishedPharmaceuticalProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Established Pharmaceutical Products, segment of the entity.", "label": "Established Pharmaceutical Products [Member]", "terseLabel": "Established Pharmaceutical Products" } } }, "localname": "EstablishedPharmaceuticalProductsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_HeartFailureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the Heart Failure, segment of the entity.", "label": "Heart Failure [Member]", "terseLabel": "Heart Failure" } } }, "localname": "HeartFailureMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_IncomeLossFromContinuingOperationsAllocatedToCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations allocated to common shares during the reporting period.", "label": "Income (Loss) from Continuing Operations Allocated to Common Shares", "terseLabel": "Earnings from continuing operations allocated to common shares" } } }, "localname": "IncomeLossFromContinuingOperationsAllocatedToCommonShares", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "abt_KeyEmergingMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the key emerging markets, segment of the entity.", "label": "Key Emerging Markets [Member]", "terseLabel": "Key Emerging Markets" } } }, "localname": "KeyEmergingMarketsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_LegalProceedingsAndEnvironmentalExposuresMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss contingencies related to legal proceedings and environmental exposures.", "label": "Legal Proceedings And Environmental Exposures [Member]", "terseLabel": "Legal proceedings and environmental exposures" } } }, "localname": "LegalProceedingsAndEnvironmentalExposuresMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "abt_LongTermNotesDueIn2020At2.80PercentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents 2.80 percent long-term notes, which are due in 2020.", "label": "Long Term Notes Due In2020 At2.80 Percent [Member]", "terseLabel": "2.80% Notes, due 2020" } } }, "localname": "LongTermNotesDueIn2020At2.80PercentMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails" ], "xbrltype": "domainItemType" }, "abt_LossContingencyRangeOfPossibleLossMaximumAggregateSites": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The estimated maximum loss, for all sites, from the contingency related to the environmental clean up in the United States and Puerto Rico.", "label": "Loss Contingency Range of Possible Loss, Maximum Aggregate Sites", "terseLabel": "Maximum expected cleanup exposure in aggregate" } } }, "localname": "LossContingencyRangeOfPossibleLossMaximumAggregateSites", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "abt_LossContingencyRangeOfPossibleLossMaximumIndividualSite": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The estimated maximum loss, per individual site, from the contingency related to the environmental clean up in the United States and Puerto Rico.", "label": "Loss Contingency Range of Possible Loss, Maximum Individual Site", "terseLabel": "Maximum expected cleanup exposure for individual site" } } }, "localname": "LossContingencyRangeOfPossibleLossMaximumIndividualSite", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "abt_MedicalDevicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The medical devices segment of the entity.", "label": "Medical Devices [Member]", "terseLabel": "Medical Devices" } } }, "localname": "MedicalDevicesMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_MinimumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Minimum Length Of Time Hedged In Cash Flow Hedge 1", "terseLabel": "Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MinimumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "durationItemType" }, "abt_MolecularMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the molecular, segment of the entity.", "label": "Molecular [Member]", "terseLabel": "Molecular" } } }, "localname": "MolecularMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_NeuromodulationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the neuromodulation, segment of the entity.", "label": "Neuromodulation [Member]", "terseLabel": "Neuromodulation" } } }, "localname": "NeuromodulationMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for a new accounting pronouncement that has been issued but not yet adopted.", "label": "Recently Accounting Standards Not Yet Adopted", "terseLabel": "Recent Accounting Standards Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureNewAccountingStandardsPolicies" ], "xbrltype": "textBlockItemType" }, "abt_NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represent Noncontrolling Interests' share of income, net of distributions, share repurchases and business combinations.", "label": "Noncontrolling Interests Share of Income Net of Distributions and Share Repurchases and Business Combinations", "terseLabel": "Noncontrolling Interests' share of income, business combinations, net of distributions and share repurchases" } } }, "localname": "NoncontrollingInterestsShareOfIncomeNetOfDistributionsAndShareRepurchasesAndBusinessCombinations", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "abt_NutritionalProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The nutritional products segment of the entity.", "label": "Nutritional Products [Member]", "terseLabel": "Nutritional Products" } } }, "localname": "NutritionalProductsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "abt_OtherCostAndExpenseOperatingAndNonoperating": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The reconciling item from segment operating income or loss to consolidated earnings or loss before income tax expense or benefit, related to net other income or expenses.", "label": "Other Cost and Expense, Operating and Nonoperating", "negatedLabel": "Other, net" } } }, "localname": "OtherCostAndExpenseOperatingAndNonoperating", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "abt_OtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the other, segment of the entity.", "label": "Other [Member]", "terseLabel": "Other" } } }, "localname": "OtherMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase, and research and development assets.", "label": "Payments to Acquire Businesses, Net of Cash Acquired, And Research and Development in Process", "negatedLabel": "Acquisitions of businesses and technologies, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquiredAndResearchAndDevelopmentInProcess", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "abt_PediatricNutritionalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the pediatric nutritionals, segment of the entity.", "label": "Pediatric Nutritionals [Member]", "terseLabel": "Pediatric Nutritionals" } } }, "localname": "PediatricNutritionalsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_PointOfCareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the point of care, segment of the entity.", "label": "Point Of Care [Member]", "terseLabel": "Point of Care" } } }, "localname": "PointOfCareMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of Post-employment obligations and amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other liabilities expected to be paid after one year or operating cycle, if longer.", "label": "Post-employment Obligations, Deferred Income Taxes and Other Long-term Liabilities", "terseLabel": "Post-employment obligations, deferred income taxes and other long-term liabilities" } } }, "localname": "PostEmploymentObligationsDeferredIncomeTaxesAndOtherLongTermLiabilities", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "abt_PostemploymentObligationsAndOtherLongTermLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Postemployment Obligations and Other Long Term Liabilities [Abstract]", "terseLabel": "Post-employment Obligations and Other Long-term Liabilities:" } } }, "localname": "PostemploymentObligationsAndOtherLongTermLiabilitiesAbstract", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "abt_PrepaidExpenseAndOtherReceivables": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other receivables that are expected to be realized within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Receivables", "terseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpenseAndOtherReceivables", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "abt_PrepaidExpensesAndOtherReceivablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prepaid expenses and other receivables.", "label": "Prepaid Expenses And Other Receivables [Member]", "terseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpensesAndOtherReceivablesMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abt_RapidDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the rapid diagnostics, segment of the entity.", "label": "Rapid Diagnostics [Member]", "terseLabel": "Rapid Diagnostics" } } }, "localname": "RapidDiagnosticsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_RestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted stock awards.", "label": "Restricted Stock Awards [Member]", "terseLabel": "Restricted stock awards" } } }, "localname": "RestrictedStockAwardsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails" ], "xbrltype": "domainItemType" }, "abt_RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the cardiovascular and neuromodulation segment, and Alere Inc. (Alere) into the diagnostics segment, in order to leverage economies of scale and reduce costs.", "label": "Restructuring Plan Business Acquisition St. Jude And Alere Inc. [Member]", "terseLabel": "Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations" } } }, "localname": "RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "domainItemType" }, "abt_RestructuringPlanStreamlineOperationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The restructuring plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses.", "label": "Restructuring Plan Streamline Operations [Member]", "terseLabel": "Restructuring Plan from 2017 to 2020" } } }, "localname": "RestructuringPlanStreamlineOperationsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "domainItemType" }, "abt_RestructuringReservePeriodCashSettledAndOtherAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.", "label": "Restructuring Reserve Period Cash Settled and Other Adjustments", "negatedLabel": "Payments and other adjustments" } } }, "localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "abt_RevenueremainingperformanceObligationExpectedTimingPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of revenue recognized for remaining performance obligations", "label": "RevenueRemainingPerformance Obligation Expected Timing Percentage", "terseLabel": "Percentage of remaining performance obligation expected to be recognized in period" } } }, "localname": "RevenueremainingperformanceObligationExpectedTimingPercentage", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "percentItemType" }, "abt_RhythmManagementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the rhythm management, segment of the entity.", "label": "Rhythm Management [Member]", "terseLabel": "Rhythm Management" } } }, "localname": "RhythmManagementMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_ScheduleOfLongTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Schedule of Long Term Investments [Table Text Block]", "terseLabel": "Schedule of long-term investments" } } }, "localname": "ScheduleOfLongTermInvestmentsTableTextBlock", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "abt_StJudeMedicalInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information relating to acquisition of St. Jude Medical, Inc.", "label": "St Jude Medical Inc. [Member]", "terseLabel": "St Jude Medical" } } }, "localname": "StJudeMedicalInc.Member", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "abt_StructuralHeartMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the structural heart, segment of the entity.", "label": "Structural Heart [Member]", "terseLabel": "Structural Heart" } } }, "localname": "StructuralHeartMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_TaxCutsAndJobsActOf2017TransitionTaxIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) from transition tax to Tax Cuts and Jobs Act of 2017.", "label": "Tax Cuts and Jobs Act of 2017, Transition Tax, Income Tax Expense (Benefit)", "negatedLabel": "Reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA)" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxIncomeTaxExpenseBenefit", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "monetaryItemType" }, "abt_TaxesOnEarningsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent taxes on earnings concepts included in a table.", "label": "Taxes on Earnings [Line Items]", "terseLabel": "Taxes on Earnings" } } }, "localname": "TaxesOnEarningsLineItems", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "stringItemType" }, "abt_TaxesOnEarningsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of taxes on earnings.", "label": "Taxes On Earnings [Table]" } } }, "localname": "TaxesOnEarningsTable", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "stringItemType" }, "abt_VascularProductsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "It represents the vascular products, segment of the entity.", "label": "Vascular Products [Member]", "terseLabel": "Vascular" } } }, "localname": "VascularProductsMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "abt_YenDenominatedLongTermDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to yen denominated Long-term debt.", "label": "Yen Denominated Long Term Debt [Member]", "terseLabel": "Yen-denominated long-term debt" } } }, "localname": "YenDenominatedLongTermDebtMember", "nsuri": "http://www.abbott.com/20200331", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "U [S]", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r422" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r423" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r425" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r424" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.", "label": "Exchange [Domain]", "terseLabel": "Exchange [Domain]" } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "X C H [I]", "terseLabel": "Chicago Stock Exchange" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "X N Y [S]", "terseLabel": "New York Stock Exchange" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2019-01-31", "presentation": [ "http://www.abbott.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "srt_CondensedCashFlowStatementTable": { "auth_ref": [ "r108", "r297" ], "lang": { "en-US": { "role": { "label": "Condensed Cash Flow Statement [Table]" } } }, "localname": "CondensedCashFlowStatementTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "stringItemType" }, "srt_CondensedCashFlowStatementsCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Cash Flow Statements, Captions [Line Items]", "terseLabel": "Cash Flows Statement Disclosures" } } }, "localname": "CondensedCashFlowStatementsCaptionsLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r134", "r143" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAdjustmentMember": { "auth_ref": [ "r110", "r111", "r112", "r113" ], "lang": { "en-US": { "role": { "label": "Restatement Adjustment [Member]", "terseLabel": "Restatement Adjustment" } } }, "localname": "RestatementAdjustmentMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restatement [Domain]", "terseLabel": "Restatement [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r145", "r229", "r232", "r409", "r417", "r418" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]", "terseLabel": "Changes in accumulated other comprehensive income (loss), net of income taxes" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update201613 [Member]", "terseLabel": "2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "terseLabel": "Allowance for Doubtful Accounts" } } }, "localname": "AccountsNotesAndLoansReceivableLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r18", "r43" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Summary of activity of allowance for doubtful accounts" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r14", "r30", "r147", "r148", "r230" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Trade receivables, less allowances of $389 in 2020 and $384 in 2019" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r26", "r375", "r395" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Other accrued liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r61", "r67", "r68", "r248", "r305" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment [Member]", "terseLabel": "Net Actuarial (Losses) and Prior Service (Costs) and Credits" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r184" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r67", "r75", "r304" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain Loss Net Cash Flow Hedge Parent [Member]", "terseLabel": "Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r62", "r67" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax", "negatedLabel": "Net actuarial (losses) and prior service (cost) and credits" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r58", "r64", "r66", "r67", "r351", "r359", "r360" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Cumulative foreign currency translation (loss) adjustments" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Changes in accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r64", "r66", "r67" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)", "totalLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Changes in Accumulated Other Comprehensive Income (Loss)", "terseLabel": "Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r67", "r68", "r305" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss):" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r59", "r67", "r68", "r305" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Translation Adjustment [Member]", "terseLabel": "Cumulative Foreign Currency Translation Adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Supplemental Financial Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities -" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r127", "r128", "r129", "r130", "r131", "r132" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "All Other Segments [Member]", "terseLabel": "Other" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r263", "r279", "r283" ], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "negatedLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r149", "r157", "r158", "r161" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning period", "terseLabel": "Impact of adopting ASU 2016-13" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r35", "r149", "r157" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Trade receivables, allowances (in dollars)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedLabel": "Amounts charged off and other deductions" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r101", "r175", "r178" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Outstanding Common Stock Options Having No Dilutive Effect (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "sharesItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r64" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "terseLabel": "Cumulative gains (losses) on derivative instruments designated as cash flow hedges" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r138", "r373", "r394" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r15", "r16", "r55" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r341" ], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Equity securities" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r265", "r281" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails", "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r320", "r325" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r291", "r292" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business acquisitions" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r294", "r295", "r296" ], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Contingent consideration related to business combinations" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "verboseLabel": "Research & development (R&D) asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r353", "r354" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Carrying Reported Amount Fair Value Disclosure [Member]", "terseLabel": "Carrying Value" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r12", "r39", "r103" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r97", "r103", "r104" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents, End of Period", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r97", "r358" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Decrease in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r316" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedges" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Contract Liabilities" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueOtherContractAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r49", "r200", "r382", "r402" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation and Environmental Matters" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r199", "r209" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Litigation and Environmental Matters" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared per common share" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Shares:" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, authorized shares" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesHeldInEmployeeTrust": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees.", "label": "Common Stock, Shares Held in Employee Trust", "terseLabel": "Securities in mutual funds held in a rabbi trust" } } }, "localname": "CommonStockSharesHeldInEmployeeTrust", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, issued shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r214" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common shares, without par value Authorized - 2,400,000,000 shares, Issued at stated capital amount - Shares: 2020: 1,978,112,501; 2019: 1,976,855,085" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r71", "r73", "r74" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "verboseLabel": "Changes in Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Schedule of changes in contract liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r222", "r223", "r230" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Balance at March 31, 2020", "periodStartLabel": "Balance at December 31, 2019" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueOtherContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized related to contract liability balance" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueOtherContractAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r84" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods Sold", "terseLabel": "Cost of products sold, excluding amortization of intangible assets" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r83" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating cost and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Impact of adoption of new accounting standards" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt and Lines of Credit" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Lines of Credit" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCredit" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r24", "r26", "r27", "r374", "r376", "r391" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt and Lines of Credit" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r106", "r215", "r216", "r217", "r218", "r362", "r363", "r365", "r390" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtMember": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates.", "label": "Debt [Member]", "terseLabel": "Debt" } } }, "localname": "DebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease reasonably possible in gross unrecognized tax benefits" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Deferred income taxes and other assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r246", "r257", "r260" ], "calculation": { "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gains (Losses)", "negatedLabel": "Actuarial loss, net" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r247", "r258", "r260" ], "calculation": { "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "verboseLabel": "Prior service cost (credit)" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r239", "r240", "r241", "r259", "r260" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Contributions by Employer", "terseLabel": "Company contributions", "verboseLabel": "Pension contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Retirement Plans" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r245", "r256", "r260" ], "calculation": { "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return on Plan Assets", "negatedLabel": "Expected return on plans assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r238", "r244", "r255", "r260" ], "calculation": { "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost on projected benefit obligations" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r242", "r253", "r260" ], "calculation": { "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost", "totalLabel": "Net cost - continuing operations" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Defined Benefit Plan, Net Periodic Benefit Cost [Abstract]", "terseLabel": "Defined benefit plan net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r237", "r243", "r254", "r260" ], "calculation": { "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost - benefits earned during the period" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r101", "r182" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r56", "r57", "r323", "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Fair Value - Assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r56", "r57", "r323", "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Fair Value - Liabilities" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r321", "r324", "r328", "r331" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Derivatives and Fair Value Measures" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Financial Instruments, Derivatives and Fair Value Measures" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r318", "r321", "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r318", "r321", "r328", "r331", "r332", "r336", "r338" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Gain (loss) on derivatives" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r312", "r314" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "verboseLabel": "Gross notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r107", "r311", "r313", "r314", "r318", "r319", "r326", "r328", "r334", "r335", "r338" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivative instruments, notional amount and fair value" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated As Hedging Instrument [Member]", "terseLabel": "Designated as hedging instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of reportable segment included under sales category" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Incentive Stock Program" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incentive Stock Program" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Financial Information" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common shares" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r18", "r45" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r81", "r110", "r118", "r121", "r122", "r123", "r126", "r387", "r406" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Net earnings (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic Earnings Per Common Share" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r81", "r110", "r118", "r121", "r122", "r123", "r126", "r387", "r406" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Net earnings (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Diluted Earnings Per Common Share" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "stringItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r358" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Salaries, wages and commissions" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Total unrecognized compensation cost, recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r279" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "verboseLabel": "Excess tax benefits from share based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails", "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r40", "r139", "r155" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Investments in two publicly traded companies", "terseLabel": "Equity method investments carrying value" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r20", "r25", "r152", "r381", "r392", "r416" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r153" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investment without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r154" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Unrealized gain" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r352" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate Of Fair Value Fair Value Disclosure [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair value, asset and liability measures" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r341", "r342", "r343", "r347" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r341", "r353", "r354" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r341", "r353" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of carrying values and fair values of certain financial instruments" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r240", "r241", "r260", "r342", "r366" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r341", "r348" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r341", "r342", "r344", "r345", "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueHedgingMember": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.", "label": "Fair Value Hedging [Member]", "terseLabel": "Fair value hedges" } } }, "localname": "FairValueHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r240", "r241", "r260", "r342", "r367" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Quoted Prices in Active Markets" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r240", "r241", "r260", "r342", "r368" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Significant Other Observable Inputs" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r240", "r241", "r260", "r342", "r369" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Significant Unobservable Inputs" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r346", "r349" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "Estimated annual amortization expense, intangible assets, 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Estimated annual amortization expense, intangible assets, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Estimated annual amortization expense, intangible assets, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Estimated annual amortization expense, intangible assets, 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r179" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Estimated annual amortization expense, intangible assets, 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Decrease in intangible assets due to foreign currency translation adjustments" } } }, "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r177", "r371" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross amount of amortizable intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r324" ], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Asset at Fair Value", "terseLabel": "Foreign currency forward exchange contracts, receivable position", "verboseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue": { "auth_ref": [ "r324" ], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.", "label": "Foreign Currency Cash Flow Hedge Liability at Fair Value", "negatedLabel": "Foreign currency forward exchange contracts, (payable) position", "verboseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignCurrencyCashFlowHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r355", "r356", "r357" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Net foreign exchange (gain) loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward exchange contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r166", "r168" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r170" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation Adjustments", "negatedLabel": "Decrease in goodwill due to foreign currency translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r101", "r167", "r169", "r172" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Amount of reductions of goodwill relating to impairments" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r333" ], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Fair value of hedged long-term debt" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r318", "r332" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r151" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Impairment of investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r78", "r110", "r372", "r384", "r407" ], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Earnings from continuing operations before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r300" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Earnings from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r76", "r81", "r118", "r121", "r122", "r383", "r385", "r387", "r403" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r76", "r81", "r118", "r121", "r122", "r123", "r387", "r403", "r406" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Continuing operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r10", "r81", "r404" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Earnings from discontinued operations, net of tax" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r79", "r81", "r120", "r121", "r122", "r387", "r404", "r406" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "terseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r120", "r121", "r122", "r309" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Discontinued operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statement of Earnings" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Taxes on Earnings" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Earnings" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureTaxesOnEarnings" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r137", "r289" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Tax expense (benefit) on earnings from continuing operations" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r100" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade receivables" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r100" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r100" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Investment" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r119", "r125" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive Common Stock Options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r180" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible assets related to in-process R&D acquired in a business combination" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r174", "r176" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net of amortization" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r77", "r136", "r361", "r364", "r389" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense.", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r388" ], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Net interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateDerivativeAssetsAtFairValue": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.", "label": "Interest Rate Derivative Assets, at Fair Value", "terseLabel": "Interest rate swap derivative financial instruments, assets" } } }, "localname": "InterestRateDerivativeAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Asset at Fair Value", "terseLabel": "Interest rate hedge contracts, receivable position" } } }, "localname": "InterestRateFairValueHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r36", "r165" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r13", "r54", "r164" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventories:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r38", "r165" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r37", "r165" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r86", "r135" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest (income)" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r410", "r411", "r414", "r415" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r410", "r411", "r414", "r415" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r34", "r378", "r400" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Shareholders' Investment" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Investment" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r341" ], "calculation": { "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r27", "r212", "r376", "r397" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt.", "verboseLabel": "Term loan" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "negatedLabel": "Total Long-Term Debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long Term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r40" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Investments", "verboseLabel": "Long-term Investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Long-term Investments [Abstract]", "terseLabel": "Investments" } } }, "localname": "LongTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r200", "r201", "r202", "r204", "r205", "r206", "r208", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r200", "r201", "r202", "r204", "r205", "r206", "r208", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "terseLabel": "Recorded accrual balance for legal proceedings and exposures" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyEstimateOfPossibleLoss": { "auth_ref": [ "r203", "r207", "r210" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.", "label": "Loss Contingency, Estimate of Possible Loss", "terseLabel": "Estimation of possible loss" } } }, "localname": "LossContingencyEstimateOfPossibleLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r200", "r201", "r202", "r204", "r205", "r206", "r208", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r141", "r142" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Material Reconciling Items [Member]", "terseLabel": "Reconciling items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [ "r339" ], "lang": { "en-US": { "role": { "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "terseLabel": "Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold" } } }, "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r53", "r377", "r399" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling Interests in Subsidiaries" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "Allowances for Doubtful Accounts and Product Returns" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash (Used in) Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r97" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash (Used in) Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r97", "r99", "r102" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flow From (Used in) Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r69", "r72", "r80", "r102", "r125", "r386", "r405" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net earnings", "totalLabel": "Net Earnings", "verboseLabel": "Net Earnings" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r110", "r116" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net earnings allocated to common shares" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationIncomeStatementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net investment hedges" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "New Accounting Pronouncements and Changes in Accounting Principles [Text Block]", "terseLabel": "New Accounting Standards" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureNewAccountingStandards" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureNewAccountingStandardsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non Us [Member]", "terseLabel": "Int'l" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r298" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interests in Subsidiaries:" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Nondesignated [Member]", "terseLabel": "Not designated as hedging instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails", "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.abbott.com/role/DisclosureSegmentInformationDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Earnings", "totalLabel": "Operating earnings" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r134", "r143" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Total Reportable Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r11", "r310" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r17", "r18", "r19", "r45" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAggregatedInvestmentsMember": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.", "label": "Other Aggregated Investments [Member]", "terseLabel": "Other" } } }, "localname": "OtherAggregatedInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r62", "r64", "r300", "r304" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent", "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $15 in 2020 and $7 in 2019" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r300", "r301", "r304" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation gain (loss) adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r67", "r75" ], "calculation": { "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other comprehensive income (loss) before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r64" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges, net of taxes of $48 in 2020 and $(8) in 2019" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Net gains (losses) for derivative instruments designated as cash flow hedges, taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r60", "r64", "r322", "r327", "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain (loss) Recognized in Other Comprehensive Income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r70", "r73", "r300", "r301", "r304" ], "calculation": { "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Net current period comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": { "auth_ref": [ "r62", "r65", "r300" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax", "negatedLabel": "Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (costs) and credits, taxes" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r87" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r235", "r249", "r250", "r261" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefit Plans Defined Benefit [Member]", "terseLabel": "Medical and Dental Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForOtherTaxes": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for taxes classified as other.", "label": "Payments for Other Taxes", "terseLabel": "Payment of cash taxes" } } }, "localname": "PaymentsForOtherTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromInvestments": { "auth_ref": [ "r108" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.", "label": "Payments for (Proceeds from) Investments", "negatedLabel": "Sales (purchases) of other investment securities, net" } } }, "localname": "PaymentsForProceedsFromInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r90", "r92", "r108" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of common shares" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r94" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r91" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisitions of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r234", "r249", "r250", "r261" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plans Defined Benefit [Member]", "terseLabel": "Defined Benefit Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r350" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion At Fair Value Fair Value Disclosure [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Post-Employment Benefits" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PostemploymentBenefitsDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.", "label": "Postemployment Benefits Disclosure [Text Block]", "terseLabel": "Post-Employment Benefits" } } }, "localname": "PostemploymentBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized shares" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, issued shares" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r28" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r108" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net borrowings (repayments) of short-term debt and other" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r93", "r282" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r69", "r72", "r96", "r138", "r144", "r300", "r302", "r303", "r307", "r308" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r183" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r21", "r22", "r185", "r401" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Net property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r82", "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Provisions/charges to income" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r67", "r68" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "terseLabel": "Income (expense) and Gain (loss) Reclassified into Income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r67", "r68", "r75" ], "calculation": { "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Amounts reclassified from accumulated other comprehensive income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r95" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "verboseLabel": "Repayments of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r95" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r285", "r419" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Research & development expense" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring Plans" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring Plans" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring and Related Cost [Line Items]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringAndRelatedCostLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r101", "r188", "r193", "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring charges in 2020" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r189", "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Accrued balance at end of the period", "periodStartLabel": "Accrued balance at beginning of the period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r219", "r398" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Earnings employed in the business" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Earnings Employed in the Business:" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r234", "r235", "r249", "r250", "r261" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r234", "r235", "r249", "r250", "r261" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Defined Benefit Plan and Other Postretirement Benefit Plan [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails", "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r228", "r229" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net Sales to External Customers" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "Indicates (true false) whether optional exemption was applied not to disclose amount of transaction price allocated to and explanation of expected timing of revenue recognition for remaining performance obligation, when contract has expected duration of one year or less or right to consideration corresponds directly to performance completed.", "label": "Revenue, Practical Expedient, Remaining Performance Obligation [true/false]", "terseLabel": "Practical expedient in remaining performance obligations related to contracts" } } }, "localname": "RevenuePracticalExpedientRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenuePracticalExpedientDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r225" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation", "terseLabel": "Remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Remaining Performance Obligations" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Expected timing of satisfication period (in months)" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r67" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of accumulated other comprehensive income (loss), net of taxes" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r291", "r292" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r249", "r250", "r251", "r252", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r321", "r328", "r332" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of derivatives gain (loss) in OCI and earnings" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r326" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of the amounts and location of certain derivative financial instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r341", "r342" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r171", "r173" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r191", "r192", "r195" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r191", "r192", "r195" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of restructuring activity" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r133", "r138", "r140", "r141", "r171" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r133", "r138", "r140", "r141", "r171" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of segment information - net sales and operating earnings" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r265", "r281" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails", "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r267", "r274", "r276" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of stock options outstanding and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r0", "r1", "r2", "r3" ], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Segment Discontinued Operations [Member]", "terseLabel": "Discontinued operations" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Segment Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Information" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Information", "verboseLabel": "Revenue" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r85", "r163" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense.", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r100" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants in period, restricted stock (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Incentive Stock Program" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails", "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "verboseLabel": "Awards and units granted during period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Incentive stock program, shares reserved for future grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable options, number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable options, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Stock options granted during the period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r269", "r281" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Stock options outstanding, number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Stock options outstanding, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r262", "r266" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails", "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value of options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable options, weighted-average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options outstanding, weighted-average remaining life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r23", "r374", "r396" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term borrowings" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r25", "r379", "r380", "r381", "r393" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "verboseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r9", "r138", "r171", "r187", "r190", "r197", "r408" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails", "http://www.abbott.com/role/DisclosureRevenueDetails", "http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails", "http://www.abbott.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r50", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statement of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Balance Sheet" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statement of Comprehensive Income" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Consolidated Statement of Shareholders' Investment" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r28", "r29", "r214", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issued under incentive stock programs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r214", "r219", "r272" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issued under incentive stock programs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r214", "r219" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r28", "r29", "r219", "r264", "r275" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r50", "r214", "r219" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issued under incentive stock programs" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r32", "r33", "r150" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "End of the period", "periodStartLabel": "Beginning of the period", "totalLabel": "Total Abbott Shareholders' Investment" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails", "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r298", "r299", "r306" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total Shareholders' Investment" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders' Investment:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfInvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Summary of Investment Holdings [Line Items]", "terseLabel": "Components of long-term investments" } } }, "localname": "SummaryOfInvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfInvestmentHoldingsTable": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "The summary of investment holding table is used for any listing of investment in a summary form. Table lists the 50 largest investments and any other investment the value of which exceeded one percent of net asset value of the registrant as of the close of the period.", "label": "Summary of Investment Holdings [Table]" } } }, "localname": "SummaryOfInvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information:", "verboseLabel": "Cash flow disclosures" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "auth_ref": [ "r286", "r287" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.", "label": "Tax Adjustments, Settlements, and Unusual Provisions", "negatedLabel": "Net tax benefits primarily as a result of the resolution of various tax positions related to prior years" } } }, "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails", "http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r52", "r220" ], "lang": { "en-US": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock Common [Member]", "terseLabel": "Common Shares Held in Treasury:" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment", "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r52", "r220" ], "lang": { "en-US": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Common shares held in treasury, shares" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r52", "r220", "r221" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedLabel": "Common shares held in treasury, at cost - Shares: 2020: 209,267,175 ; 2019: 214,351,838" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r29", "r214", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r214", "r219", "r220" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type Of Adoption [Member]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type Of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/DisclosureRestructuringPlansDetails", "http://www.abbott.com/role/DisclosureRestructuringPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r117", "r123" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r115", "r123" ], "calculation": { "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118950378&loc=SL82887624-210437" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130558-203045" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28511-109314" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(i)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C.4,6)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r421": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r422": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r423": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r424": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r425": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" } }, "version": "2.1" } XML 62 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Millions

Mar. 31, 2020

Dec. 31, 2019

Condensed Consolidated Balance Sheet

Trade receivables, allowances (in dollars) $ 389 $ 384

Preferred shares, par value (in dollars per share) $ 1 $ 1

Preferred shares, authorized shares 1,000,000 1,000,000

Preferred shares, issued shares 0 0

Common shares, authorized shares 2,400,000,000 2,400,000,000

Common shares, issued shares 1,978,112,501 1,976,855,085

Common shares held in treasury, shares 209,267,175 214,351,838

X

- Definition
Amount of allowance for credit loss on accounts receivable, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446
+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of previously issued common shares repurchased by the issuing entity and held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockCommonShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 63 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statement of Earnings - USD ($)
shares in Thousands, $ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Condensed Consolidated Statement of Earnings

Net sales $ 7,726 $ 7,535

Cost of products sold, excluding amortization of intangible assets 3,281 3,160

Amortization of intangible assets 561 486

Research and development 578 672

Selling, general and administrative 2,548 2,478

Total operating cost and expenses 6,968 6,796

Operating earnings 758 739

Interest expense 139 171

Interest (income) (18) (23)

Net foreign exchange (gain) loss 5 6

Other (income) expense, net (1) (47)

Earnings from continuing operations before taxes 633 632

Tax expense (benefit) on earnings from continuing operations 89 (40)

Earnings from continuing operations 544 672

Earnings from discontinued operations, net of tax 20

Net Earnings $ 564 $ 672

Basic Earnings Per Common Share

Continuing operations (in dollars per share) $ 0.31 $ 0.38

Discontinued operations (in dollars per share) 0.01

Net earnings (in dollars per share) 0.32 0.38

Diluted Earnings Per Common Share

Continuing operations (in dollars per share) 0.30 0.38

Discontinued operations (in dollars per share) 0.01

Net earnings (in dollars per share) $ 0.31 $ 0.38

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) 1,768,901 1,763,278

Dilutive Common Stock Options (in shares) 11,677 13,295

Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) 1,780,578 1,776,573

Outstanding Common Stock Options Having No Dilutive Effect (in shares) 4,035 4,011

X

- Definition
The aggregate expense (excluding discontinued operations) charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
No definition available.
+ Details

Name: abt_AmortizationOfIntangibleAssetsExcludingDiscontinuedOperations

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894
+ Details

Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(20))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(13))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3B
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(12))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(14))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 5.E)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256
+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 28A
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 64 R52.htm IDEA: XBRL DOCUMENT v3.20.1

Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) - USD ($)
$ in Millions

Mar. 31, 2020

Dec. 31, 2019

Fair value, asset and liability measures

Long-term Investments $ 790 $ 883

Equity securities

Fair value, asset and liability measures

Long-term Investments 741 836

Carrying Value

Fair value, asset and liability measures

Total Long-Term Debt (18,068) (17,938)

Foreign currency forward exchange contracts, receivable position 364 148

Foreign currency forward exchange contracts, (payable) position (189) (89)

Interest rate hedge contracts, receivable position 216 48

Carrying Value | Equity securities

Fair value, asset and liability measures

Long-term Investments 741 836

Carrying Value | Other

Fair value, asset and liability measures

Long-term Investments 49 47

Fair Value

Fair value, asset and liability measures

Total Long-Term Debt (20,998) (20,772)

Foreign currency forward exchange contracts, receivable position 364 148

Foreign currency forward exchange contracts, (payable) position (189) (89)

Interest rate hedge contracts, receivable position 216 48

Fair Value | Equity securities

Fair value, asset and liability measures

Long-term Investments 741 836

Fair Value | Other

Fair value, asset and liability measures

Long-term Investments $ 49 $ 47

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value as of the balance sheet date of all foreign currency derivative assets designated as cash flow hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ForeignCurrencyCashFlowHedgeAssetAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of all foreign currency derivative liabilities designated as cash flow hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_ForeignCurrencyCashFlowHedgeLiabilityAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959
+ Details

Name: us-gaap_InterestRateFairValueHedgeAssetAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermDebtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_InvestmentTypeAxis=us-gaap_OtherAggregatedInvestmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R56.htm IDEA: XBRL DOCUMENT v3.20.1

Taxes on Earnings (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Taxes on Earnings

Reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA) $ 78

Excess tax benefits from share based compensation $ 47 $ 65

Minimum

Taxes on Earnings

Decrease reasonably possible in gross unrecognized tax benefits 230

Maximum

Taxes on Earnings

Decrease reasonably possible in gross unrecognized tax benefits 520

Discontinued operations

Taxes on Earnings

Net tax benefits primarily as a result of the resolution of various tax positions related to prior years $ 20

X

- Definition
Amount of income tax expense (benefit) from transition tax to Tax Cuts and Jobs Act of 2017.
+ References
No definition available.
+ Details

Name: abt_TaxCutsAndJobsActOf2017TransitionTaxIncomeTaxExpenseBenefit

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent taxes on earnings concepts included in a table.
+ References
No definition available.
+ Details

Name: abt_TaxesOnEarningsLineItems

Namespace Prefix: abt_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)(3)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of tax benefit for recognition of expense of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28511-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28446-109314
+ Details

Name: us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 66 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Supplemental Financial Information - Income Statement (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Supplemental Financial Information

Earnings from continuing operations allocated to common shares $ 541 $ 668

Net earnings allocated to common shares $ 561 $ 668

X

- Definition
The amount of net income (loss) from continuing operations allocated to common shares during the reporting period.
+ References
No definition available.
+ Details

Name: abt_IncomeLossFromContinuingOperationsAllocatedToCommonShares

Namespace Prefix: abt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 67 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Revenue (Details)
$ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

segment

Mar. 31, 2019

USD ($)

segment

Revenue

Number of reportable segments | segment 4 4

Net sales $ 7,726 $ 7,535

U.S.

Revenue

Net sales 2,856 2,754

Int'l

Revenue

Net sales 4,870 4,781

Established Pharmaceutical Products

Revenue

Net sales 1,044 992

Established Pharmaceutical Products | Int'l

Revenue

Net sales 1,044 992

Nutritional Products

Revenue

Net sales 1,904 1,792

Nutritional Products | U.S.

Revenue

Net sales 812 747

Nutritional Products | Int'l

Revenue

Net sales 1,092 1,045

Diagnostic Products

Revenue

Net sales 1,826 1,841

Diagnostic Products | U.S.

Revenue

Net sales 803 724

Diagnostic Products | Int'l

Revenue

Net sales 1,023 1,117

Medical Devices

Revenue

Net sales 2,937 2,895

Medical Devices | U.S.

Revenue

Net sales 1,233 1,275

Medical Devices | Int'l

Revenue

Net sales 1,704 1,620

Other

Revenue

Net sales 15 15

Other | U.S.

Revenue

Net sales 8 8

Other | Int'l

Revenue

Net sales 7 7

Key Emerging Markets | Established Pharmaceutical Products

Revenue

Net sales 813 752

Key Emerging Markets | Established Pharmaceutical Products | Int'l

Revenue

Net sales 813 752

Other | Established Pharmaceutical Products

Revenue

Net sales 231 240

Other | Established Pharmaceutical Products | Int'l

Revenue

Net sales 231 240

Pediatric Nutritionals | Nutritional Products

Revenue

Net sales 1,089 1,029

Pediatric Nutritionals | Nutritional Products | U.S.

Revenue

Net sales 518 453

Pediatric Nutritionals | Nutritional Products | Int'l

Revenue

Net sales 571 576

Adult Nutritionals | Nutritional Products

Revenue

Net sales 815 763

Adult Nutritionals | Nutritional Products | U.S.

Revenue

Net sales 294 294

Adult Nutritionals | Nutritional Products | Int'l

Revenue

Net sales 521 469

Core Laboratory | Diagnostic Products

Revenue

Net sales 989 1,061

Core Laboratory | Diagnostic Products | U.S.

Revenue

Net sales 267 249

Core Laboratory | Diagnostic Products | Int'l

Revenue

Net sales 722 812

Molecular | Diagnostic Products

Revenue

Net sales 139 108

Molecular | Diagnostic Products | U.S.

Revenue

Net sales 65 40

Molecular | Diagnostic Products | Int'l

Revenue

Net sales 74 68

Point of Care | Diagnostic Products

Revenue

Net sales 138 135

Point of Care | Diagnostic Products | U.S.

Revenue

Net sales 103 109

Point of Care | Diagnostic Products | Int'l

Revenue

Net sales 35 26

Rapid Diagnostics | Diagnostic Products

Revenue

Net sales 560 537

Rapid Diagnostics | Diagnostic Products | U.S.

Revenue

Net sales 368 326

Rapid Diagnostics | Diagnostic Products | Int'l

Revenue

Net sales 192 211

Rhythm Management | Medical Devices

Revenue

Net sales 474 514

Rhythm Management | Medical Devices | U.S.

Revenue

Net sales 228 252

Rhythm Management | Medical Devices | Int'l

Revenue

Net sales 246 262

Electrophysiology | Medical Devices

Revenue

Net sales 388 405

Electrophysiology | Medical Devices | U.S.

Revenue

Net sales 164 174

Electrophysiology | Medical Devices | Int'l

Revenue

Net sales 224 231

Heart Failure | Medical Devices

Revenue

Net sales 203 184

Heart Failure | Medical Devices | U.S.

Revenue

Net sales 152 143

Heart Failure | Medical Devices | Int'l

Revenue

Net sales 51 41

Vascular | Medical Devices

Revenue

Net sales 625 709

Vascular | Medical Devices | U.S.

Revenue

Net sales 230 266

Vascular | Medical Devices | Int'l

Revenue

Net sales 395 443

Structural Heart | Medical Devices

Revenue

Net sales 318 324

Structural Heart | Medical Devices | U.S.

Revenue

Net sales 136 136

Structural Heart | Medical Devices | Int'l

Revenue

Net sales 182 188

Neuromodulation | Medical Devices

Revenue

Net sales 177 193

Neuromodulation | Medical Devices | U.S.

Revenue

Net sales 137 152

Neuromodulation | Medical Devices | Int'l

Revenue

Net sales 40 41

Diabetes Care | Medical Devices

Revenue

Net sales 752 566

Diabetes Care | Medical Devices | U.S.

Revenue

Net sales 186 152

Diabetes Care | Medical Devices | Int'l

Revenue

Net sales $ 566 $ 414

X

- Definition
Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_OtherMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_MolecularMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_PointOfCareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_RhythmManagementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_HeartFailureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_VascularProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_StructuralHeartMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_NeuromodulationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=abt_DiabetesCareMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Basis of Presentation
3 Months Ended

Mar. 31, 2020

Basis of Presentation

Basis of Presentation
Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2019. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 69 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Changes in Accumulated Other Comprehensive Income (Loss)
3 Months Ended

Mar. 31, 2020

Changes in Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated Other Comprehensive Income (Loss)
Note 5 — Changes in Accumulated Other Comprehensive Income (Loss)

The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:

Three Months Ended March 31

Cumulative Gains

(Losses) on

Net Actuarial

Derivative

Cumulative Foreign

(Losses) and Prior

Instruments

Currency Translation

Service (Costs)

Designated as

Adjustments

and Credits

Cash Flow Hedges
(in millions)

2020

2019

2020

2019

2020

2019
Balance at January 1

$
(4,924)

$
(4,912)

$
(3,540)

$
(2,726)

$
(1)

$
52
Other comprehensive income (loss) before reclassifications

(1,144)

122

7

(1)

176

(17)
Amounts reclassified from accumulated other comprehensive income

—

—

50

24

(10)

(12)
Net current period comprehensive income (loss)

(1,144)

122

57

23

166

(29)
Balance at March 31

$
(6,068)

$
(4,790)

$
(3,483)

$
(2,703)

$
165

$
23

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange (gain) loss; and amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 12 for additional details.

X

- References
No definition available.
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-URI http://asc.fasb.org/topic&trid=2134417
+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 abt-20200331x10q_htm.xml IDEA: XBRL DOCUMENT 0000001800 us-gaap:SegmentDiscontinuedOperationsMember 2020-01-01 2020-03-31 0000001800 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000001800 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2020-01-01 2020-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2019-01-01 2019-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2020-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000001800 us-gaap:RetainedEarningsMember 2019-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2019-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000001800 us-gaap:RetainedEarningsMember 2019-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2019-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000001800 us-gaap:RetainedEarningsMember 2018-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2018-12-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000001800 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000001800 us-gaap:EmployeeStockOptionMember 2020-03-31 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0000001800 abt:RestrictedStockAwardsMember 2020-01-01 2020-03-31 0000001800 2022-04-01 2020-03-31 0000001800 2020-04-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2020-01-01 2020-03-31 0000001800 country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2020-01-01 2020-03-31 0000001800 country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:VascularProductsMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:HeartFailureMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2020-01-01 2020-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2020-01-01 2020-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2020-01-01 2020-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:MolecularMember 2020-01-01 2020-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:NutritionalProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember 2020-01-01 2020-03-31 0000001800 country:US us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000001800 country:US abt:NutritionalProductsMember 2020-01-01 2020-03-31 0000001800 country:US abt:MedicalDevicesMember 2020-01-01 2020-03-31 0000001800 country:US abt:DiagnosticProductsMember 2020-01-01 2020-03-31 0000001800 abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2020-01-01 2020-03-31 0000001800 abt:NutritionalProductsMember abt:AdultNutritionalsMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:VascularProductsMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:StructuralHeartMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:RhythmManagementMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:NeuromodulationMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:HeartFailureMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:ElectrophysiologyMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember abt:DiabetesCareMember 2020-01-01 2020-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember abt:OtherMember 2020-01-01 2020-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2020-01-01 2020-03-31 0000001800 abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2020-01-01 2020-03-31 0000001800 abt:DiagnosticProductsMember abt:PointOfCareMember 2020-01-01 2020-03-31 0000001800 abt:DiagnosticProductsMember abt:MolecularMember 2020-01-01 2020-03-31 0000001800 abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember 2020-01-01 2020-03-31 0000001800 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000001800 country:US 2020-01-01 2020-03-31 0000001800 abt:NutritionalProductsMember 2020-01-01 2020-03-31 0000001800 abt:MedicalDevicesMember 2020-01-01 2020-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember 2020-01-01 2020-03-31 0000001800 abt:DiagnosticProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:NonUsMember abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:NutritionalProductsMember abt:AdultNutritionalsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:VascularProductsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:StructuralHeartMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:RhythmManagementMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:NeuromodulationMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:HeartFailureMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:ElectrophysiologyMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember abt:DiabetesCareMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:OtherMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:PointOfCareMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:MolecularMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2019-01-01 2019-03-31 0000001800 country:US abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2019-01-01 2019-03-31 0000001800 country:US abt:NutritionalProductsMember abt:AdultNutritionalsMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:VascularProductsMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:StructuralHeartMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:RhythmManagementMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:NeuromodulationMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:HeartFailureMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:ElectrophysiologyMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember abt:DiabetesCareMember 2019-01-01 2019-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2019-01-01 2019-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:PointOfCareMember 2019-01-01 2019-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:MolecularMember 2019-01-01 2019-03-31 0000001800 country:US abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:NutritionalProductsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:MedicalDevicesMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:EstablishedPharmaceuticalProductsMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember abt:DiagnosticProductsMember 2019-01-01 2019-03-31 0000001800 country:US us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000001800 country:US abt:NutritionalProductsMember 2019-01-01 2019-03-31 0000001800 country:US abt:MedicalDevicesMember 2019-01-01 2019-03-31 0000001800 country:US abt:DiagnosticProductsMember 2019-01-01 2019-03-31 0000001800 abt:NutritionalProductsMember abt:PediatricNutritionalsMember 2019-01-01 2019-03-31 0000001800 abt:NutritionalProductsMember abt:AdultNutritionalsMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:VascularProductsMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:StructuralHeartMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:RhythmManagementMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:NeuromodulationMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:HeartFailureMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:ElectrophysiologyMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember abt:DiabetesCareMember 2019-01-01 2019-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember abt:OtherMember 2019-01-01 2019-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember abt:KeyEmergingMarketsMember 2019-01-01 2019-03-31 0000001800 abt:DiagnosticProductsMember abt:RapidDiagnosticsMember 2019-01-01 2019-03-31 0000001800 abt:DiagnosticProductsMember abt:PointOfCareMember 2019-01-01 2019-03-31 0000001800 abt:DiagnosticProductsMember abt:MolecularMember 2019-01-01 2019-03-31 0000001800 abt:DiagnosticProductsMember abt:CoreLaboratoryMember 2019-01-01 2019-03-31 0000001800 us-gaap:NonUsMember 2019-01-01 2019-03-31 0000001800 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000001800 country:US 2019-01-01 2019-03-31 0000001800 abt:NutritionalProductsMember 2019-01-01 2019-03-31 0000001800 abt:MedicalDevicesMember 2019-01-01 2019-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember 2019-01-01 2019-03-31 0000001800 abt:DiagnosticProductsMember 2019-01-01 2019-03-31 0000001800 abt:RestructuringPlanStreamlineOperationsMember 2020-03-31 0000001800 abt:RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member 2020-03-31 0000001800 abt:RestructuringPlanStreamlineOperationsMember 2019-12-31 0000001800 abt:RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member 2019-12-31 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlanStreamlineOperationsMember 2020-01-01 2020-03-31 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member 2020-01-01 2020-03-31 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember abt:RestructuringPlanStreamlineOperationsMember 2020-01-01 2020-03-31 0000001800 us-gaap:ResearchAndDevelopmentExpenseMember abt:RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member 2020-01-01 2020-03-31 0000001800 us-gaap:CostOfSalesMember abt:RestructuringPlanStreamlineOperationsMember 2020-01-01 2020-03-31 0000001800 us-gaap:CostOfSalesMember abt:RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member 2020-01-01 2020-03-31 0000001800 abt:CepheaValveTechnologiesInc.Member 2019-01-01 2019-03-31 0000001800 abt:LongTermNotesDueIn2020At2.80PercentMember 2019-02-24 2019-02-24 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-03-31 0000001800 us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-03-31 0000001800 us-gaap:NondesignatedMember 2019-01-01 2019-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000001800 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000001800 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000001800 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2020-01-01 2020-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2020-01-01 2020-03-31 0000001800 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2019-01-01 2019-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:MedicalDevicesMember 2019-01-01 2019-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2019-01-01 2019-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2019-01-01 2019-03-31 0000001800 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0000001800 srt:MinimumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2020-03-31 0000001800 srt:MaximumMember abt:LegalProceedingsAndEnvironmentalExposuresMember 2020-03-31 0000001800 abt:LegalProceedingsAndEnvironmentalExposuresMember 2020-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2020-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2020-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2020-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2020-03-31 0000001800 us-gaap:OtherInvestmentsMember 2020-03-31 0000001800 us-gaap:EquitySecuritiesMember 2020-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2019-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2019-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2019-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2019-12-31 0000001800 us-gaap:OtherInvestmentsMember 2019-12-31 0000001800 us-gaap:EquitySecuritiesMember 2019-12-31 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 abt:NutritionalProductsMember 2020-03-31 0000001800 abt:MedicalDevicesMember 2020-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember 2020-03-31 0000001800 abt:DiagnosticProductsMember 2020-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-12-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-31 0000001800 us-gaap:LongTermDebtMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 us-gaap:LongTermDebtMember us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-12-31 0000001800 abt:PrepaidExpensesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000001800 srt:MinimumMember 2020-03-31 0000001800 srt:MaximumMember 2020-03-31 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000001800 abt:YenDenominatedLongTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-01-01 2019-12-31 0000001800 abt:LongTermNotesDueIn2020At2.80PercentMember 2019-02-24 0000001800 us-gaap:RetainedEarningsMember 2020-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2020-03-31 0000001800 us-gaap:CommonStockMember 2020-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2019-12-31 0000001800 us-gaap:CommonStockMember 2019-12-31 0000001800 us-gaap:TreasuryStockCommonMember 2019-03-31 0000001800 us-gaap:CommonStockMember 2019-03-31 0000001800 us-gaap:TreasuryStockCommonMember 2018-12-31 0000001800 us-gaap:CommonStockMember 2018-12-31 0000001800 abt:StJudeMedicalInc.Member us-gaap:EquitySecuritiesMember 2020-03-31 0000001800 2019-03-31 0000001800 2018-12-31 0000001800 abt:CepheaValveTechnologiesInc.Member 2019-03-31 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000001800 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2020-03-31 0000001800 exch:XNYS 2020-01-01 2020-03-31 0000001800 exch:XCHI 2020-01-01 2020-03-31 0000001800 2022-04-01 2020-01-01 2020-03-31 0000001800 2020-04-01 2020-01-01 2020-03-31 0000001800 abt:RestructuringPlanStreamlineOperationsMember 2020-01-01 2020-03-31 0000001800 abt:RestructuringPlanBusinessAcquisitionSt.JudeAndAlereInc.Member 2020-01-01 2020-03-31 0000001800 2019-12-31 0000001800 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000001800 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000001800 2020-03-31 0000001800 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000001800 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000001800 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0000001800 2020-01-01 2020-03-31 0000001800 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0000001800 2019-01-01 2019-03-31 iso4217:USD pure shares iso4217:USD shares abt:segment P12M 2000000000 true 0000001800 --12-31 2020 Q1 false 2000000000 P5Y P5Y 10-Q true 2020-03-31 false 1-2189 ABBOTT LABORATORIES IL 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 Common Shares, Without Par Value ABT NYSE CHX Yes Yes Large Accelerated Filer false false false 1768845326 7726000000 7535000000 3281000000 3160000000 561000000 486000000 578000000 672000000 2548000000 2478000000 6968000000 6796000000 758000000 739000000 139000000 171000000 18000000 23000000 -5000000 -6000000 1000000 47000000 633000000 632000000 89000000 -40000000 544000000 672000000 20000000 564000000 672000000 0.31 0.38 0.01 0.32 0.38 0.30 0.38 0.01 0.31 0.38 1768901000 1763278000 11677000 13295000 1780578000 1776573000 4035000 4011000 564000000 672000000 -1144000000 122000000 -15000000 -7000000 -57000000 -23000000 48000000 -8000000 166000000 -29000000 -921000000 116000000 -357000000 788000000 -6068000000 -4924000000 3483000000 3540000000 165000000 -1000000 -9386000000 -8465000000 3377000000 3860000000 291000000 280000000 389000000 384000000 5292000000 5425000000 2873000000 2784000000 615000000 560000000 1080000000 972000000 4568000000 4316000000 1970000000 1786000000 15498000000 15667000000 790000000 883000000 16707000000 16799000000 8800000000 8761000000 7907000000 8038000000 16265000000 17025000000 22927000000 23195000000 3390000000 3079000000 66777000000 67887000000 204000000 201000000 3181000000 3252000000 949000000 1237000000 4408000000 4035000000 637000000 635000000 165000000 226000000 1264000000 1277000000 10808000000 10863000000 16804000000 16661000000 8738000000 9062000000 1 1 1000000 1000000 0 0 2400000000 2400000000 1978112501 1976855085 23731000000 23853000000 209267175 214351838 9913000000 10147000000 25786000000 25847000000 -9386000000 -8465000000 30218000000 31088000000 209000000 213000000 30427000000 31301000000 66777000000 67887000000 1976855085 1971189465 23853000000 23512000000 1257416 2283041 53000000 76000000 245000000 237000000 -420000000 -364000000 1978112501 1973472506 23731000000 23461000000 214351838 215570043 -10147000000 -9962000000 5333626 6544927 253000000 303000000 248963 266128 19000000 20000000 209267175 209291244 -9913000000 -9679000000 25847000000 24560000000 -5000000 564000000 672000000 0.36 0.32 641000000 568000000 -21000000 51000000 25786000000 24613000000 -8465000000 -7586000000 -921000000 116000000 -9386000000 -7470000000 213000000 198000000 -4000000 6000000 209000000 204000000 564000000 672000000 267000000 267000000 561000000 486000000 233000000 226000000 104000000 170000000 437000000 286000000 369000000 483000000 715000000 712000000 360000000 335000000 78000000 36000000 -2000000 -3000000 -15000000 -393000000 -396000000 51000000 13000000 1000000 500000000 236000000 217000000 89000000 127000000 638000000 565000000 -735000000 -1142000000 -70000000 4000000 -483000000 -822000000 3860000000 3844000000 3377000000 3022000000 Note 1 — Basis of PresentationThe accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2019. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions. Note 2 — New Accounting StandardsRecently Adopted Accounting StandardsIn June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.Recent Accounting Standards Not Yet AdoptedIn December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements. Recently Adopted Accounting StandardsIn June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet. Recent Accounting Standards Not Yet AdoptedIn December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements. Note 3 — RevenueAbbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.The following table provides revenues by sales category:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:31.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, 2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:31.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, 2019</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:33.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">U.S.</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Int’l</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">U.S.</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Int’l</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Established Pharmaceutical Products —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Key Emerging Markets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 813</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 813</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 752</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 752</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Other</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 231</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 231</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 240</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 240</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,044</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,044</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 992</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 992</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Nutritionals —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Pediatric Nutritionals</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 518</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 571</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,089</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 453</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 576</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,029</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Adult Nutritionals</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 294</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 521</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 815</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 294</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 469</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 763</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 812</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,092</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,904</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 747</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,045</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,792</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Diagnostics —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Core Laboratory</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 267</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 722</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 989</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 249</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 812</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,061</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Molecular</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 65</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 74</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 139</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 40</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 68</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 108</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Point of Care</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 103</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 35</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 138</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 109</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 26</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 135</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Rapid Diagnostics</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 192</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 560</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 326</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 211</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 537</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 803</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,826</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 724</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,117</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,841</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Medical Devices -</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Rhythm Management</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 228</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 246</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 474</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 252</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 262</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 514</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Electrophysiology</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 164</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 224</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 388</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 174</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 231</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 405</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Heart Failure</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 152</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 51</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 203</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 143</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 41</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 184</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Vascular</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 230</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 395</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 625</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 266</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 443</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 709</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Structural Heart</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 136</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 182</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 318</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 136</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 188</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 324</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Neuromodulation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 137</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 40</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 177</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 152</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 41</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 193</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Diabetes Care</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 186</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 566</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 752</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 414</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 566</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,233</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,704</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,275</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,620</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 2,895</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,856</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,870</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,726</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,754</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,781</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,535</td></tr></table>Remaining Performance ObligationsAs of March 31, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $3.4 billion in the Diagnostics segment and approximately $400 million in the Medical Devices segment. Abbott expects to recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 17 percent over the subsequent 12 months and the remainder thereafter. These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.Other Contract Assets and LiabilitiesAbbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements. Changes in the contract liabilities during the period are as follows:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">Contract Liabilities</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">Balance at December 31, 2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 294</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Unearned revenue from cash received during the period</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 105</td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Revenue recognized related to contract liability balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (94)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">Balance at March 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 305</td></tr></table> 4 4 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:31.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, 2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:31.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31, 2019</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:33.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">U.S.</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Int’l</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">U.S.</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Int’l</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Established Pharmaceutical Products —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Key Emerging Markets</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 813</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 813</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 752</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 752</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Other</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 231</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 231</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 240</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 240</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,044</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,044</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 992</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 992</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Nutritionals —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Pediatric Nutritionals</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 518</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 571</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,089</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 453</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 576</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,029</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Adult Nutritionals</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 294</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 521</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 815</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 294</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 469</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 763</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 812</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,092</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,904</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 747</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,045</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,792</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Diagnostics —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Core Laboratory</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 267</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 722</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 989</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 249</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 812</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,061</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Molecular</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 65</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 74</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 139</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 40</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 68</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 108</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Point of Care</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 103</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 35</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 138</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 109</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 26</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 135</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Rapid Diagnostics</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 368</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 192</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 560</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 326</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 211</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 537</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 803</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,023</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,826</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 724</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,117</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 1,841</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Medical Devices -</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Rhythm Management</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 228</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 246</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 474</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 252</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 262</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 514</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Electrophysiology</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 164</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 224</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 388</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 174</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 231</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 405</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Heart Failure</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 152</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 51</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 203</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 143</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 41</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 184</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Vascular</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 230</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 395</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 625</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 266</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 443</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 709</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Structural Heart</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 136</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 182</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 318</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 136</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 188</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 324</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Neuromodulation</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 137</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 40</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 177</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 152</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 41</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 193</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Diabetes Care</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 186</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 566</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 752</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 152</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 414</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 566</td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,233</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,704</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,275</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"> 1,620</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"> 2,895</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Other</td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:33.47%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,856</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,870</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,726</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,754</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,781</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,535</td></tr></table> 813000000 813000000 752000000 752000000 231000000 231000000 240000000 240000000 1044000000 1044000000 992000000 992000000 518000000 571000000 1089000000 453000000 576000000 1029000000 294000000 521000000 815000000 294000000 469000000 763000000 812000000 1092000000 1904000000 747000000 1045000000 1792000000 267000000 722000000 989000000 249000000 812000000 1061000000 65000000 74000000 139000000 40000000 68000000 108000000 103000000 35000000 138000000 109000000 26000000 135000000 368000000 192000000 560000000 326000000 211000000 537000000 803000000 1023000000 1826000000 724000000 1117000000 1841000000 228000000 246000000 474000000 252000000 262000000 514000000 164000000 224000000 388000000 174000000 231000000 405000000 152000000 51000000 203000000 143000000 41000000 184000000 230000000 395000000 625000000 266000000 443000000 709000000 136000000 182000000 318000000 136000000 188000000 324000000 137000000 40000000 177000000 152000000 41000000 193000000 186000000 566000000 752000000 152000000 414000000 566000000 1233000000 1704000000 2937000000 1275000000 1620000000 2895000000 8000000 7000000 15000000 8000000 7000000 15000000 2856000000 4870000000 7726000000 2754000000 4781000000 7535000000 3400000000 400000000 0.60 P24M 0.17 P12M <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:84.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">Contract Liabilities</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">Balance at December 31, 2019</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 294</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Unearned revenue from cash received during the period</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> 105</td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"> Revenue recognized related to contract liability balance</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (94)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;">Balance at March 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 305</td></tr></table> 294000000 105000000 -94000000 305000000 Note 4 — Supplemental Financial InformationShares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended March 31, 2020 and 2019 were $541 million and $668 million, respectively. Net earnings allocated to common shares for the three months ended March 31, 2020 and 2019 were $561 million and $668 million, respectively.Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2020 includes $320 million of pension contributions and the payment of cash taxes of approximately $125 million. The first three months of 2019 includes $313 million of pension contributions and the payment of cash taxes of approximately $185 million.Earnings from discontinued operations, net of tax, in the first quarter of 2020 include the recognition of $20 million of tax benefits as a result of the resolution of various tax positions related to the previous sale of a business that was reported as a discontinued operation.The following summarizes the activity for the first three months of 2020 related to the allowance for doubtful accounts as of March 31, 2020:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:87.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Allowance for Doubtful Accounts</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Balance at December 31, 2019 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 228</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Impact of adopting ASU 2016-13</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 7</td></tr><tr><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Provisions/charges to income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 21</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Amounts charged off and other deductions</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15)</td></tr><tr><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Balance at March 31, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 241</td></tr></table>The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivables. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.The components of long-term investments as of March 31, 2020 and December 31, 2019 are as follows:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:10.5%;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.77%;margin:0pt;padding:0pt;">Long-term Investments</td><td style="background-color:#cceeff;vertical-align:bottom;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;">Equity securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> 741</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> 836</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.77%;margin:0pt;padding:0pt;">Other</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 49</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 47</td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 790</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 883</td></tr></table>Abbott’s long-term investments as of March 31, 2020, declined versus the balance as of December 31, 2019, due in part to the impairment of an investment for approximately $50 million.Abbott's equity securities as of March 31, 2020, include approximately $289 million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.Abbott also holds certain investments as of March 31, 2020 with a carrying value of approximately $275 million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $162 million that do not have a readily determinable fair value. The $162 million carrying value includes cumulative unrealized gains of approximately $50 million.In the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired a research & development (R&D) asset valued at $102 million, which was immediately expensed. The $102 million of expense was recorded in the R&D line of Abbott's Condensed Consolidated Statement of Earnings. 541000000 668000000 561000000 668000000 320000000 125000000 313000000 185000000 -20000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:87.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Allowance for Doubtful Accounts</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Balance at December 31, 2019 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 228</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Impact of adopting ASU 2016-13</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 7</td></tr><tr><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Provisions/charges to income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 21</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Amounts charged off and other deductions</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15)</td></tr><tr><td style="vertical-align:bottom;width:87.22%;margin:0pt;padding:0pt;">Balance at March 31, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 241</td></tr></table> 228000000 7000000 21000000 15000000 241000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;width:10.5%;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:73.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:2.21%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.77%;margin:0pt;padding:0pt;">Long-term Investments</td><td style="background-color:#cceeff;vertical-align:bottom;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;">Equity securities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"> 741</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> 836</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:73.77%;margin:0pt;padding:0pt;">Other</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 49</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 47</td></tr><tr><td style="vertical-align:bottom;width:73.77%;margin:0pt;padding:0pt;">Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 790</td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 883</td></tr></table> 741000000 836000000 49000000 47000000 790000000 883000000 50000000 289000000 275000000 162000000 162000000 50000000 102000000 102000000 Note 5 — Changes in Accumulated Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="17" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:64.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Cumulative Gains</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">(Losses) on</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Net Actuarial</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Derivative</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.86%;margin:0pt;padding:0pt;">Cumulative Foreign</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">(Losses) and Prior</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Instruments</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.86%;margin:0pt;padding:0pt;">Currency Translation</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Service (Costs)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Designated as </td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Adjustments</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">and Credits</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cash Flow Hedges</td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:32.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Balance at January 1</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,924)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,912)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,540)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,726)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 52</td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Other comprehensive income (loss) before reclassifications</td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> (1,144)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> (1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 176</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> (17)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Amounts reclassified from accumulated other comprehensive income</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12)</td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Net current period comprehensive income (loss)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,144)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 57</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 166</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (29)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Balance at March 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,068)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (4,790)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3,483)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,703)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 165</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23</td></tr></table>Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange (gain) loss; and amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 12 for additional details. <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="17" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:64.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Cumulative Gains</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">(Losses) on</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Net Actuarial</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Derivative</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.86%;margin:0pt;padding:0pt;">Cumulative Foreign</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">(Losses) and Prior</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Instruments</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.86%;margin:0pt;padding:0pt;">Currency Translation</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Service (Costs)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;margin:0pt;padding:0pt;">Designated as </td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Adjustments</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">and Credits</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:19.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Cash Flow Hedges</td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:32.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Balance at January 1</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,924)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,912)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,540)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,726)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 52</td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Other comprehensive income (loss) before reclassifications</td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> (1,144)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 7</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> (1)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"> 176</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> (17)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Amounts reclassified from accumulated other comprehensive income</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12)</td></tr><tr><td style="vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Net current period comprehensive income (loss)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,144)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 122</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 57</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 23</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 166</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (29)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:32.87%;margin:0pt;padding:0pt;">Balance at March 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,068)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (4,790)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3,483)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (2,703)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 165</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 23</td></tr></table> -4924000000 -4912000000 -3540000000 -2726000000 -1000000 52000000 -1144000000 122000000 7000000 -1000000 176000000 -17000000 -50000000 -24000000 10000000 12000000 -1144000000 122000000 57000000 23000000 166000000 -29000000 -6068000000 -4790000000 -3483000000 -2703000000 165000000 23000000 Note 6 — Goodwill and Intangible AssetsThe total amount of goodwill reported was $22.9 billion at March 31, 2020 and $23.2 billion at December 31, 2019. Foreign currency translation adjustments decreased goodwill by approximately $268 million in the first three months of 2020. The amount of goodwill related to reportable segments at March 31, 2020 was $2.8 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.6 billion for the Diagnostic Products segment, and $16.1 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the first three months of 2020. The gross amount of amortizable intangible assets, primarily product rights and technology was $27.3 billion as of March 31, 2020 and $27.6 billion as of December 31, 2019, and accumulated amortization was $12.3 billion as of March 31, 2020 and $11.9 billion as of December 31, 2019. Foreign currency translation adjustments decreased intangible assets by $204 million for the first three months of 2020. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.1 billion in 2020, $2.0 billion in 2021, 2022, and 2023 and $1.9 billion in 2024.Indefinite-lived intangible assets, which relate to in-process R&D acquired in a business combination, were approximately $1.2 billion and $1.3 billion as of March 31, 2020 and December 31, 2019, respectively. 22900000000 23200000000 -268000000 2800000000 286000000 3600000000 16100000000 0 27300000000 27600000000 12300000000 11900000000 -204000000 2100000000 2000000000.0 1900000000 1200000000 1300000000 Note 7 — Restructuring PlansFrom 2017 to 2020, Abbott management approved restructuring plans as part of the integration of the acquisitions of St. Jude Medical into the Medical Devices segment, and Alere Inc. (Alere) into the Diagnostic Products segment, in order to leverage economies of scale and reduce costs. In the first three months of 2020, charges of $9 million were recognized, of which $3 million is recorded in Cost of products sold, $1 million is recorded in Research and development and $5 million as Selling, general and administrative expense. The following summarizes the activity for the first three months of 2020 related to these actions and the status of the related accrual as of March 31, 2020:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:86.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:86.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Accrued balance at December 31, 2019</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 46</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;">Restructuring charges recorded in 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 9</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;">Payments and other adjustments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (18)</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;">Accrued balance at March 31, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 37</td></tr></table>From 2017 to 2020, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first three months of 2020, charges of $23 million were recognized, of which $1 million is recorded in Cost of products sold, $1 million is recorded in Research and development and $21 million as Selling, general and administrative expense. The following summarizes the activity for the first three months of 2020 related to these restructuring actions and the status of the related accrual as of March 31, 2020:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:86.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Accrued balance at December 31, 2019</td><td style="background-color:#cceeff;vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 79</td></tr><tr><td style="vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;">Restructuring charges recorded in 2020</td><td style="vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 23</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;">Payments and other adjustments</td><td style="background-color:#cceeff;vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8)</td></tr><tr><td style="vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;">Accrued balance at March 31, 2020</td><td style="vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 94</td></tr></table> 9000000 3000000 1000000 5000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:86.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:86.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Accrued balance at December 31, 2019</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 46</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;">Restructuring charges recorded in 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 9</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;">Payments and other adjustments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (18)</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:86.7%;margin:0pt;padding:0pt;">Accrued balance at March 31, 2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 37</td></tr></table> 46000000 9000000 18000000 37000000 23000000 1000000 1000000 21000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:86.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;">Accrued balance at December 31, 2019</td><td style="background-color:#cceeff;vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 79</td></tr><tr><td style="vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;">Restructuring charges recorded in 2020</td><td style="vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 23</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;">Payments and other adjustments</td><td style="background-color:#cceeff;vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8)</td></tr><tr><td style="vertical-align:bottom;width:86.7%;margin:0pt;padding:0pt;">Accrued balance at March 31, 2020</td><td style="vertical-align:bottom;width:2.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 94</td></tr></table> 79000000 23000000 8000000 94000000 Note 8 — Incentive Stock ProgramIn the first three months of 2020, Abbott granted 3,956,637 stock options, 568,471 restricted stock awards and 5,042,550 restricted stock units under its incentive stock program. At March 31, 2020, approximately 112 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2020 is as follows:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercisable</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Number of shares </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 32,412,976</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 23,330,203</td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Weighted average remaining life (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 6.5</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5.5</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Weighted average exercise price </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 53.83</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 44.69</td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Aggregate intrinsic value (in millions) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 849</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 798</td></tr></table>The total unrecognized share-based compensation cost at March 31, 2020 amounted to approximately $687 million which is expected to be recognized over the next three years. 3956637 568471 5042550 112000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercisable</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Number of shares </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 32,412,976</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 23,330,203</td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Weighted average remaining life (years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 6.5</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 5.5</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Weighted average exercise price </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 53.83</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 44.69</td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;">Aggregate intrinsic value (in millions) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 849</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"> 798</td></tr></table> 32412976 23330203 P6Y6M P5Y6M 53.83 44.69 849000000 798000000 687000000 P3Y Note 9 — Debt and Lines of CreditOn February 24, 2019, Abbott redeemed the $500 million outstanding principal amount of its 2.80% Notes due 2020. 500000000 0.0280 Note 10 — Financial Instruments, Derivatives and Fair Value MeasuresCertain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $7.0 billion at March 31, 2020 and $6.8 billion at December 31, 2019 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2020 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months. Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2020 and December 31, 2019, Abbott held the gross notional amount of $9.5 billion and $9.1 billion, respectively, of such foreign currency forward exchange contracts.Abbott has designated a yen-denominated, 5-year term loan of approximately $554 million and $546 million as of March 31, 2020 and December 31, 2019, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.Abbott is a party to interest rate hedge contracts totaling approximately $2.9 billion at March 31, 2020 and December 31, 2019 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2020 and December 31, 2019:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value - Assets</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value - Liabilities</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">March 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">Dec. 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">March 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">Dec. 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:26.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;width:19.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Balance Sheet Caption</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Balance Sheet Caption</td></tr><tr><td style="background-color:auto;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Interest rate swaps designated as fair value hedges</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 48</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">Deferred income taxes and other assets</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Post-employment obligations, deferred income taxes and other long-term liabilities</td></tr><tr><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:19.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts: </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Hedging instruments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 247</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 110</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">Prepaid expenses and other receivables</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 92</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 56</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Other accrued liabilities</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Others not designated as hedges</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 117</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 38</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">Prepaid expenses and other receivables</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 97</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 33</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Other accrued liabilities</td></tr><tr><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Debt designated as a hedge of net investment in a foreign subsidiary</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">n/a</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 554</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 546</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Long-term debt</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 743</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 635</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"></td></tr></table>The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2020 and 2019. <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.16%;margin:0pt;padding:0pt;">Gain (loss) Recognized in Other </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.92%;margin:0pt;padding:0pt;">Income (expense) and Gain (loss)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Comprehensive Income (loss)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reclassified into Income</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Income Statement Caption</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.71%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts designated as cash flow hedges</td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"> 227</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"> (19)</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 11</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> 15</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;">Cost of products sold</td></tr><tr><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.71%;margin:0pt;padding:0pt;">Debt designated as a hedge of net investment in a foreign subsidiary</td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"> (8)</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;">n/a</td></tr><tr><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.71%;margin:0pt;padding:0pt;">Interest rate swaps designated as fair value hedges</td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;">n/a</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;">n/a</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 168</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> 43</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;">Interest expense</td></tr></table>Losses of $165 million and gains of $49 million were recognized in the three months ended March 31, 2020 and 2019, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line. The carrying values and fair values of certain financial instruments as of March 31, 2020 and December 31, 2019 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2019</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Carrying</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Fair</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Carrying</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="background-color:auto;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="background-color:auto;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="background-color:auto;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Long-term Investment Securities:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 741</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 741</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 836</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 836</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Other </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 49</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 49</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 47</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 47</td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Total Long-term Debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (18,068)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (20,998)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (17,938)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (20,772)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Foreign Currency Forward Exchange Contracts:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Receivable position </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 148</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 148</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">(Payable) position </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (189)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (189)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (89)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (89)</td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Interest Rate Hedge Contracts:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Receivable position</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 48</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 48</td></tr></table>The fair value of the debt was determined based on significant other observable inputs, including current interest rates.The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Basis of Fair Value Measurement</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Quoted</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Significant</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Prices in</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Other</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Outstanding</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Active</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Observable</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Balances</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Markets</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Inputs</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">March 31, 2020:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 304</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 304</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:43.02%;margin:0pt;padding:0pt;">Interest rate swap derivative financial instruments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Assets </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 884</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 304</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Fair value of hedged long-term debt </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 3,064</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 3,064</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 189</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 189</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Contingent consideration related to business combinations </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,320</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,253</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">December 31, 2019:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Equity securities </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 357</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 357</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Interest rate swap derivative financial instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 148</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 148</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 553</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 357</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Fair value of hedged long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 2,890</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 2,890</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 89</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 89</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Contingent consideration related to business combinations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 68</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 68</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Liabilities </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,047</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,979</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 68</td></tr></table>The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value. 7000000000.0 6800000000 P18M 9500000000 9100000000 554000000 546000000 2900000000 2900000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:36.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value - Assets</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="7" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:33.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Fair Value - Liabilities</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">March 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">Dec. 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">March 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;">Dec. 31,</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:26.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;width:19.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Balance Sheet Caption</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Balance Sheet Caption</td></tr><tr><td style="background-color:auto;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Interest rate swaps designated as fair value hedges</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 48</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">Deferred income taxes and other assets</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Post-employment obligations, deferred income taxes and other long-term liabilities</td></tr><tr><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:19.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts: </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Hedging instruments</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 247</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 110</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">Prepaid expenses and other receivables</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 92</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 56</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Other accrued liabilities</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Others not designated as hedges</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 117</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 38</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">Prepaid expenses and other receivables</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 97</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> 33</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Other accrued liabilities</td></tr><tr><td style="vertical-align:top;width:26.19%;margin:0pt;padding:0pt;">Debt designated as a hedge of net investment in a foreign subsidiary</td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:19.79%;margin:0pt;padding:0pt;">n/a</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 554</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 546</td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.75%;margin:0pt;padding:0pt;">Long-term debt</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:26.19%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:19.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 743</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 635</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:16.75%;margin:0pt;padding:0pt;"></td></tr></table> 216000000 48000000 247000000 110000000 92000000 56000000 117000000 38000000 97000000 33000000 554000000 546000000 580000000 196000000 743000000 635000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.16%;margin:0pt;padding:0pt;">Gain (loss) Recognized in Other </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.92%;margin:0pt;padding:0pt;">Income (expense) and Gain (loss)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Comprehensive Income (loss)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Reclassified into Income</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;width:2.39%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;width:1.79%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Income Statement Caption</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:36.71%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.71%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts designated as cash flow hedges</td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"> 227</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"> (19)</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 11</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> 15</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;">Cost of products sold</td></tr><tr><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.71%;margin:0pt;padding:0pt;">Debt designated as a hedge of net investment in a foreign subsidiary</td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"> (8)</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;">n/a</td></tr><tr><td style="vertical-align:top;width:36.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:36.71%;margin:0pt;padding:0pt;">Interest rate swaps designated as fair value hedges</td><td style="background-color:#cceeff;vertical-align:bottom;width:1.95%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;">n/a</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;">n/a</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"> 168</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> 43</td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;">Interest expense</td></tr></table> 227000000 -19000000 11000000 15000000 -8000000 168000000 43000000 -165000000 49000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.01%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:22.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2019</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Carrying</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Fair</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Carrying</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;">Fair</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;width:2.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="background-color:auto;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="background-color:auto;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td><td style="background-color:auto;vertical-align:bottom;width:2.3%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Long-term Investment Securities:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 741</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 741</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 836</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 836</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Other </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 49</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 49</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 47</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 47</td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Total Long-term Debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (18,068)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (20,998)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (17,938)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (20,772)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Foreign Currency Forward Exchange Contracts:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Receivable position </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 148</td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 148</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">(Payable) position </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (189)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (189)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (89)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> (89)</td></tr><tr><td style="vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Interest Rate Hedge Contracts:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.27%;margin:0pt;padding:0pt;">Receivable position</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 48</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"> 48</td></tr></table> 741000000 741000000 836000000 836000000 49000000 49000000 47000000 47000000 18068000000 20998000000 17938000000 20772000000 364000000 364000000 148000000 148000000 189000000 189000000 89000000 89000000 216000000 216000000 48000000 48000000 <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="8" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:40.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Basis of Fair Value Measurement</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Quoted</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Significant</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Prices in</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Other</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;">Significant</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Outstanding</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Active</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;">Observable</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;">Unobservable</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:43.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Balances</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Markets</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Inputs</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Inputs</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">March 31, 2020:</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Equity securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 304</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 304</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:43.02%;margin:0pt;padding:0pt;">Interest rate swap derivative financial instruments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 216</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 364</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Assets </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 884</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 304</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 580</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Fair value of hedged long-term debt </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 3,064</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 3,064</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 189</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 189</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Contingent consideration related to business combinations </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,320</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,253</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 67</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">December 31, 2019:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Equity securities </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 357</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 357</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Interest rate swap derivative financial instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 48</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 148</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 148</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 553</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 357</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 196</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Fair value of hedged long-term debt </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 2,890</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 2,890</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Foreign currency forward exchange contracts </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 89</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"> 89</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Contingent consideration related to business combinations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 68</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 68</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:43.02%;margin:0pt;padding:0pt;">Total Liabilities </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,047</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,979</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 68</td></tr></table> 304000000 304000000 216000000 216000000 364000000 364000000 884000000 304000000 580000000 3064000000 3064000000 189000000 189000000 67000000 67000000 3320000000 3253000000 67000000 357000000 357000000 48000000 48000000 148000000 148000000 553000000 357000000 196000000 2890000000 2890000000 89000000 89000000 68000000 68000000 3047000000 2979000000 68000000 Note 11 — Litigation and Environmental MattersAbbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $90 million to $125 million. The recorded accrual balance at March 31, 2020 for these proceedings and exposures was approximately $110 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations. 4000000 10000000 90000000 125000000 110000000 Note 12 — Post-Employment BenefitsRetirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized in continuing operations for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows: <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.38%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Defined Benefit Plans</td><td style="background-color:auto;vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Medical and Dental Plans</td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.38%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Service cost - benefits earned during the period </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> 85</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> 64</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 12</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> 6</td></tr><tr><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Interest cost on projected benefit obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> 75</td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> 84</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 12</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> 13</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Expected return on plan assets </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> (192)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> (178)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> (7)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> (7)</td></tr><tr><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Net amortization of:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Actuarial loss, net </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> 63</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> 33</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 8</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> 6</td></tr><tr><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Prior service cost (credit) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Net cost - continuing operations</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10</td></tr></table>Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first three months of 2020 and 2019, $320 million and $313 million, respectively, were contributed to defined benefit plans and $11 million was contributed to the post-employment medical and dental benefit plans in each year. <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.38%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Defined Benefit Plans</td><td style="background-color:auto;vertical-align:bottom;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Medical and Dental Plans</td></tr><tr><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:51.38%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.79%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.87%;border-top:1px solid #000000;margin:0pt;padding:0pt;">March 31, </td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:51.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Service cost - benefits earned during the period </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> 85</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> 64</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 12</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> 6</td></tr><tr><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Interest cost on projected benefit obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> 75</td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> 84</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 12</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> 13</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Expected return on plan assets </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> (192)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> (178)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> (7)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> (7)</td></tr><tr><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Net amortization of:</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Actuarial loss, net </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"> 63</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> 33</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"> 8</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"> 6</td></tr><tr><td style="vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Prior service cost (credit) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:51.38%;margin:0pt;padding:0pt;">Net cost - continuing operations</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 31</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 18</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10</td></tr></table> 85000000 64000000 12000000 6000000 75000000 84000000 12000000 13000000 192000000 178000000 7000000 7000000 -63000000 -33000000 -8000000 -6000000 -7000000 -8000000 31000000 3000000 18000000 10000000 320000000 313000000 11000000 11000000 Note 13 — Taxes on EarningsTaxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2020, taxes on earnings from continuing operations include approximately $47 million in excess tax benefits associated with share-based compensation. Earnings from discontinued operations, net of tax, in the first three months of 2020 reflect the recognition of $20 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. In the first three months of 2019, taxes on earnings from continuing operations include a $78 million reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA) and approximately $65 million in excess tax benefits associated with share-based compensation. Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between $230 million and $520 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through 2015 and the former St. Jude Medical consolidated group which are settled through 2013. 47000000 -20000000 -78000000 65000000 230000000 520000000 Note 14 — Segment InformationAbbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world. Abbott’s reportable segments are as follows:Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology and Heart Failure, Vascular, Neuromodulation, Structural Heart and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.<table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="11" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:43.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.67%;margin:0pt;padding:0pt;">Net Sales to </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.69%;margin:0pt;padding:0pt;">Operating </td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">External Customers</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Earnings</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Established Pharmaceutical Products</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,044</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 992</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 181</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 159</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Nutritional Products</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,904</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,792</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 459</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 380</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Diagnostic Products</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,826</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,841</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 405</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 434</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Medical Devices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,895</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 803</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 847</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Total Reportable Segments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 7,711</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 7,520</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,848</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 1,820</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Net sales</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,726</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,535</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Corporate functions and benefit plans costs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (132)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (102)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Net interest expense </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (121)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (148)</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Share-based compensation (a) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (233)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (226)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Amortization of intangible assets</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (561)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (486)</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Other, net (b)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (168)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (226)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Earnings from continuing operations before taxes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 633</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 632</td></tr></table><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;">Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;">Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three months ended March 31, 2019 also includes a charge associated with an R&D asset acquired and immediately expensed.</td></tr></table> <table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"> </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="11" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:43.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three Months Ended March 31</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.67%;margin:0pt;padding:0pt;">Net Sales to </td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.69%;margin:0pt;padding:0pt;">Operating </td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;"></td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">External Customers</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td colspan="5" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:20.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Earnings</td></tr><tr><td style="background-color:auto;vertical-align:bottom;width:53.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in millions)</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="background-color:auto;vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2019</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Established Pharmaceutical Products</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,044</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 992</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 181</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 159</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Nutritional Products</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,904</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,792</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 459</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 380</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Diagnostic Products</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,826</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,841</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 405</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 434</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Medical Devices</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,895</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 803</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 847</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Total Reportable Segments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 7,711</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 7,520</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> 1,848</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> 1,820</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Net sales</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,726</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,535</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Corporate functions and benefit plans costs</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (132)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (102)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Net interest expense </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (121)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (148)</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Share-based compensation (a) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (233)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (226)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Amortization of intangible assets</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"> (561)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;margin:0pt;padding:0pt;"> (486)</td></tr><tr><td style="vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Other, net (b)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (168)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (226)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:53.42%;margin:0pt;padding:0pt;">Earnings from continuing operations before taxes</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 633</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 632</td></tr></table><div style="font-family:'Times New Roman';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;">Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;">Other, net includes integration costs associated with the acquisition of St. Jude Medical and Alere, and restructuring charges. Other, net for the three months ended March 31, 2019 also includes a charge associated with an R&D asset acquired and immediately expensed.</td></tr></table> 1044000000 992000000 181000000 159000000 1904000000 1792000000 459000000 380000000 1826000000 1841000000 405000000 434000000 2937000000 2895000000 803000000 847000000 7711000000 7520000000 1848000000 1820000000 15000000 15000000 7726000000 7535000000 132000000 102000000 -121000000 -148000000 233000000 226000000 561000000 486000000 168000000 226000000 633000000 632000000 0.50 0.50 XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 280 331 1 false 77 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.abbott.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Statement of Earnings Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings Condensed Consolidated Statement of Earnings Statements 2 false false R3.htm 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome Condensed Consolidated Statement of Comprehensive Income Statements 3 false false R4.htm 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Balance Sheet Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet Condensed Consolidated Balance Sheet Statements 5 false false R6.htm 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical Condensed Consolidated Balance Sheet (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Consolidated Statement of Shareholders' Investment Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestment Condensed Consolidated Statement of Shareholders' Investment Statements 7 false false R8.htm 00405 - Statement - Condensed Consolidated Statement of Shareholders' Investment (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfShareholdersInvestmentParenthetical Condensed Consolidated Statement of Shareholders' Investment (Parenthetical) Statements 8 false false R9.htm 00500 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 9 false false R10.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 10 false false R11.htm 10201 - Disclosure - New Accounting Standards Sheet http://www.abbott.com/role/DisclosureNewAccountingStandards New Accounting Standards Notes 11 false false R12.htm 10301 - Disclosure - Revenue Sheet http://www.abbott.com/role/DisclosureRevenue Revenue Notes 12 false false R13.htm 10401 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformation Supplemental Financial Information Notes 13 false false R14.htm 10501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) Sheet http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLoss Changes in Accumulated Other Comprehensive Income (Loss) Notes 14 false false R15.htm 10601 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 15 false false R16.htm 10701 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/DisclosureRestructuringPlans Restructuring Plans Notes 16 false false R17.htm 10801 - Disclosure - Incentive Stock Program Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgram Incentive Stock Program Notes 17 false false R18.htm 10901 - Disclosure - Debt and Lines of Credit Sheet http://www.abbott.com/role/DisclosureDebtAndLinesOfCredit Debt and Lines of Credit Notes 18 false false R19.htm 11001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 19 false false R20.htm 11101 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters Litigation and Environmental Matters Notes 20 false false R21.htm 11201 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefits Post-Employment Benefits Notes 21 false false R22.htm 11301 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/DisclosureTaxesOnEarnings Taxes on Earnings Notes 22 false false R23.htm 11401 - Disclosure - Segment Information Sheet http://www.abbott.com/role/DisclosureSegmentInformation Segment Information Notes 23 false false R24.htm 20202 - Disclosure - New Accounting Standards (Policies) Sheet http://www.abbott.com/role/DisclosureNewAccountingStandardsPolicies New Accounting Standards (Policies) Policies http://www.abbott.com/role/DisclosureNewAccountingStandards 24 false false R25.htm 30303 - Disclosure - Revenue (Tables) Sheet http://www.abbott.com/role/DisclosureRevenueTables Revenue (Tables) Tables http://www.abbott.com/role/DisclosureRevenue 25 false false R26.htm 30403 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/DisclosureSupplementalFinancialInformation 26 false false R27.htm 30503 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossTables Changes in Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLoss 27 false false R28.htm 30703 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/DisclosureRestructuringPlans 28 false false R29.htm 30803 - Disclosure - Incentive Stock Program (Tables) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramTables Incentive Stock Program (Tables) Tables http://www.abbott.com/role/DisclosureIncentiveStockProgram 29 false false R30.htm 31003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures 30 false false R31.htm 31203 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/DisclosurePostEmploymentBenefits 31 false false R32.htm 31403 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/DisclosureSegmentInformation 32 false false R33.htm 40301 - Disclosure - Revenue (Details) Sheet http://www.abbott.com/role/DisclosureRevenueDetails Revenue (Details) Details http://www.abbott.com/role/DisclosureRevenueTables 33 false false R34.htm 40302 - Disclosure - Revenue - Remaining Performance Obligations (Details) Sheet http://www.abbott.com/role/DisclosureRevenueRemainingPerformanceObligationsDetails Revenue - Remaining Performance Obligations (Details) Details 34 false false R35.htm 40303 - Disclosure - Revenue - Practical Expedient (Details) Sheet http://www.abbott.com/role/DisclosureRevenuePracticalExpedientDetails Revenue - Practical Expedient (Details) Details 35 false false R36.htm 40304 - Disclosure - Revenue - Other Contract Assets and Liabilities (Details) Sheet http://www.abbott.com/role/DisclosureRevenueOtherContractAssetsAndLiabilitiesDetails Revenue - Other Contract Assets and Liabilities (Details) Details 36 false false R37.htm 40401 - Disclosure - Supplemental Financial Information - Income Statement (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationIncomeStatementDetails Supplemental Financial Information - Income Statement (Details) Details 37 false false R38.htm 40402 - Disclosure - Supplemental Financial Information - Cash Flows (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationCashFlowsDetails Supplemental Financial Information - Cash Flows (Details) Details 38 false false R39.htm 40403 - Disclosure - Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationAllowanceForDoubtfulAccountsDetails Supplemental Financial Information - Allowance for Doubtful Accounts (Details) Details 39 false false R40.htm 40404 - Disclosure - Supplemental Financial Information - Investments (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationInvestmentsDetails Supplemental Financial Information - Investments (Details) Details 40 false false R41.htm 40405 - Disclosure - Supplemental Financial Information - General (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationGeneralDetails Supplemental Financial Information - General (Details) Details 41 false false R42.htm 40501 - Disclosure - Changes in Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossDetails Changes in Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.abbott.com/role/DisclosureChangesInAccumulatedOtherComprehensiveIncomeLossTables 42 false false R43.htm 40601 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsGoodwillDetails Goodwill and Intangible Assets - Goodwill (Details) Details 43 false false R44.htm 40602 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 44 false false R45.htm 40701 - Disclosure - Restructuring Plans (Details) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansDetails Restructuring Plans (Details) Details http://www.abbott.com/role/DisclosureRestructuringPlansTables 45 false false R46.htm 40801 - Disclosure - Incentive Stock Program - General (Details) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramGeneralDetails Incentive Stock Program - General (Details) Details 46 false false R47.htm 40802 - Disclosure - Incentive Stock Program - Options (Details) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramOptionsDetails Incentive Stock Program - Options (Details) Details 47 false false R48.htm 40901 - Disclosure - Debt and Lines of Credit (Details) Sheet http://www.abbott.com/role/DisclosureDebtAndLinesOfCreditDetails Debt and Lines of Credit (Details) Details http://www.abbott.com/role/DisclosureDebtAndLinesOfCredit 48 false false R49.htm 41001 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresContractsDetails Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) Details http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables 49 false false R50.htm 41002 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresLocationOfDerivativeInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Location of Derivative Instruments (Details) Details 50 false false R51.htm 41003 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresGainOrLossDetails Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) Details 51 false false R52.htm 41004 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValueAndFairValueDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Value and Fair Value (Details) Details 52 false false R53.htm 41005 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresBasesOfMeasurementDetails Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) Details 53 false false R54.htm 41101 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters 54 false false R55.htm 41201 - Disclosure - Post-Employment Benefits - (Details) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails Post-Employment Benefits - (Details) Details http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables 55 false false R56.htm 41301 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/DisclosureTaxesOnEarnings 56 false false R57.htm 41401 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/DisclosureSegmentInformationTables 57 false false All Reports Book All Reports abt-20200331x10q.htm abt-20200331.xsd abt-20200331_cal.xml abt-20200331_def.xml abt-20200331_lab.xml abt-20200331_pre.xml abt-20200331xex31d1.htm abt-20200331xex31d2.htm abt-20200331xex32d1.htm abt-20200331xex32d2.htm http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/exch/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 72 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Debt and Lines of Credit
3 Months Ended

Mar. 31, 2020

Debt and Lines of Credit

Debt and Lines of Credit
Note 9 — Debt and Lines of Credit

On February 24, 2019, Abbott redeemed the $500 million outstanding principal amount of its 2.80% Notes due 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Taxes on Earnings
3 Months Ended

Mar. 31, 2020

Taxes on Earnings

Taxes on Earnings
Note 13 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2020, taxes on earnings from continuing operations include approximately $47 million in excess tax benefits associated with share-based compensation. Earnings from discontinued operations, net of tax, in the first three months of 2020 reflect the recognition of $20 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. In the first three months of 2019, taxes on earnings from continuing operations include a $78 million reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA) and approximately $65 million in excess tax benefits associated with share-based compensation.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease between $230 million and $520 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2016 are settled except for the federal income tax returns of the former Alere consolidated group which are settled through 2015 and the former St. Jude Medical consolidated group which are settled through 2013.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Supplemental Financial Information (Tables)
3 Months Ended

Mar. 31, 2020

Supplemental Financial Information

Summary of activity of allowance for doubtful accounts

(in millions)

Allowance for Doubtful Accounts

Balance at December 31, 2019

$
228
Impact of adopting ASU 2016-13

7
Provisions/charges to income

21
Amounts charged off and other deductions

(15)
Balance at March 31, 2020

$
241

Schedule of long-term investments

March 31,

December 31,
(in millions)

2020

2019
Long-term Investments

Equity securities

$
741

$
836
Other

49

47
Total

$
790

$
883

X

- Definition
Tabular disclosure of the investments which are intended to be held for an extended period of time (longer than one operating cycle).
+ References
No definition available.
+ Details

Name: abt_ScheduleOfLongTermInvestmentsTableTextBlock

Namespace Prefix: abt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of allowance for credit loss on accounts receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 20
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447
+ Details

Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureTextBlockSupplementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 75 R47.htm IDEA: XBRL DOCUMENT v3.20.1

Incentive Stock Program - Options (Details)
$ / shares in Units, $ in Millions
3 Months Ended

Mar. 31, 2020

USD ($)

$ / shares

shares

Incentive Stock Program

Total unrecognized compensation cost $ 687

Total unrecognized compensation cost, recognition period 3 years

Stock options

Incentive Stock Program

Stock options outstanding, number of shares | shares 32,412,976

Exercisable options, number of shares | shares 23,330,203

Stock options outstanding, weighted-average remaining life 6 years 6 months

Exercisable options, weighted-average remaining life 5 years 6 months

Stock options outstanding, weighted-average exercise price (in dollars per share) | $ / shares $ 53.83

Exercisable options, weighted-average exercise price (in dollars per share) | $ / shares $ 44.69

Aggregate intrinsic value of options outstanding $ 849

Aggregate intrinsic value of options exercisable $ 798

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 76 R43.htm IDEA: XBRL DOCUMENT v3.20.1

Goodwill and Intangible Assets - Goodwill (Details) - USD ($)
$ in Millions
3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Goodwill and Intangible Assets

Goodwill $ 22,927 $ 23,195

Decrease in goodwill due to foreign currency translation adjustments 268

Amount of reductions of goodwill relating to impairments 0

Established Pharmaceutical Products

Goodwill and Intangible Assets

Goodwill 2,800

Nutritional Products

Goodwill and Intangible Assets

Goodwill 286

Diagnostic Products

Goodwill and Intangible Assets

Goodwill 3,600

Medical Devices

Goodwill and Intangible Assets

Goodwill $ 16,100

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266
+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

New Accounting Standards (Policies)	3 Months Ended
New Accounting Standards (Policies)	Mar. 31, 2020
New Accounting Standards
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-13, Financial Instruments – Credit Losses, which changes the methodology to be used to measure credit losses for certain financial instruments and financial assets, including trade receivables. The new methodology requires the recognition of an allowance that reflects the current estimate of credit losses expected to be incurred over the life of the financial asset. Abbott adopted the standard on January 1, 2020 and recorded a cumulative adjustment that was not significant to Earnings employed in the business in the Condensed Consolidated Balance Sheet.
Recent Accounting Standards Not Yet Adopted	Recent Accounting Standards Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard becomes effective for Abbott in the first quarter of 2021 and early adoption is permitted. Abbott does not expect adoption of this new standard to have a material impact on its condensed consolidated financial statements.

Restructuring Plans (Details) $ in Millions	3 Months Ended
Restructuring Plans (Details) $ in Millions	Mar. 31, 2020 USD ($)
Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations
Restructuring costs
Accrued balance at beginning of the period	$ 46
Restructuring charges in 2020	9
Payments and other adjustments	(18)
Accrued balance at end of the period	37
Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations \| Cost of products sold
Restructuring costs
Restructuring charges in 2020	3
Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations \| Research and development
Restructuring costs
Restructuring charges in 2020	1
Restructuring Plan in 2017 to 2020, St Jude and Alere Integrations \| Selling, general and administrative expense
Restructuring costs
Restructuring charges in 2020	5
Restructuring Plan from 2017 to 2020
Restructuring costs
Accrued balance at beginning of the period	79
Restructuring charges in 2020	23
Payments and other adjustments	(8)
Accrued balance at end of the period	94
Restructuring Plan from 2017 to 2020 \| Cost of products sold
Restructuring costs
Restructuring charges in 2020	1
Restructuring Plan from 2017 to 2020 \| Research and development
Restructuring costs
Restructuring charges in 2020	1
Restructuring Plan from 2017 to 2020 \| Selling, general and administrative expense
Restructuring costs
Restructuring charges in 2020	$ 21

Supplemental Financial Information - General (Details) - Cephea Valve Technologies, Inc $ in Millions	3 Months Ended
	Mar. 31, 2019 USD ($)
Business acquisitions
Research & development (R&D) asset	$ 102
Research & development expense	$ 102

Financial Instruments, Derivatives and Fair Value Measures - Contracts (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Designated as hedging instrument \| Yen-denominated long-term debt \| Net investment hedges
Derivative instruments, notional amount and fair value
Term loan	$ 554	$ 546
Debt Instrument, Term	5 years	5 years
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Gross notional amount	$ 7,000	$ 6,800
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold	12 months
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold	18 months
Designated as hedging instrument \| Interest rate swaps \| Fair value hedges
Derivative instruments, notional amount and fair value
Gross notional amount	$ 2,900	2,900
Not designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Gross notional amount	$ 9,500	$ 9,100

Debt and Lines of Credit (Details) - 2.80% Notes, due 2020 $ in Millions	Feb. 24, 2019 USD ($)
Debt and Lines of Credit
Repayments of debt	$ 500
Interest rate percentage	2.80%

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets
Gross amount of amortizable intangible assets	$ 27,300	$ 27,600
Accumulated amortization of intangible assets	12,300	11,900
Decrease in intangible assets due to foreign currency translation adjustments	(204)
Estimated annual amortization expense, intangible assets, 2020	2,100
Estimated annual amortization expense, intangible assets, 2021	2,000
Estimated annual amortization expense, intangible assets, 2022	2,000
Estimated annual amortization expense, intangible assets, 2023	2,000
Estimated annual amortization expense, intangible assets, 2024	1,900
Indefinite-lived intangible assets related to in-process R&D acquired in a business combination	$ 1,200	$ 1,300

Supplemental Financial Information - Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Investments
Long-term Investments	$ 790	$ 883
Equity method investments carrying value	275
Equity investment without readily determinable fair value	162
Unrealized gain	50
Impairment of investments	50
Equity securities
Investments
Long-term Investments	741	836
Other
Investments
Long-term Investments	49	$ 47
St Jude Medical \| Equity securities
Investments
Securities in mutual funds held in a rabbi trust	$ 289

Financial Instruments, Derivatives and Fair Value Measures - Gain or Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Not designated as hedging instrument
Gain (loss) on derivatives
Income (expense) and Gain (loss) Reclassified into Income	$ (165)	$ 49
Foreign currency forward exchange contracts \| Cash flow hedges \| Designated as hedging instrument \| Cost of products sold
Gain (loss) on derivatives
Gain (loss) Recognized in Other Comprehensive Income (loss)	227	(19)
Income (expense) and Gain (loss) Reclassified into Income	11	15
Debt \| Net investment hedges \| Designated as hedging instrument
Gain (loss) on derivatives
Gain (loss) Recognized in Other Comprehensive Income (loss)	(8)
Interest rate swaps \| Fair value hedges \| Designated as hedging instrument \| Interest expense
Gain (loss) on derivatives
Income (expense) and Gain (loss) Reclassified into Income	$ 168	$ 43

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flow From (Used in) Operating Activities:
Net earnings	$ 564	$ 672
Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation	267	267
Amortization of intangible assets	561	486
Share-based compensation	233	226
Trade receivables	(104)	(170)
Inventories	(437)	(286)
Other, net	(369)	(483)
Net Cash From Operating Activities	715	712
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(360)	(335)
Acquisitions of businesses and technologies, net of cash acquired		(78)
Sales (purchases) of other investment securities, net	(36)	2
Other	3	15
Net Cash (Used in) Investing Activities	(393)	(396)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other	51	13
Repayments of long-term debt	(1)	(500)
Purchases of common shares	(236)	(217)
Proceeds from stock options exercised	89	127
Dividends paid	(638)	(565)
Net Cash (Used in) Financing Activities	(735)	(1,142)
Effect of exchange rate changes on cash and cash equivalents	(70)	4
Net Decrease in Cash and Cash Equivalents	(483)	(822)
Cash and Cash Equivalents, Beginning of Year	3,860	3,844
Cash and Cash Equivalents, End of Period	$ 3,377	$ 3,022

Post-Employment Benefits - (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	$ 85	$ 64
Interest cost on projected benefit obligations	75	84
Expected return on plans assets	(192)	(178)
Net amortization of:
Actuarial loss, net	63	33
Net cost - continuing operations	31	3
Post-employment Obligations and Other Long-term Liabilities:
Company contributions	320	313
Medical and Dental Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	12	6
Interest cost on projected benefit obligations	12	13
Expected return on plans assets	(7)	(7)
Net amortization of:
Actuarial loss, net	8	6
Prior service cost (credit)	(7)	(8)
Net cost - continuing operations	18	10
Post-employment Obligations and Other Long-term Liabilities:
Company contributions	$ 11	$ 11

Condensed Consolidated Balance Sheet - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 3,377	$ 3,860
Short-term investments	291	280
Trade receivables, less allowances of $389 in 2020 and $384 in 2019	5,292	5,425
Inventories:
Finished products	2,873	2,784
Work in process	615	560
Materials	1,080	972
Total inventories	4,568	4,316
Prepaid expenses and other receivables	1,970	1,786
Total Current Assets	15,498	15,667
Investments	790	883
Property and equipment, at cost	16,707	16,799
Less: accumulated depreciation and amortization	8,800	8,761
Net property and equipment	7,907	8,038
Intangible assets, net of amortization	16,265	17,025
Goodwill	22,927	23,195
Deferred income taxes and other assets	3,390	3,079
Total Assets	66,777	67,887
Current Liabilities:
Short-term borrowings	204	201
Trade accounts payable	3,181	3,252
Salaries, wages and commissions	949	1,237
Other accrued liabilities	4,408	4,035
Dividends payable	637	635
Income taxes payable	165	226
Current portion of long-term debt	1,264	1,277
Total Current Liabilities	10,808	10,863
Long-term debt	16,804	16,661
Post-employment obligations, deferred income taxes and other long-term liabilities	8,738	9,062
Commitments and Contingencies
Shareholders' Investment:
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued
Common shares, without par value Authorized - 2,400,000,000 shares, Issued at stated capital amount - Shares: 2020: 1,978,112,501; 2019: 1,976,855,085	23,731	23,853
Common shares held in treasury, at cost - Shares: 2020: 209,267,175 ; 2019: 214,351,838	(9,913)	(10,147)
Earnings employed in the business	25,786	25,847
Accumulated other comprehensive income (loss)	(9,386)	(8,465)
Total Abbott Shareholders' Investment	30,218	31,088
Noncontrolling Interests in Subsidiaries	209	213
Total Shareholders' Investment	30,427	31,301
Total Liabilities and Shareholders' Investment	$ 66,777	$ 67,887

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2020 shares
Document and Entity Information
Document Type	10-Q
Document Transition Report	false
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2020
Entity File Number	1-2189
Entity Registrant Name	ABBOTT LABORATORIES
Entity Tax Identification Number	36-0698440
Entity Incorporation, State or Country Code	IL
Entity Address, State or Province	IL
Entity Address, Address Line One	100 Abbott Park Road
Entity Address, City or Town	Abbott Park
Entity Address, Postal Zip Code	60064-6400
City Area Code	224
Local Phone Number	667-6100
Title of 12(b) Security	Common Shares, Without Par Value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	1,768,845,326
Entity Central Index Key	0000001800
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
New York Stock Exchange
Document and Entity Information
Security Exchange Name	NYSE
Trading Symbol	ABT
Chicago Stock Exchange
Document and Entity Information
Security Exchange Name	CHX

Supplemental Financial Information - Cash Flows (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flow disclosures
Payment of cash taxes	$ 125	$ 185
Discontinued operations
Cash flow disclosures
Net tax benefits primarily as a result of the resolution of various tax positions related to prior years	20
Defined Benefit Plans
Cash flow disclosures
Pension contributions	$ 320	$ 313

Revenue - Remaining Performance Obligations (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Diagnostic Products
Remaining Performance Obligations
Remaining performance obligations	$ 3,400
Medical Devices
Remaining Performance Obligations
Remaining performance obligations	$ 400
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-01
Remaining Performance Obligations
Expected timing of satisfication period (in months)	24 months
Percentage of remaining performance obligation expected to be recognized in period	60.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Remaining Performance Obligations
Expected timing of satisfication period (in months)	12 months
Percentage of remaining performance obligation expected to be recognized in period	17.00%

Incentive Stock Program - General (Details)	3 Months Ended
Incentive Stock Program - General (Details)	Mar. 31, 2020 shares
Incentive Stock Program
Incentive stock program, shares reserved for future grants	112,000,000
Stock options
Incentive Stock Program
Stock options granted during the period (in shares)	3,956,637
Restricted stock awards
Incentive Stock Program
Grants in period, restricted stock (in shares)	568,471
Restricted stock units
Incentive Stock Program
Awards and units granted during period (in shares)	5,042,550

Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	$ 31,088
Net current period comprehensive income (loss)	(921)	$ 116
End of the period	30,218
Cumulative Foreign Currency Translation Adjustments
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	(4,924)	(4,912)
Other comprehensive income (loss) before reclassifications	(1,144)	122
Net current period comprehensive income (loss)	(1,144)	122
End of the period	(6,068)	(4,790)
Net Actuarial (Losses) and Prior Service (Costs) and Credits
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	(3,540)	(2,726)
Other comprehensive income (loss) before reclassifications	7	(1)
Amounts reclassified from accumulated other comprehensive income	50	24
Net current period comprehensive income (loss)	57	23
End of the period	(3,483)	(2,703)
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
Changes in accumulated other comprehensive income (loss), net of income taxes
Beginning of the period	(1)	52
Other comprehensive income (loss) before reclassifications	176	(17)
Amounts reclassified from accumulated other comprehensive income	(10)	(12)
Net current period comprehensive income (loss)	166	(29)
End of the period	$ 165	$ 23

Financial Instruments, Derivatives and Fair Value Measures - Bases of Measurement (Details) - Recurring - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Fair value, asset and liability measures
Equity securities	$ 304	$ 357
Interest rate swap derivative financial instruments, assets	216	48
Foreign currency forward exchange contracts	364	148
Total Assets	884	553
Fair value of hedged long-term debt	3,064	2,890
Foreign currency forward exchange contracts	189	89
Contingent consideration related to business combinations	67	68
Total Liabilities	3,320	3,047
Quoted Prices in Active Markets
Fair value, asset and liability measures
Equity securities	304	357
Total Assets	304	357
Significant Other Observable Inputs
Fair value, asset and liability measures
Interest rate swap derivative financial instruments, assets	216	48
Foreign currency forward exchange contracts	364	148
Total Assets	580	196
Fair value of hedged long-term debt	3,064	2,890
Foreign currency forward exchange contracts	189	89
Total Liabilities	3,253	2,979
Significant Unobservable Inputs
Fair value, asset and liability measures
Contingent consideration related to business combinations	67	68
Total Liabilities	$ 67	$ 68

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
Segment Information (Details) - USD ($) $ in Millions	Mar. 31, 2020	Mar. 31, 2019
Segment Information
Net Sales to External Customers	$ 7,726	$ 7,535
Operating Earnings	758	739
Amortization of intangible assets	(561)	(486)
Earnings from continuing operations before taxes	$ 633	$ 632
Annual share-based awards recognized in first quarter (as a percent)	50.00%	50.00%
Established Pharmaceutical Products
Segment Information
Net Sales to External Customers	$ 1,044	$ 992
Nutritional Products
Segment Information
Net Sales to External Customers	1,904	1,792
Diagnostic Products
Segment Information
Net Sales to External Customers	1,826	1,841
Medical Devices
Segment Information
Net Sales to External Customers	2,937	2,895
Other
Segment Information
Net Sales to External Customers	15	15
Total Reportable Segments
Segment Information
Net Sales to External Customers	7,711	7,520
Operating Earnings	1,848	1,820
Total Reportable Segments \| Established Pharmaceutical Products
Segment Information
Net Sales to External Customers	1,044	992
Operating Earnings	181	159
Total Reportable Segments \| Nutritional Products
Segment Information
Net Sales to External Customers	1,904	1,792
Operating Earnings	459	380
Total Reportable Segments \| Diagnostic Products
Segment Information
Net Sales to External Customers	1,826	1,841
Operating Earnings	405	434
Total Reportable Segments \| Medical Devices
Segment Information
Net Sales to External Customers	2,937	2,895
Operating Earnings	803	847
Reconciling items
Segment Information
Corporate functions and benefit plan costs	(132)	(102)
Net interest expense	(121)	(148)
Share-based compensation	(233)	(226)
Amortization of intangible assets	(561)	(486)
Other, net	$ (168)	$ (226)

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Condensed Consolidated Balance Sheet
Trade receivables, allowances (in dollars)	$ 389	$ 384
Preferred shares, par value (in dollars per share)	$ 1	$ 1
Preferred shares, authorized shares	1,000,000	1,000,000
Preferred shares, issued shares	0	0
Common shares, authorized shares	2,400,000,000	2,400,000,000
Common shares, issued shares	1,978,112,501	1,976,855,085
Common shares held in treasury, shares	209,267,175	214,351,838

Condensed Consolidated Statement of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Condensed Consolidated Statement of Earnings
Net sales	$ 7,726	$ 7,535
Cost of products sold, excluding amortization of intangible assets	3,281	3,160
Amortization of intangible assets	561	486
Research and development	578	672
Selling, general and administrative	2,548	2,478
Total operating cost and expenses	6,968	6,796
Operating earnings	758	739
Interest expense	139	171
Interest (income)	(18)	(23)
Net foreign exchange (gain) loss	5	6
Other (income) expense, net	(1)	(47)
Earnings from continuing operations before taxes	633	632
Tax expense (benefit) on earnings from continuing operations	89	(40)
Earnings from continuing operations	544	672
Earnings from discontinued operations, net of tax	20
Net Earnings	$ 564	$ 672
Basic Earnings Per Common Share
Continuing operations (in dollars per share)	$ 0.31	$ 0.38
Discontinued operations (in dollars per share)	0.01
Net earnings (in dollars per share)	0.32	0.38
Diluted Earnings Per Common Share
Continuing operations (in dollars per share)	0.30	0.38
Discontinued operations (in dollars per share)	0.01
Net earnings (in dollars per share)	$ 0.31	$ 0.38
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,768,901	1,763,278
Dilutive Common Stock Options (in shares)	11,677	13,295
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,780,578	1,776,573
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	4,035	4,011

Taxes on Earnings (Details) - USD ($) $ in Millions	3 Months Ended
Taxes on Earnings (Details) - USD ($) $ in Millions	Mar. 31, 2020	Mar. 31, 2019
Taxes on Earnings
Reduction to the transition tax related to the Tax Cut and Jobs Act (TCJA)		$ 78
Excess tax benefits from share based compensation	$ 47	$ 65
Minimum
Taxes on Earnings
Decrease reasonably possible in gross unrecognized tax benefits	230
Maximum
Taxes on Earnings
Decrease reasonably possible in gross unrecognized tax benefits	520
Discontinued operations
Taxes on Earnings
Net tax benefits primarily as a result of the resolution of various tax positions related to prior years	$ 20

Supplemental Financial Information - Income Statement (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Supplemental Financial Information
Earnings from continuing operations allocated to common shares	$ 541	$ 668
Net earnings allocated to common shares	$ 561	$ 668

Revenue (Details) $ in Millions	3 Months Ended
Revenue (Details) $ in Millions	Mar. 31, 2020 USD ($) segment	Mar. 31, 2019 USD ($) segment
Revenue
Number of reportable segments \| segment	4	4
Net sales	$ 7,726	$ 7,535
U.S.
Revenue
Net sales	2,856	2,754
Int'l
Revenue
Net sales	4,870	4,781
Established Pharmaceutical Products
Revenue
Net sales	1,044	992
Established Pharmaceutical Products \| Int'l
Revenue
Net sales	1,044	992
Nutritional Products
Revenue
Net sales	1,904	1,792
Nutritional Products \| U.S.
Revenue
Net sales	812	747
Nutritional Products \| Int'l
Revenue
Net sales	1,092	1,045
Diagnostic Products
Revenue
Net sales	1,826	1,841
Diagnostic Products \| U.S.
Revenue
Net sales	803	724
Diagnostic Products \| Int'l
Revenue
Net sales	1,023	1,117
Medical Devices
Revenue
Net sales	2,937	2,895
Medical Devices \| U.S.
Revenue
Net sales	1,233	1,275
Medical Devices \| Int'l
Revenue
Net sales	1,704	1,620
Other
Revenue
Net sales	15	15
Other \| U.S.
Revenue
Net sales	8	8
Other \| Int'l
Revenue
Net sales	7	7
Key Emerging Markets \| Established Pharmaceutical Products
Revenue
Net sales	813	752
Key Emerging Markets \| Established Pharmaceutical Products \| Int'l
Revenue
Net sales	813	752
Other \| Established Pharmaceutical Products
Revenue
Net sales	231	240
Other \| Established Pharmaceutical Products \| Int'l
Revenue
Net sales	231	240
Pediatric Nutritionals \| Nutritional Products
Revenue
Net sales	1,089	1,029
Pediatric Nutritionals \| Nutritional Products \| U.S.
Revenue
Net sales	518	453
Pediatric Nutritionals \| Nutritional Products \| Int'l
Revenue
Net sales	571	576
Adult Nutritionals \| Nutritional Products
Revenue
Net sales	815	763
Adult Nutritionals \| Nutritional Products \| U.S.
Revenue
Net sales	294	294
Adult Nutritionals \| Nutritional Products \| Int'l
Revenue
Net sales	521	469
Core Laboratory \| Diagnostic Products
Revenue
Net sales	989	1,061
Core Laboratory \| Diagnostic Products \| U.S.
Revenue
Net sales	267	249
Core Laboratory \| Diagnostic Products \| Int'l
Revenue
Net sales	722	812
Molecular \| Diagnostic Products
Revenue
Net sales	139	108
Molecular \| Diagnostic Products \| U.S.
Revenue
Net sales	65	40
Molecular \| Diagnostic Products \| Int'l
Revenue
Net sales	74	68
Point of Care \| Diagnostic Products
Revenue
Net sales	138	135
Point of Care \| Diagnostic Products \| U.S.
Revenue
Net sales	103	109
Point of Care \| Diagnostic Products \| Int'l
Revenue
Net sales	35	26
Rapid Diagnostics \| Diagnostic Products
Revenue
Net sales	560	537
Rapid Diagnostics \| Diagnostic Products \| U.S.
Revenue
Net sales	368	326
Rapid Diagnostics \| Diagnostic Products \| Int'l
Revenue
Net sales	192	211
Rhythm Management \| Medical Devices
Revenue
Net sales	474	514
Rhythm Management \| Medical Devices \| U.S.
Revenue
Net sales	228	252
Rhythm Management \| Medical Devices \| Int'l
Revenue
Net sales	246	262
Electrophysiology \| Medical Devices
Revenue
Net sales	388	405
Electrophysiology \| Medical Devices \| U.S.
Revenue
Net sales	164	174
Electrophysiology \| Medical Devices \| Int'l
Revenue
Net sales	224	231
Heart Failure \| Medical Devices
Revenue
Net sales	203	184
Heart Failure \| Medical Devices \| U.S.
Revenue
Net sales	152	143
Heart Failure \| Medical Devices \| Int'l
Revenue
Net sales	51	41
Vascular \| Medical Devices
Revenue
Net sales	625	709
Vascular \| Medical Devices \| U.S.
Revenue
Net sales	230	266
Vascular \| Medical Devices \| Int'l
Revenue
Net sales	395	443
Structural Heart \| Medical Devices
Revenue
Net sales	318	324
Structural Heart \| Medical Devices \| U.S.
Revenue
Net sales	136	136
Structural Heart \| Medical Devices \| Int'l
Revenue
Net sales	182	188
Neuromodulation \| Medical Devices
Revenue
Net sales	177	193
Neuromodulation \| Medical Devices \| U.S.
Revenue
Net sales	137	152
Neuromodulation \| Medical Devices \| Int'l
Revenue
Net sales	40	41
Diabetes Care \| Medical Devices
Revenue
Net sales	752	566
Diabetes Care \| Medical Devices \| U.S.
Revenue
Net sales	186	152
Diabetes Care \| Medical Devices \| Int'l
Revenue
Net sales	$ 566	$ 414

Incentive Stock Program - Options (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($) $ / shares shares
Incentive Stock Program
Total unrecognized compensation cost	$ 687
Total unrecognized compensation cost, recognition period	3 years
Stock options
Incentive Stock Program
Stock options outstanding, number of shares \| shares	32,412,976
Exercisable options, number of shares \| shares	23,330,203
Stock options outstanding, weighted-average remaining life	6 years 6 months
Exercisable options, weighted-average remaining life	5 years 6 months
Stock options outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 53.83
Exercisable options, weighted-average exercise price (in dollars per share) \| $ / shares	$ 44.69
Aggregate intrinsic value of options outstanding	$ 849
Aggregate intrinsic value of options exercisable	$ 798